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ABSTRACT 
Microfluidic Selection of Aptamers towards Applications in Precision Medicine 
Timothy R. Olsen 
 Precision medicine represents a shift in medicine where large datasets are gathered for massive 
patient groups to draw correlations between disease cohorts. An individual patient can then be compared 
to these large datasets to determine the best treatment strategy. While electronic health records and next 
generation sequencing techniques have enabled much of the early applications for precision medicine, the 
human genome only represents a fraction of the information present and important to a person’s health. A 
person’s proteome (peptides and proteins) and glycome (glycans and glycosylation patterns) contain 
biomarkers that indicate health and disease; however, tools to detect and analyze such biomarkers remain 
scarce. Thus, precision medicine databases are lacking a major source of phenotypic data due to the 
absence of available methods to explore these domains, despite the potential of such data to allow further 
stratification of patients and individualized therapeutic strategies. 
 Available methods to detect non-nucleic acid biomarkers are currently not well suited to address 
the needs of precision medicine. Mass spectrometry techniques, while capable of generating high 
throughput data, lack standardization, require extensive preparative steps, and have many sources of errors. 
Immunoassays rely on antibodies which are time consuming and expensive to produce for newly 
discovered biomarkers. Aptamers, analogous to antibodies but composed of nucleotides and isolated 
through in vitro methods, have potential to identify non-nucleic acid biomarkers but methods to isolate 
aptamers remain labor and resource intensive and time consuming. 
 Recently, microfluidic technology has been applied to the aptamer discovery process to reduce the 
aptamer development time, while consuming smaller amounts of reagents. Methods have been 
demonstrated that employ capillary electrophoresis, magnetic mixers, and integrated functional chambers 
to select aptamers. However, these methods are not yet able to fully integrate the entire aptamer discovery 
process on a single chip and must rely on off-chip processes to identify aptamers. 
 In this thesis, new approaches for aptamer selection are developed that aim to integrate the entire 
process for aptamer discovery on a single chip. These approaches are capable of performing efficient 
aptamer selection and polymerase chain reaction based amplification while utilizing highly efficient bead-
based reactions. The approaches use pressure driven flow, electrokinetic flow or a combination of both to 
transfer aptamer candidates through multiple rounds of affinity selection and PCR amplification within a 
single microfluidic device. As such, the approaches are capable of isolating aptamer candidates within a 
day while consuming <500 µg of a target molecule. 
 The utility of the aptamer discovery approach is then demonstrated with examples in precision 
medicine over a broad spectrum (small molecule to protein) of molecular targets. Seeking to demonstrate 
the potential of the device to generate probes capable of accessing the human glycome (an emerging 
source of precision medicine biomarkers), aptamers are isolated against gangliosides GM1, GM3, and GD3, 
and a glycosylated peptide. Finally, personalized, patient specific aptamers are isolated against a multiple 
myeloma patient serum sample. The aptamers have high affinity only for the patient derived antibody.  
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Chapter 1: Introduction 
1.1. Precision Medicine 
Precision medicine involves precisely adapting therapies to subclasses of disease by incorporating 
individualized genetic, biomarker, phenotypic, or psychosocial characteristics of a patient [1]. Precision 
medicine looks to address the reductionist nature of traditional medicine which generally disregards 
underlying mechanisms of symptoms, and may define multiple unique diseases into one disease with 
shared symptoms [2]. Essentially precision medicine seeks to stratify individuals into smaller groups and 
apply treatments which have been demonstrated to be effective in those groups [3, 4]. It is in opposition to 
traditional medicine which has sought to find a single treatment that helps the most people (one size fits 
all), rather effective treatments for targeted population groups are desired. 
The goal of precision medicine is to enable clinical decisions based on an individual’s variations in 
genes, proteins, environment and lifestyle. This information allows clinicians to tailor disease treatment and 
prevention strategies for subgroups of disease with similar symptoms. Thus, there is increased emphasis 
on the identification of new biomarkers which can be used to reveal these underlying mechanisms affecting 
a patient’s health.  
While the concept of tailored treatments has been around for millennia, the ability to interpret large 
datasets is new [5]. Diagnosis and treatment traditionally relied on physical exams, signs and symptoms, 
experience and personal expertise. Now technological advances are allowing the generation of massive 
data networks from large patient cohorts which can be mined to find the underlying mechanisms of healthy 
and disease conditions [6] (Figure 1.1). A confluence of biological, computational, computer, and 
engineering has enabled these large datasets to be generated and analyzed. Thus, precision medicine is 
not a new concept, rather it is a shift in the way information is collected and organized which alters the way 
research is conducted and patients are treated.  
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Figure 1.1: Precision medicine research strategy. “Omics” information is gathered to group patients and 
develop personalized therapies [7].  
1.1.1. Examples of Precision Medicine 
While precision medicine has been applied to the study and treatment of many diseases, a few 
examples on precision medicine in cystic fibrosis, cancer, and the glycome will serve to illustrate the 
applications and promise of this emerging and exciting paradigm of medicine.  
1.1.1.1. Cystic Fibrosis 
The genetic make-up of a person contributes to a patient’s health and has been found to be useful in 
making optimal treatment decisions [8]. One case where this is strongly observed is in cystic fibrosis. Of 
the over 1,900 cystic fibrosis related mutations, it has been found that 80% of U.S. patients have the 
F508del mutation [9]. As a result, therapies that modulate the function of protein related to this mutation 
have been developed [10]. Additional therapies (lumacaftor/ivacaftor) have been released for individuals 
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that contain two copies of this mutation. Therefore, clinicians today can request genetic tests for cystic 
fibrosis patients and tailor the treatment based on the presence of a genomic biomarker from the test. 
1.1.1.2. Adenocarcinoma 
The application of precision medicine to cancer has also attracted considerable interest, especially in 
lung cancer treatment. Lung cancer was previously divided into small cell carcinoma, non-small cell 
squamous cell carcinoma, non-small cell adenocarcinoma and large cell carcinoma subtypes which 
were identified by histology. The application of high-throughput sequencing techniques has now found 
more than 15 genes related to oncogenesis of lung cancer (Figure 1.2) [11]. Of these, a mutation to the 
epidermal growth factor receptor (EGFR) gene within positive non-small cell lung adenocarcinoma is 
now its own taxon within adenocarcinoma and has a unique treatment strategy relying on tyrosine kinase 
inhibitors [12]. Additional treatment strategies for the other mutations still attract interest and have 
potential to become their own adenocarcinoma subtypes if companion therapeutics emerge [13]. 
 
Figure 1.2: A time history of the identification of genomic biomarkers for lung cancer [14]. 
1.1.1.3. Glycome 
 While considered still in its infancy, the study of a patient’s glycome, particularly the IgG glycome, 
has been used to make personalized therapy decisions. Galactosylation levels of IgG have been shown to 
be useful indicators of rheumatoid arthritis, and osteoarthritis [7, 15-19]. Furthermore, N-glycome profiling 
has been used on cardiac surgery patients and it has been found that the glycosylation patterns of patients 
before and after surgery could be used to cluster patients and predict the severity of the inflammatory 
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response resultant from surgery. Thus, the glycosylation patterns could be used to inform individual surgery 
maintenance strategies [16]. 
1.1.2. Tools for Identifying Precision Medicine Biomarkers 
Precision medicine relies on the identification of biomarkers to stratify patients. Here an overview on 
the available techniques to identify genomic and proteomic biomarkers are discussed.  
1.1.2.1. High-Throughput Sequencing 
Substantial progress in precision medicine has been from the introduction of high-throughput genomic 
technologies combined with computational frameworks and electronic health records. With sequencing time 
and cost following a trend similar to Moore’s Law, today it is possible to sequence an entire human genome 
for under $1000 in a day [20, 21].  This accessibility has led to many clinical studies on genomics and, as 
expected, genomic information has revealed many of the genetic bases of cancer. Today molecular testing 
is routinely used for breast, lung, and colorectal cancers [22]. Further national efforts plan to combine 
electronic health records with newly acquired genomic information on large populations to create a 
database that can be data mined to discover new disease correlations [23]. The ambitious Precision 
Medicine Initiative (also known as All of Us) seeks to sequence one million American genomes with a near-
term focus on cancers and a longer-term focus on other disease and health factors [4].  
High-throughput sequencing allows analysis of an entire human genome in a single reaction. Typically, 
a genome (~3.2 billion bases) is fragmented into many shorter sequences, on the order of hundreds of 
bases, which are then read by a sequencer. Most modern sequencers use an optical readout (fluorophore) 
or changes in ionic concentration (detection of H+ ions) to gather sequence information either during a DNA 
ligation reaction, where a fluorescently modified probe hybridizes to the DNA fragment, or during DNA 
synthesis, where polymerase and a probe are used to generate a signal during DNA elongation. In either 
case, the sequence of the fragments are obtained which are then compiled back into a complete genome 
[20]. At the most basic level, researchers and clinicians can then investigate a genome for known mutations 
or new biomarkers may be identified by correlating patient groups, disease and mutations. 
Genomics offers insight into hereditary predisposition for many conditions but is unable to detect the 
extent of disease manifestation or the response of the disease to therapy. Moving one layer up, the 
transcriptome has also been extensively explored using the same techniques as genomic technologies. 
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High-throughput determination of the transcript levels of thousands of genes is possible, but this information 
is not easily translated to functional proteins and their post-translational modifications, which have long 
been recognized as important in many diseases [24-28].  
Other –omics fields, such as proteomics, transcriptomics, and glycomics, among others, also contain 
a wealth of information relevant to health, disease and precision medicine. While 40,000 genes exist in the 
human genome, the human proteome is estimated to contain more than 500,000 proteins [29]. Adding to 
this complexity, half of the human proteins are further modified through glycosylation [30]. Protein 
biomarkers can be prognostic or predictive; however, there remain limited tools for the identification of non-
nucleic acid biomarkers in disease [31]. 
1.1.3. Immunoassays for Biomarker Identification 
Immunoassays, diagnostic tests which use an antibody with affinity and specificity for a molecule of 
interest, remain the gold standard and the most commonly used diagnostic assays for the measurement of 
phenotypic biomarkers [32]. In an immunoassay the presence or concentration of a biomarker is achieved 
through a specific binding interaction between the antibody and the biomarker [33]. The first immunoassays 
were developed in the 1960s using radioisotopes for labeling and a gamma counter for measuring [34]. 
While these tests can be performed at high sensitivity and low cost, the potential health and safety concerns 
led to the development of enzyme based methods, including the enzyme linked immunosorbent assay 
(ELISA) [35]. ELISA is usually performed in multiple steps where antigens from a sample are first 
conjugated to a surface. Then a specific antibody, with an enzyme linked to it, for the antigen of interest is 
applied to the surface. Finally a substrate for the enzyme is added which results in some detectable signal, 
usually a color change of the substrate.  
ELISA is used in many clinical tests but it is limited by the quality and breadth of available antibodies. 
Successful assays rely on antibodies that are able to be immobilized while maintaining the activity of the 
antigen, that are accessible to antigens in solution and that have low non-specific absorption [32]. 
Furthermore, for a particular antigen to be measured with high sensitivity an antibody with high affinity must 
be available. While antibodies remain the fastest growing group of pharmaceutical molecules, the average 
time to develop an antibody is 8 years and the average cost is $2.8 billion [36]. Currently there are 30 
 6 
 
monoclonal antibodies approved for clinical use by the FDA and, there are 205 assays approved by the 
FDA for measurement of proteins, translating to approximately 1% of the human protein gene products [37, 
38]. In the last 15 years there have been only 1.5 new protein analytes introduced per year [39].  
1.1.4. Mass Spectrometry 
Mass spectrometry offers a high throughput method to analyze proteins in a sample. It is capable of 
determining the molecular weight, amino acid sequence, and post-translational modifications of its 
constituent sample [40]. The technique involves the ionization of chemical species and then the sorting of 
ions based on mass-to-charge ratio. As such, the technique involves two steps: ionization and detection. 
During ionization a neutral molecule becomes ionized through the addition or loss of charge by protonation, 
deprotonation, cationization, electron ejection, or electron capture. Each ionization method has advantages 
and limitations for particular classes of molecules. For example, deprotonation is very useful for acidic 
species, and peptides are often ionized by protonation. Once ionized the molecules travel through a vacuum, 
sometimes through a quadrupole, which filters or fragment ions, and finally to a detector. The result is a 
large set of data on the various mass and charges in the original sample, usually in the form of a spectrum 
of peaks at various mass points. This spectrum can be compared to known reference spectrum to identify 
the original contents of the sample [41-43] 
While Mass spectrometry is a powerful tool that has been used in numerous precision proteomics 
applications the clinical adoption of mass spectrometry is still met with challenges [44-57]. Generally, the 
mass spectrometry field lacks standardization despite a multitude of normalization efforts [58]. This places 
a significant burden on preparative steps which has resulted in large variations in reproducibility [59]. 
Considering the wide range of concentrations peptides exist in serum, separation methods are usually 
necessary prior to MS to obtain sufficient resolution but this also limits its potential throughput [48]. Thus, 
disease biomarkers identified by mass spectrometry have still been from highly abundant proteins and less 
abundant proteins remain difficult to discern [60, 61].  Large proteins are not able to be analyzed in native 
form by MS and instead require fragmentation by trypsin prior to analysis, but this digestion introduces a 
major source of error and can produce variable results if reaction conditions are not carefully optimized [62, 
63]. These shortcomings are perhaps best illustrated by the OVA1 test for ovarian cancer which was initially 
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developed on an MS based system but could not reach clinically acceptable levels of precision [64]. In the 
end, the test was re-engineered onto an immunoassay [65]. Ultimately mass spectrometry remains a 
seldom used tool in clinical practice, and no mass spectrometry devices have been approved for the 
measure of proteins and peptides by the FDA for marketing or for clinical trials [66].  
1.2. Aptamers  
Aptamers represent an emerging class of molecules with potential for sensitively detecting non-nucleic 
acid biomarkers in standardized assays, and therefore could be attractive reagents for identifying precision 
medicine biomarkers. Aptamers are single stranded oligonucleotides that can bind to a biomarker with high 
specificity and affinity. They were originally discovered in 1990 by the independent research of Larry Gold 
(who coined the term for the aptamer discovery process – systematic evolution of ligands by exponential 
enrichment) and Jack Szostak (who named these affinity reagents “aptamers”) [67, 68]. It was immediately 
clear from these early efforts that RNA was a “shape not a tape,” and a new affinity molecule had been 
discovered with potential for measuring a wide range of targets [69]. Indeed aptamers have been presented 
with affinities to basically all types of molecules including small molecules [70], peptides [71], amino acids 
[72, 73], proteins [74, 75], cells [76, 77], viruses [78, 79], inorganic compounds [80, 81] and bacteria [82].  
 Aptamers have several advantages over other affinity reagents (such as antibodies). First, new 
aptamers are discovered through a totally in-vitro process obviating the need for host animals and 
immunogenics [78, 83-86]. Once discovered, aptamers can be synthesized by a DNA synthesizer which 
can produce oligonucleotides at low cost and with limited batch-to-batch variability, and lyophilized allowing 
storage for long periods of time at room temperature without degradation. Binding interactions can be 
reversed with generally mild conditions which do not degrade the analyte or ligand and allow reusability of 
either or both molecules [87]. Aptamers also can be easily modified to incorporate fluorophores (fluorescein, 
TAMRA, Cy5, ROX, and Alexa among many others), attachment linkers (biotin, thiol, amine), or modified 
bases.  Furthermore aptamers have little or no immunogenicity and have much lower molecular weight than 
antibodies allowing much higher diffusion rates [88]. The selection conditions can be modified to 
accommodate the conditions for which the aptamer is being developed to be used in (including physiological 
conditions), unlike antibodies which can only be selected for in physiological conditions [89]. 
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 Although early aptamers were composed of unmodified RNA, aptamers can also be composed of 
deoxyribosenucleicacids (DNA) [90]. While, double-stranded DNA forms a double helical structure, single-
stranded DNA and RNA will form a three-dimensional secondary structure resultant from the intramolecular 
base pairing between complementary base pairs [87, 90]. In both cases helices, loops, bulges, and 
junctions are possible. No difference has been found between RNA and DNA aptamers in terms of the 
broadness of potential target molecules nor in the affinity of the aptamer towards the target; however, DNA 
aptamers benefit from the inherently more stable nature of DNA [87].  
1.2.1. Isolation of Aptamers 
 Aptamers are generated through an in-vitro process termed systematic evolution of ligands by 
exponential enrichment (SELEX) which is a form of combinatorial chemistry where large libraries are 
synthesized and screened for their affinities towards a target [86, 87, 91]. This process relies on a 
synthesized starting library which features a randomized region (10-80 nucleotides long) flanked by a 
defined 5’ end and a defined 3’ end [92]. Consequently, a library will be composed of a large diversity of 
single-stranded oligonucleotides (1015 different sequence) that can all be amplified by a single set of 
polymerase chain reaction (PCR) primers due to the defined 5’ and 3’ regions. The diversity of the library 
is sufficiently large that it is assumed oligonucleotide strands exist with high affinity towards a target of 
interest in the library.  
SELEX is a discovery process, where sequences of high affinity are found from a large, highly 
diverse library. In general, these high affinity strands are isolated from the library through repeated cycles 
of affinity selection, partitioning and amplification [87]. Affinity selection consists of incubating the library 
with a target molecule of interest, either by immobilizing the target on a column and flowing oligonucleotides 
across the column or by weakly immobilizing the library and using the target to elute binding strands. Once 
the library has been incubated with the target, non-binding and weakly binding candidates are removed 
from the target by buffer washes, leaving only library members which strongly bind to the target. Then the 
target is subjected to changes in temperature or ionic conditions to release the binding library members 
from the target. A second selection phase is also possible where the eluted library members which 
previously bound to the target are incubated with a molecule similar to the target (named the counter target) 
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for which the desired aptamer is sought not to bind. In this case, the sequences which do not bind to the 
counter target are collected and the sequences which bind to the counter target are discarded. This 
selection phase is termed counter selection and is designed to remove oligonucleotide members which 
non-specifically bind to the target. These released members are collected and amplified by PCR using 
forward and reverse primers complementing the defined region on the library. PCR generates double-
stranded sequences that are reduced to single stranded sequences by affinity methods or other methods 
[93]. The now single-stranded DNA is reintroduced to the target to start another round. Therefore, the 
oligonucleotides which bound strongly in the first round must now compete with each other for binding in 
the second round. The process continues until the starting library has sufficiently converged to a few 
sequences of high affinity. It is possible to monitor the affinity of the entire oligonucleotide pool (which will 
contain many different sequences) or to sequence the members of the pool and test individual sequence’s 
affinity and specificity (Figure 1.3). 
 
Figure 1.3: The SELEX process, consisting of multiple rounds of selection, counter selection, 
amplification, and conditioning. An aptamer library is incubated with a molecular target. Weakly binding 
oligonucleotides are removed by buffer washes. A counter target is then introduced, and oligonucleotides 
with affinity towards the counter target are removed. The remaining strands are PCR amplified, 
conditioned back to single-stranded oligonucleotides, and the process continues. 
Selection
Target
Wash
Amplification
Random library
Evaluation
Counter Target
Counter Selection
Conditioning
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While aptamers have been employed in many relevant applications and for a wide range of targets, 
the application of aptamers to precision medicine fields remains unexplored because the time and resource 
consuming nature of the SELEX process. Significant effort has been placed on automating this process 
with coupled robotic selection and amplification; however, the sample consumption remains too wasteful to 
realistically approach precision applications.  
1.3. Generation of Aptamers with Microfluidic Technology 
Naturally microfluidic and lab-on-chip technologies which seek to provide integrated fluidic reaction 
modules in microscale geometries, have been under development for the rapid selection of aptamers at 
low cost [94, 95]. Generally, the selection stage of the SELEX process relies on the efficient and specific 
capture of candidate oligonucleotide strands on target functionalized surfaces. Because surface area 
scales at l2 where l is the length of an object, and volume scales at l3, the surface area to volume scales at 
l-1 meaning as objects become smaller the surface-area-to-volume ratio increases. The larger surface-area-
to-volume ratios allow more intimate interactions between the aptamer candidates and targets with reduced 
surface area available for structural materials which can make the selection process unsuccessful from 
non-specific binding.  As such, more binding sites are available for a given volume in microfluidic systems. 
Further, microfluidic systems can be highly integrated, efficiently transitioning from various stages of 
selection while handling small amounts of material, reducing the amount of waste generated and 
decreasing the amount of time spent on labor intensive procedures. Particularly attractive, these 
approaches have a high potential for automation and multiplexing to allow high-throughput SELEX.  
In general, microfluidic SELEX approaches rely on the advances from the computing industry which 
made high resolution, high throughput, and small scale chips possible [96]. Most of the reported devices 
are made of polydimethylsiloxane (PDMS), a clear, biologically inert, polymer with the ability to have small 
features imprinted into its surface [97]. Furthermore, PDMS is able to be strongly sealed to many substrates 
by simply exposing both surfaces to oxygen plasma and then placing them in contact with one another [98]. 
Typically, a mold featuring chambers and channels is fabricated by photolithography in clean room settings 
onto a silicon substrate using additive processes [97]. Liquid PDMS is then poured onto the mold and 
allowed to harden by heating. The hardened PDMS is peeled off, inlets and outlets are punched, and it is 
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bonded to another substrate to complete the fabrication. More complicated architectures with multiple layers 
of PDMS bonded to each other are possible and are usually necessary when valves, pumps, or mixers are 
integrated into the system. [99]. 
1.3.1. CE-SELEX 
Capillary-electrophoresis SELEX systems (CE-SELEX) were the first microfluidic systems applied to 
aptamer generation [100]. This method involves incubating an aptamer library with a target molecule and 
subjecting them to capillary electrophoresis based separation. Capillary electrophoresis can finely separate 
molecules based on size and charge, thus, a complex formed by an aptamer candidate binding to a target 
molecule can be distinguished and collected from free aptamer and from free target. The isolated complex 
is then amplified by PCR, conditioned back to single-stranded oligonucleotides are reintroduced to the 
target for further rounds of capillary electrophoresis. This approach has been used for proteins (IgE) [100], 
human immunodeficiency virus-reverse transcriptase (HIV-RT) [101], human vascular endothelial growth 
factor 165 (hVEGF165) [102], α-fetoprotein [103], and human epididymis protein 4 (HE4) [104]. The 
approach has been further improved to allow selections without intermediate amplification steps between 
selections and has been termed Non-Equilibrium Capillary Electrophoresis of Equilibrium Mixtures 
(NECEEM) [105]. The NECEEM method was used to isolate aptamers with affinity towards the h-RAS 
protein. 
One advantage of the CE-SELEX method is the separation principle can also be used to evaluate 
binding parameters including dissociation equilibrium constants and rate constants [100-105]. This can be 
important because aptamers can be sensitive to the conditions they were selected in, resulting in aptamers 
with high affinity to the target during the selection stage but limited affinity towards the target in other binding 
assessment assays. Furthermore, CE-SELEX allows binding interactions to occur in solution without the 
need for potentially target altering functionalization onto a surface [100].  
Conventional CE-SELEX is limited to molecules that generate large mobility shifts, including large, 
charged molecules, although examples have been presented with small molecules including the 580 Da 
small-molecule N-methyl mesoporphyrin IX when additional rounds of selection were used [102]. Another 
limitation of CE-SELEX is the small sample volumes the system is able to accommodate. Injection volumes 
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are less than 10 nL which limits the diversity of the library used in the selection process [95]. Even at high 
concentrations of DNA, a 10 nL volume practically features only 1012-1013 oligonucleotides which is orders 
of magnitude less than traditional SELEX. Furthermore, the approach only seeks to speed up the selection 
stage and still relies on labor intensive conventional PCR and strand separation to start a new round of 
SELEX. 
1.3.2. Magnetic SELEX 
Microfluidic approaches which use carefully designed mixers to increase selection stringency have 
been developed to speed up the SELEX process. Soh and coworkers developed a system consisting of a 
microchannel with imbedded micropatterned ferromagnetic patterns to enable sensitive control of magnetic 
beads in the channel [106]. Target-functionalized magnetic beads were mixed with aptamer library and 
introduced under constant flow into two channel inlets on the outside of the channel while a magnet is held 
beneath the device. Ferromagentic structures focus the magnetic beads from the outside of the channel to 
the center of the channel under continuous laminar flow conditions. As a result, target functionalized 
magnetic beads and aptamer candidates which have bound to them traverse down the center channel to a 
center outlet while non-binding aptamer candidates remain in solution phase at the perimeter of the channel 
and exit the device through the two waste outlets. The collected sequences are then PCR amplified and 
conditioned back to single-stranded oligonucleotides. A bulk pool affinity (KD) after only a single round of 
SELEX was found to be 33 nM [106]. An improved device was developed to reduce the dependence on 
carefully setting up the device under a microscope and to improve the device robustness. In the improved 
device, target functionalized beads are mixed with library and injected in the device [106]. Rather than 
focusing the magnetic beads to the center of the channel, the device immobilizes the magnetic target-
functionalized beads on micro patterned Ni features while a magnetic field is applied by a permanent 
magnet. Buffer is then introduced to wash away weakly, and non-binding aptamer candidates. Finally, after 
sufficient washing, the magnetic field is removed and the target-functionalized beads and their bound 
aptamers were collected. These devices have been used to isolate aptamers in under 4 rounds towards 
streptavidin [107], Botulinum neurotoxin type A [108], apolipoprotein A [109], platelet derived growth factor 
B [107], and thrombin [109] with nanomolar dissociation constants. These devices improve the selection 
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stage of SELEX but do not offer improvements to the other phases of the SELEX including counter selection, 
amplification and strand separation processes. 
1.3.3. Non-Magnetic Bead-Based SELEX 
Magnetic beads provide a convenient method to immobilize a target functionalized surface within a 
chamber while increasing the binding sites but the high degree control afforded by microfabrication 
techniques make non-magnetic immobilization possible. A simplified selection chip consisting of a single 
channel with two pinched regions was developed [110]. Counter target-functionalized were injected through 
an inlet connected to one pinched region filling the channel with counter target beads up to the pinched 
region. Downstream to that pinched region was a second pinched region with another inlet. Target beads 
were introduced through this inlet to create a second region filled with target beads. The pinch regions 
prevented microbeads from passing allowing devoted regions of the channel to be filled with target and 
counter target beads.  Thus, a fluidic channel with a counter target-functionalized bead region and a target-
functionalized bead region was created. An aptamer library was then injected through this channel such 
that aptamer candidates would first interact with the counter-target beads, removing library members with 
affinity towards the counter target, before reaching the target-functionalized bead region and being allowed 
to bind to the target-functionalized beads. The target-functionalized region was then washed to remove 
weakly binding oligonucleotides, and finally eluted and collected. From the aptamer candidates were 
amplified off-chip and conditioned back to single stranded DNA, and reinjected into a freshly setup device. 
The chip was used for six rounds of SELEX to isolate an anti-myoglobulin aptamer (KD = 4.93 nM). 
Another microfluidic chip was presented foregoing beads altogether. Instead a protein microarray was 
created and then bonded to a microfluidic network of channels [111]. As such, aptamers flow across a 
series of counter-target regions before reaching the region of the target molecule. After interaction with the 
target molecule and washing, the fluidic network was torn off the microarray. Since a microarray was being 
used, it could be readily scanned to monitor the success of the selection process. The method was used to 
isolate a Lactoferrin aptamer in seven rounds with dissociation constants down to 0.92 nM. While, using a 
microarray to deposit target and counter target molecules allowed a straightforward immobilization 
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procedure it also limited the target region to a small area located on the bottom of the fluidic channel. 
Compared with bead filled channels, this method has reduced surface area devoted to target presentation.  
SELEX on whole cells have been performed using an inertial device (termed I-SELEX) [112]. The I-
SELEX device is a spiraling channel with inlets for sheath flow and samples, and outlets for waste and 
sample collection. Library was mixed with red blood cells and then injected in the sample inlet. Dean drag 
forces cause solution phase aptamers to migrate towards the outer wall while aptamers bound to the red 
blood cells remain on the inner channel. Similar to the magnetic bead based devices, this method allows 
efficient portioning of binding sequences from non-binders under constant flow conditions which have the 
additional benefit of simultaneously washing the target. After five rounds of SELEX, aptamers with 
nanomolar affinity were found towards cell surface markers.  
1.3.4. Sol-Gel SELEX 
Microfluidic approaches have also focused on increasing the target presentation to increase the 
selection efficiency. These techniques seek to overcome the concern for biased selection procedures which 
only select aptamers for targets immobilized in a specific manner. Sol-gels have been used to encapsulate 
and immobilize targets in a more native state within microfluidic channels [113-115]. Sol-gels with target 
proteins are mixed and deposited as a droplet onto a substrate. A PDMS mold with patterned microchannels 
is exposed to oxygen plasma, along with the sol-gel substrate, and is stamped onto the substrate to 
complete the fabrication. The porosity of the gel allows oligonucleotides to access the trapped target 
molecules and the device uses integrated heaters for thermal based elution to disrupt binding interactions 
between the target and aptamer candidates. Sol-gel SELEX device have identified aptamers towards the 
TATA binding protein [116], a yeast transcription factor [115], enhanced green fluorescent protein, and a 
heat shock factor. The sol-gels allow a high density of protein making it an attractive option for multiplexed 
selections which have been performed with 5 parallel selections each for aptamers with a different target. 
However, sol-gel preparation is a lengthy process that takes more than 12 hours, and the library must be 
incubated with the target for long periods of time (~1 hr) to allow diffusion of library members into the sol-
gel, and presented devices use small reaction chambers (0.22 µL) during this incubation process limiting 
the diversity of the library for the selection process.  
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1.3.5. Integrated Microfluidic Systems 
Rather than speed up a single stage of the SELEX process, researches have tried to use the ability 
of microfluidic devices to integrate the many different reactions of SELEX into a single fluidic architecture. 
The SELEX process relies on repeated rounds of affinity binding, partitioning and elution of binding library 
members, PCR based amplification of these members, and conditioning of the PCR product back to single-
stranded DNA for further rounds of SELEX. Taken individually, all these steps have been demonstrated on 
dedicated microfluidic devices. By combining the substeps of SELEX onto a single-platform, the process 
can be performed with minimal sample loss between stages, low-volumes and thus low sample 
consumption for the entire process, and with a higher degree of automation. 
1.3.5.1. Automatic Integrated Systems 
An early effort in an integrated SELEX process was presented by Hybarger, et al. where a series of 
reagent-loaded microlines and a microline reaction chamber to fully automate the steps of transcription, 
selection, reverse-transcription, and amplification [117]. The automated system was used to find an anti-
lysozyme aptamer. Despite the use of microfluidics the overall footprint of the system, and reagent 
consumption remained quite large. However, it remains the only integrated SELEX device demonstrated to 
be capable of performing reverse-transcription and transcription which are necessary for the handling RNA 
libraries.  
1.3.5.2. Integrated Devices Capable of Accomplishing a Single Round of SELEX 
The first chip-based microfluidic approaches were presented by Gwo-Bin Lee’s group [114, 118]. 
The devices consisted of a glass substrate with a patterned heater and temperature sensor and two PDMS 
slabs – one bearing a fluidic network where SELEX would occur and the other bearing microfluidic flow 
control elements. The fluidic network featured reaction chambers for selection, PCR chambers, while the 
control elements consisted of micromixers and microvalves to direct oligonucleotides through the SELEX 
process. Targets are functionalized with magnetic beads off-chip, mixed with the aptamer library and this 
mixture is injected into the chip using the integrated micropumps while a magnet was held beneath the 
reaction chamber to immobilize the target functionalized beads. Buffer is then introduced into the chip to 
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remove solution-phase, weakly binding oligonucleotides from the target functionalized beads. Following 
washing, PCR reagents were introduced into the chamber and the integrated heater was used to amplify 
the remaining aptamer candidates. These systems have been further developed to include counter target 
chambers and dedicated PCR chambers [118]. Such embodiments rely on eluting target binding 
oligonucleotides by using off-chip heaters placed beneath the selection chamber. The eluted product was 
pumped through a chamber containing counter-targets before finally reaching the PCR chamber for 
amplification. Early devices were used to isolate anti-protein aptamers but later devices were used to isolate 
aptamers with affinity towards whole cells.  
Ultimately, the presented integrated systems could complete a round of SELEX in ~1 hour which 
is a drastic improvement over conventional SELEX (~1 day). While these systems stored all reaction 
materials on the device itself, it severely limits the volumes for some of the SELEX stages. For example, 
washes to remove weakly binding oligonucleotides could only use volumes up to 300 µL. Moreover, the 
devices are only capable of performing a single round of the SELEX (one incubation, elution, partition of 
binding strands, and amplification of binding strands) and must be transferred to a new device for further 
rounds. Furthermore, the devices still rely on manual, off-chip processes to condition the amplified product 
back to a solution of single stranded oligonucleotides that does not include the complement generated 
during the PCR product.  
1.3.5.3. Integrated Devices Capable of Accomplishing Multiple Rounds of SELEX 
Integrated devices capable of multiple rounds of SELEX on a single device have also been pursued 
[119, 120]. These devices have, thus far, been PDMS fluidic networks bonded to a substrate featuring 
heaters and temperature sensors. Generally, the devices included two reaction chambers – one for affinity 
selection and one for PCR based amplification connected by microchannels. The SELEX process is 
achieved by oscillating between these two reaction chambers. Key to these devices was the incorporation 
of bead based reactions for all steps of the SELEX process. Target functionalized beads were used for the 
selection stages and reverse primer functionalized beads were used for the PCR stage. Target-
functionalized beads were introduced into the selection chamber and held by microweir - a dam like 
constriction that allows buffer to pass but is too constrained to allow the passage of the much larger beads. 
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Library is injected through these selection beads causing library members with affinity towards the target 
of interest bound to target-beads in the selection chamber. The chamber is then washed to remove weakly 
binding strands. The remaining strands are eluted from their target molecules through modest increase in 
temperature and transferred to the PCR amplification chamber where they interact with reverse-primer 
functionalized beads. Due to the complimentary of the reverse primer and the 3’ end of the library members, 
hybridization occurs between the transferred library members and the reverse primers resulting in library 
members hybridized to reverse primer beads which are in turn attached to bead surfaces. Reverse primer 
functionalized beads were created by mixing biotinylated reverse primer with streptavidin beads. The 
inclusion of the reverse primers only on bead surfaces results in the generation of double stranded DNA 
where the amplified input strand is hybridized to its compliment which is in-turn tethered to the bead surface 
through biotin-streptavidin interactions. Thus, under de-hybridizing conditions (e.g. thermal denaturation or 
mild NaOH treatment) the amplified aptamer DNA can be released into the solution phase while its 
compliment which was generated as a byproduct of the PCR process remains attached to the bead surface. 
Under flow conditions the released amplified product can be transferred back to the selection chamber (with 
replenished target) for further rounds of SELEX. Additionally, these devices were shown to be able to 
sensitively control the environmental conditions of the selection process to obtain aptamers with unique 
properties. For example, by using an integrated heater and temperature sensor located under the selection 
chamber the selection temperature could be set to physiological temperature. The resulting aptamer 
candidates exhibited increased binding at physiological conditions compared to room temperature 
conditions [120]. While the overall device operation and setup were simple, the device did not feature any 
barriers between selection and amplification processes which increased the potential for unintentional 
amplification of oligonucleotides with high non-specific interactions. Aptamers were isolated with affinity 
towards IgE and glucose-boronic acid using these methods. 
Devices were also developed where the coupling between selection stages and amplification 
stages (and back) was achieved through electrokinetic methods which reduced the dependence on 
complicated fluidic handling components (e.g. syringe pumps and valves) [119]. The device featured a 
selection chamber and PCR amplification chamber which were separated by a channel filled with agarose 
gel. The agarose gel prevents diffusion from one channel to the other. When an electric field was applied 
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between the two chambers the agarose allowed migration of the aptamer candidates while preventing the 
migration of target molecules or other potential sources of cross contamination. In this way, selection and 
amplification could be performed in different buffers. In addition to demonstrating successful isolation of 
aptamers using surface immobilized targets, by weakly hybridizing DNA to beads and introducing the target 
in solution aptamers were isolated towards small molecule targets in solution. As such, the approach was 
capable of selecting aptamers towards a broad range of targets and was not limited to targets that are 
amenable to surface attachment chemistry. However, the agarose gel tended to break down after three 
rounds of selection limiting the amount of cycles performed on chip. Such an issue could be catastrophic 
for targets that require additional rounds of SELEX to obtain sufficient convergence of the starting library. 
Furthermore the device exposed the target to potentially deleterious electric fields prior to and during affinity 
selection which could compromise the integrity of the target or adversely affect target-aptamer binding. 
1.3.6. Generation of Aptamers with Microfluidics Technology Summary 
 In summary, precision medicine lacks reagents for accessing non-nucleic acid molecules. 
Aptamers are affinity reagents with potential to allow the detection of many molecules, and when combined 
with microfluidic technology could rapidily isolate aptamers. Such approaches would allow the generation 
of many precision medicine probes at low cost. Microfluidic devices have been successful in isolating 
aptamer reagents for many targets but their full potential is yet to be achieved. Currently presented 
microfluidic SELEX devices either are only capable of improving the selection stage of SELEX or are poorly 
suited to handle the many rounds of SELEX that may be necessary for highly specific aptamer isolation. It 
is the goal of this thesis to develop an approach to rapidly isolate aptamers while reducing the amount of 
resources consumed and to apply this approach to several precision medicine relevant biomarkers.  
1.4. Objective and Significance 
 This thesis seeks to develop methods for the rapid isolation of high affinity and high specificity 
affinity probes which can ultimately be applied to precision medicine. While the Human Genome Project, 
and next generation sequencing techniques have enabled much of the early applications for precision 
medicine, the human genome only represents a fraction of the information present and important to a 
person’s health. Non-nucleic acid biomarkers (peptides, proteins, and their glycosylated versions) are 
strong indicators of health and disease but tools to detect and analyze these biomarkers remain scarce. 
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Furthermore, techniques to develop new detection assays are too time consuming and resource 
consumptive to be broadly applied within precision medicine applications. The specific objectives of this 
thesis are: 
 Development of aptamer selection methods which can isolate aptamer candidates rapidly (within a 
day) for a wide range of targets while consuming small amounts of reagents and samples. Such 
methods will enable the isolation of probes at a scale capable of addressing the needs of precision 
medicine. 
  Application of the methods to biomarkers relevant to precision medicine. Aptamers will be isolated 
against glycans, glycosylated peptides, monoclonal proteins, and a patient’s tumor associated 
protein. These aptamers can potentially be applied to glycome profiling and personalized cancer 
diagnostics. 
1.5. Contributions 
1.5.1. Contributions to Engineering of Aptamer Isolation 
The engineering contributions of the thesis primarily include the development of methods that reduce the 
amount of time and materials needed to isolate aptamers. These methods are realized with microfluidic 
devices which integrate the entire SELEX process.  
 Development of an electrophoretic, and pressure-driven hybrid SELEX method. A microfluidic 
approach which combines electrophoretic and pressure-driven oligonucleotide transfers is used to 
integrate the SELEX process. The hybrid approach simplifies the device design and operation 
procedures by reduced pressure-driven flow control requirements, and avoids the potentially 
deleterious exposure of targets to electric fields prior to and during affinity selection. 
 Development of a free solution electrokinetic SELEX method. A microfluidic approach which allows 
integration of the affinity selection and amplification stages of SELEX by combining bead-based 
biochemical reactions with free solution electrokinetic oligonucleotide transfer. 
 Development of a SELEX approach which integrates selection, counter selection and amplification. 
Counter selection is incorporated into every selection round without any significant increase in 
selection time, materials, or reagents. The device is also designed to allow many rounds of SELEX 
without degradation of the device, thereby allowing selection of aptamers towards targets with high 
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similarity to their counter targets. Therefore, the device is suitable for isolating aptamers for 
precision medicine applications.  
1.5.2. Contributions to Aptamer Isolation for Precision Medicine  
This thesis contributes to precision medicine by isolating aptamers in two important applications to 
precision medicine. First, aptamers will be isolated as reagents for the study of the glycome, an emerging 
source of precision medicine biomarkers with potential to allow stratification of patients for individualized 
therapeutic strategies. Second, aptamers will also be isolated as personalized, patient-specific probes for 
cancer diagnostics. 
Isolation of aptameric probes which recognize glycans. Glycans are involved in all human development 
activities, yet few tools to sensitively analyze glycan samples exist. Towards providing reagents for 
accessing the glycome, aptamers are selected for GM1, GM3, and GD3 gangliosides, and a glycosylated 
peptide. 
Selection of personalized aptamers for multiple myeloma. Diagnosing multiple myeloma and monitoring the 
cancer progression relies on measuring cancer-affected monoclonal proteins in serum. Standard of care 
methods for detecting these monoclonal proteins are unspecific and are not sensitive Aptamers are 
selected from a multiple myeloma patient’s monoclonal protein which was purified from a patient serum 
sample.  
1.6. Organization of Thesis 
 The thesis is divided into two parts. The first part deals with the development of new microfluidic 
methods for aptamer development with the goal of developing a microfluidic technique capable of isolating 
aptamers relevant for precision medicine applications. Chapter 2 presents a hybrid microfluidic device using 
electrophoretic and pressure driven flow to isolate aptamers in an integrated manner. The approach is 
capable of performing the selection and amplification stages of the SELEX process on a single chip. 
However, the limitations of this device motivate the development of a purely electrokinetic device as 
presented in Chapter 3. This device uses free-solution electrokinetics to address the complicated handling 
procedures and limited reliability of the device presented in Chapter 2. The device is used to enrich an 
aptamer pool with affinity towards IgA. A third device is then developed in Chapter 4. The device employs 
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three chambers to perform selection, counter selection and amplification of aptamer candidates every round 
of SELEX. These stages of the SELEX process are connected in a fluidic loop with flow controlled through 
integrated valves. With this approach many rounds (up to six tested) of SELEX can be performed on a 
single device without degradation. Thus, the approach was attractive for precision medicine applications. 
Chapter 5 uses the approach developed in Chapter 4 to isolate aptamers towards glycans. Aptamers are 
generated with affinity towards gangliosides GM1, GM3, GD3 and a glycosylated peptide. The aptamers 
have potential to be used as glycome probes. Similar to Chapter 5, Chapter 6 uses the approach developed 
in Chapter 4 to isolate aptamers with affinity towards a multiple myeloma patient cancer associated 
monoclonal protein. Finally, Chapter 7 summarizes the thesis and discusses potential future directions for 
this research.
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Chapter 2: An Integrated Microfluidic SELEX Approach using Combined 
Electrokinetic and Hydrodynamic Manipulation 
2.1. Introduction 
Aptamers are single-stranded oligonucleotides (typically 12-80 nucleotides long) that function as 
specific affinity receptors towards a broad spectrum of biological targets including small molecules [70], 
peptides [71], amino acids [72, 73], proteins [74, 75], cells [76, 77], viruses [78, 79], and bacteria [82]. With 
advantages such as synthetic availability through an in vitro process, ease of coupling to other functional 
molecular groups [121, 122], reversibility of binding, long-term stability, low immunogenicity [123], low 
batch-to-batch variability [124], and long shelf life aptamers offer an attractive alternative to other affinity 
receptors, (e.g, antibodies [86, 125]) and have broad applications to basic biological sciences[126], drug 
discovery [127], and clinical diagnostics and therapeutics [125, 128].   
Aptamers are discovered from large randomized libraries of oligonucleotides through an in-vitro 
process termed systematic evolution of ligands by exponential enrichment (SELEX) [86, 87, 91]. SELEX 
involves iterative rounds of affinity selection against a target of interest, and amplification via the polymerase 
chain reaction (PCR), of target-binding oligonucleotides from large randomized libraries (up to 1014 
members) [92]. Conventional SELEX platforms require extensive manual handling of reagents, and are 
time-consuming, typically requiring a month or more to complete a single experimental run. Robotic 
automation of the SELEX procedure can alleviate these issues but the cost is prohibitive [129].  
Microfluidic technology has been emerging to enable rapid isolation of high-affinity aptamers with 
reduced reagent consumption and in much fewer rounds of iteration [118, 130]. Microfluidic affinity selection 
has been performed, in conjunction with off-chip amplification, against targets retained using silica capillary 
walls [117], microbeads [106-108, 131, 132] or sol-gels [113-115], or against cells in solution [133, 134], to 
increase selection stringency [106-108, 131-134], create more favorable biomolecular environments [113-
115], or allow simultaneous positive and negative selections [110]. Moreover, microchips have been 
developed in an attempt to integrate the overall SELEX process using pneumatically based flow control for 
isolation of aptamers against viruses[135], cells [131, 136, 137] and proteins [138, 139]. While capable of 
performing individual affinity selection and PCR amplification processes on-chip, these devices apparently 
require an off-chip procedure to retrieve single-stranded DNA from amplified products between successive 
rounds of SELEX, and do not yet allow full integration of SELEX on a microchip. We have recently 
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demonstrated integration of the entire SELEX process using solid-phase capture and amplification of 
oligonucleotides on bead surfaces, which are manipulated using either pressure-driven flow or 
electrokinetics [119, 140]. In these works we found the use of electrokinetic manipulation simplified the 
device design but involved electric fields that can potentially comprise the integrity of the target or adversely 
affect the target-aptamer binding. Pressure-driven flow, on the other hand, in general requires extensive 
flow control operations that complicate the device design and operation.  
This chapter presents a microfluidic approach to full integration of the SELEX process on a microchip. 
The approach combines the pressure-driven and electrokinetic transport of target-binding oligonucleotides 
to exploit the advantages of both methods while minimizing their individual limitations. In this hybrid 
oligonucleotide manipulation method, affinity selected oligonucleotides are electrokinetically transferred for 
PCR amplification, while the amplified oligonucleotides are subsequently transferred back using pressure-
driven flow for further affinity selection.  The hybrid approach simplifies the device design and operation 
procedures by reduced pressure-driven flow control requirements, and avoids the exposure of targets to 
electric fields prior to and during affinity selection. In addition, bead-based reactions are used to achieve 
the on-chip coupling of affinity selection and amplification of target-binding oligonucleotides, thereby 
realizing on-chip loop closure and integration of the entire SELEX process while leveraging the advantages 
of pressure-driven and electrokinetic transport without requiring offline procedures. The utility of this hybrid 
approach is demonstrated by isolation of high-affinity aptamer candidates (KD = 12 nM) against the protein 
immunoglobulin E (IgE) via four rounds of selection and amplification within 10 hours.  
 
2.2. Experimental 
2.2.1. Microbead-Based SELEX Principle  
A microbead-based SELEX procedure is integrated on a single chip using combined electrokinetic 
and pressure-driven transport of oligonucleotides for isolation of aptamers against a given target molecule 
(Figure 2.1). The procedure involves iterative rounds of affinity selection and amplification of target-binding 
oligonucleotides. Affinity selection occurs on microbeads that are functionalized with a biomolecular target. 
A randomized library of single-stranded DNA (ssDNA) oligonucleotides, each consisting of a randomized 
region flanked by two constant primer regions, is then introduced to the beads and bind to the immobilized 
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target. Weakly binding oligonucleotides are removed from the beads by multiple buffer washes. The 
remaining strongly binding oligonucleotides are released from the beads by thermally disrupting their 
binding with the target and transferred via electrokinetically migration to a second set of microbeads that 
are functionalized with reverse primers complementary to the 3’ end of the ssDNA library. The target-
binding oligonucleotides are captured by the beads via hybridization to the reverse primers. PCR reagents 
are then introduced and PCR is performed, resulting in double-stranded DNA (dsDNA) consisting duplicate 
copies of (i.e., amplified) target-binding oligonucleotides hybridized to bead-immobilized complementary 
strands. The amplified target-binding oligonucleotides are released from the beads via thermal 
denaturation, and then transferred via pressure-driven flow to a replenished set of target-functionalized 
microbeads, on which a new round of affinity selection is carried out without the presence of potentially 
damaging electric fields. This process is repeated in multiple rounds of affinity selection and amplification 
to yield aptamers with sufficient affinity to the target.  
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Figure 2.1: Microbead-based microfluidic SELEX principle. (a) Randomized ssDNA binds to target-
functionalized microbeads. (b) Weak binders are removed by washing; (c) strong binders are thermally 
released and (d) transferred for PCR amplification via electrokinetic transport. (e) The strands are 
captured by magnetic microbeads with surface-immobilized reverse primers, and (f) amplified via PCR. 
(g) The amplified single strands are thermally released from bead surfaces, and (h) transported through 
pressure-driven flow for a new round of affinity selection. 
2.2.2. Microfluidic Device Design and Operation 
The microbead-based SELEX procedure is realized in an integrated microfluidic device (Figure 
2.2). The device consists of two microchambers (respectively referred to as selection and amplification 
chambers), which are each integrated with thin-film resistive heaters and temperature sensors, and 
connected to an inlet and outlet used for the introduction of microbeads and buffers, as well as to an 
electrode port. The selection chamber also includes a microweir, a flow restriction structure (20 µm high) 
that retains microbeads while allowing fluid passage. The chambers (each 0.5 µL in volume) are 
+
-
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interconnected by reagent transport channels. One reagent transport channel (800 µm wide, 240 μm high, 
and 7 mm long) between the chambers is filled with agarose gel that allows electrokinetically driven 
oligonucleotide migration while preventing bulk flow (Figure 2.2b). The other transport channel (600 µm 
wide, 20 µm high, and 10 mm long), with a semi-circular cross section, lies below a second layer of control 
channels that are filled with pressurized oil (Figure 2.2c). Passage of reagent solution in the transport 
channel is prevented or enabled via changing the oil pressure in the control channels, which hence function 
as a microvalve. Two supplementary outlet channels sandwich the gel-filled transport channel and are used 
to allow buffer to fully fill the non-gel-occupied sections of the electrokinetic transport channel.  
 
Figure 2.2: Schematic of the microfluidic SELEX device: (a) top view, (b) A-A cross-sectional view, and (c) 
B-B cross-sectional view. The selection chamber contains microbeads that are functionalized with a target 
protein and retained by a microweir. The amplification chamber contains magnetic beads that are 
functionalized with a DNA primer and retained by an external magnet. Oligonucleotides (ssDNA) strands 
are transferred by electorkinetics from the selection chamber to the amplification chamber, and reversely 
by pressure-driven flow. 
 
 
(a) 
(b) (c) 
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The microfluidic device is capable of repeatedly performing iterative rounds of affinity selection and 
amplification. Affinity selection occurs in the selection chamber, where target-functionalized microbeads 
are introduced and immobilized by the microweir structure. A randomized ssDNA library is then introduced 
to the beads. Strongly binding oligonucleotides are captured by the target and weakly binding strands are 
removed by buffer washes. Next, reverse primer-functionalized magnetic beads are introduced into the 
amplification chamber and held via an external magnet. The oligonucleotides bound to the bead-
immobilized target are thermally released from with the selection chamber’s integrated heater, and 
electrokinetically transferred through the gel-filled channel to the amplification chamber, and captured 
therein by the bead-bound reverse primer[140]. PCR reagents are then introduced and PCR performed 
using the amplification chamber’s integrated heater and temperature sensor. The amplified ssDNA is 
thermally released from the beads, and upon the opening of the microvalve, transferred via pressure-driven 
flow to the selection chamber for further affinity selection. As such, the bead-based protocol enables on-
chip separation of amplified ssDNA from complementary strands and on-chip coupling of successive rounds 
of SELEX, thereby allowing integrated isolation of aptamers. 
2.2.3. Materials 
Agarose, PBS buffer, MgCl2, tris, boric acid, and molecular biology grade water were purchased from 
Sigma-Aldrich (St. Louis, MO). Deoxyribonucleotide triphosphates (dNTPs) and GoTaq Flexi DNA 
polymerase were obtained from Promega Corp. (Madison, WI). Randomized oligonucleotide library (5’ – 
GCC TGT TGT GAG CCT CCT GTC GAA – 45N – TTG AGC GTT TAT TCT TGT CTC CC – 3’) and primers 
(Forward Primer: 5' – FAM – GCC TGT TGT GAG CCT CCT GTC GAA -3', and Reverse Primer: 5' – dual 
biotin – GG GAG ACA AGA ATA AAC GCT CAA – 3') were synthesized and purified by Integrated DNA 
Technologies (Coralville, IA). Human Myeloma Immunoglubulin E (IgE) was purchased from Athens 
Research and Technology (Athens, GA), and NHS-activated microbeads were purchased from GE 
Healthcare (Little Chalfont, Buckinghamshire, United Kingdom). Dulbecco’s phosphate-buffered saline (D-
PBS), and streptavidin coupled magnetic beads (Dynabeads® M-270 Streptavidin) were purchased from 
Invitrogen (Carlsbad, CA). AZ-4620 positive photoresist was obtained from Clariant Corp. (Somerville, NJ) 
and SU-8 (2000, 2025, and 2075 series) negative photoresist was purchased from Microchem Corp. 
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(Westborough, MA). Polydimethylsiloxane (PDMS) was obtained from Robert McKeown Company 
(Somerville, NJ) and silicon wafers were purchased from Silicon Quest International, Inc. (San Jose, CA).  
Agarose microbeads functionalized with a protein were used for selection and magnetic 
microbeads functionalized with reverse primers were used for amplification. The beads for selection were 
functionalized with a protein through covalent coupling between the NHS groups of the microbeads and the 
amine groups of the protein. Prior to an experiment, the protein was incubated with IgE under gentle rotation 
for 1 hour at room temperature, and washed with D-PBS buffer. Unreacted NHS groups were passivated 
by incubating the functionalized beads in Tris buffer. The functionalized beads were then suspended in D-
PBS buffer. Similarly, streptavidin magnetic beads were functionalized by incubation with dual biotin 
conjugated reverse primers through covalent coupling for 30 minutes, washed with D-PBS buffer and 
suspended in D-PBS buffer. 
2.2.4. Microfluidic Device Fabrication 
 The approach was demonstrated with a PDMS microfluidic device fabricated using standard multi-
layer soft-lithography techniques. Two silicon wafers, one bearing four identical copies of the flow 
components of the device and the other bearing four identical copies of the control layer components were 
fabricated in a cleanroom setting. First, alignment marks were deposited onto the wafer so that multiple 
photolithography steps could be performed with high accuracy. This was achieved by thermally evaporating 
(Edwards 306 thermal evaporator) a silicon wafer with a 20 nm layer of chrome and a 100 nm layer of gold. 
Shipley photoresist S1813 was then spun onto the surface (6000 rpm for 50 seconds) and baked on a hot 
plate (115 ºC and 60 seconds). This coated wafer was then exposed to 80 mJ/cm2 UV light through a mask 
defining aligner marks for subsequent layers. The exposed wafer was then submerged in AZ 300 MIF 
developer for 60 seconds. Following development the wafer was rinsed with water, dried with nitrogen, and 
submerged in gold etchant. The gold etched wafer was finally submerged in chrome etchant, rinsed with 
water, and dried with nitrogen. An acetone bath was used to remove remaining photoresist, and the wafer 
was rinsed with isopropanol and dried on a hot plate at 100 ºC for 10 minutes.  
The valve controlled channel was then defined onto the wafer with alignment marks. First, a layer 
of AZ-4620 positive photoresist was spun on a silicon wafer in a two-step process. The photoresist was 
spun at 2000 rpm for 85 seconds, and baked for 85 seconds 110 ºC on a hot plate. Then the AZ-4620 was 
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reapplied to the wafer, spun again at 2000 rpm for 85 seconds and baked at 110 ºC on a hot plate for 165 
seconds. The total thickness of the photoresist from this two-step process was approximately 30 µm. This 
photoresist covered silicon wafer was then exposed, through a photomask with desired channel features 
(designed using L-Edit and custom printed by Fineline Imaging), to 1400 mJ/cm2 of energy from a mask 
aligner (SUSS MA6). The exposed wafer was submerged into AZ400K developer diluted 1:4 in water for 
10 minutes. The developed wafer was placed on a programmable hotplate (Torrey Pines Scientific) where 
the temperature was ramped from room temperature to 200 ºC over an hour long period and let to stay at 
room temperature for 4 hours. This high-temperature bake served two purposes: first it hard baked the 
photoresist such that it would be more immune to the solvent effects in subsequent photolithography 
processes and second it caused the previously square shaped channel to reflow into a semi-circular shape. 
The reflow shape allows valves to tightly close channels without the compressive force causing unsealed 
corners [141].  
Buffer channels were then built onto the silicon wafer. SU-8 2035 was spun at 4000 rpm for 50 
seconds, baked at 65 ºC for 3 minutes on a hotplate, and baked at 95 ºC for 6 minutes on a hotplate. This 
wafer was exposed to 152 mJ/cm2 of energy using a mask aligner and a custom drawn mask defining the 
desired channels. A post-bake was then performed consisting of 65 ºC for 1 minute on a hotplate and then 
95 ºC for 5 minutes on a hotplate. Following, the wafer was submerged in SU-8 developer for 5 minutes 
and rinsed with isopropanol. A hard bake was then performed, placing the wafer on a hotplate at 125 ºC for 
1 hour. 
The final fluidic layer, consisting of the large chambers and gel channel, was then fabricated onto 
the wafer. SU-8 2075 was deposited on the wafer and left to spread on a flat surface for 15 minutes. The 
wafer was spun at 300 rpm for 15 seconds to spread the photoresist and then was ramped up to 1000 rpm 
for 45 seconds. The SU-8 coated wafer was then placed on a hotplate (65 ºC) for 7 minutes. Following the 
7-minute bake the hotplate temperature was increased by 5 ºC every 10 minutes until reaching 95 ºC. After 
remaining on the hotplate for 1 hour the hotplate was cooled to room temperature with the wafer remaining 
on it. This on-plate cooling was to reduce thermal stress in the photoresist which can be caused by sudden 
changes in temperature and can potentially interfere with the adhesion of the SU-8 photosensitive epoxy 
to the silicon wafer. This pre-baked wafer was then exposed to 350 mJ/cm2 of energy through a film 
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photomask defining the chambers and gel channels. After exposure, the wafer was baked on a hotplate 
again, first at 65 ºC for 5 minutes and then at 95 ºC for 15 minutes. The hotplate was then cooled to room 
temperature with wafer remaining on the surface to reduce thermal stress. The baked wafer was then 
placed in SU-8 developer for 15 minutes and rinsed with isopropanol. This concluded the fabrication of the 
flow layer wafer of the microfluidic device. 
Meanwhile, the control layer wafer was fabricated on a second silicon substrate. SU-8 2035 was 
spun onto a piranha (4 parts sulfuric acid, and one part 30% hydrogen peroxide) cleaned silicon wafer by 
spinning at 4000 rpm for 50 seconds. A pre-bake was performed by heating the wafer on a hotplate for 65 
ºC for 3 minutes and increasing this to 95 ºC for 6 minutes. The pre-baked wafer was then exposed to 152 
mJ/cm2 of energy from a mask aligner through a mask defining the control valves. The exposed wafer was 
then baked on a hotplate for 65 ºC for 1 minute and then 95 ºC for 5 minutes. Following the bake, the wafer 
was submerged in SU-8 developer for 5 minutes, rinsed with isopropanol and hard baked at 120 ºC for 1 
hour on a hotplate.  
Heaters and temperature sensors were created on piranha cleaned glass microscope slide 
substrates by depositing first 20 nm of chrome and then 100 nm of gold using a thermal evaporator. The 
heaters and temperature sensors were patterned into these thin films through photolithographic techniques. 
Shipley S1813 was spun on the gold surface of the glass slide with a spinner with a spinning program 
defined as 300 rpm for 15 seconds, and 3000 rpm for 45 seconds with a 400 rpm/second ramp rate. The 
glass slides were heated on a hotplate at 120 ºC for 2 minutes and then exposed to 95 mJ/cm2 of energy 
with a mask aligner using a custom designed mask with defined heaters and temperature sensors. The 
exposed glass slides were immersed in AZ 300 MIF developer for 15 seconds and rinsed with water. 
Occasionally the development process was incomplete on the edges of the slides due to the beading effect 
caused during spinning. In these cases an isopropanol soaked cleanroom wipe (Texwipe TX49) was 
carefully used to remove excess photoresist. The developed slides were then immersed in first gold etchant 
for 10 seconds and then chrome etchant for 10 seconds. The etched substrate was then rinsed in water, 
dried with a nitrogen gun, and then placed on a hotplate for one hour at 120 ºC. 
The two silicon wafers were used as molds to transfer the desired features into PDMS substrates. 
30 mL of 10:1 (base: curing agent by weight) was poured onto the surface of the flow layer silicon wafer, 
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degassed in a vacuum desiccator for 30 minutes or until no bubbles were visible and heated on a hotplate 
set to 72 ºC for 30 minutes. Following complete curing the PDMS was peeled off the wafer and the four 
identical units were cut out of the slab to create individual devices. Inlets and outlets of the individual flow 
layers were then punched with a 1.2 mm autopsy punch (Harris). Meanwhile, the control layer wafer had 3 
mL of PDMS deposited on it and was spun on a spinner for 15 seconds at 300 rpm and then 1000 rpm for 
45 seconds with a 300 rpm/second ramp to create a thin film of PDMS on the surface of the wafer. This 
layer was placed on a hotplate for 20 minutes at 72 ºC. The four flow layer devices with flow channels facing 
up and the control layer silicon wafer with thin film PDMS were then placed in an oxygen plasma etcher 
together (Diener Plasma Etch) and exposed to 20 seconds of oxygen plasma at 50% power. Immediately 
after exposure to oxygen plasma, the four flow layer devices were aligned by hand onto the four control 
layer regions on the control layer silicon wafer and pressed with modest pressure to completely put the two 
oxygen plasma exposed surfaces in contact with each other. This wafer was then placed on a hotplate at 
80 ºC for 1 hour.  
While the control layer was on the hotplate, the glass slides bearing the heaters and temperature 
sensors had PDMS spun on them (300 rpm for 15 seconds, 1000 rpm for 45 seconds, 300 rpm/second 
ramp rate), and were baked at 72 ºC for 20 minutes. After the completion of the control layer with bonded 
flow layer devices baking, the flow layer devices were carefully peeled off the wafer such that the PDMS 
spun onto the control layer remained bonded to the flow layer devices and peeled off with the flow layer 
devices. The peeled off devices had inlets punched with a 1 mm autopsy punch. These four devices which 
consisted of two layers of PDMS (a thick flow layer PDMS block and a thin film control layer) were exposed 
to oxygen plasma along with the heater and temperature sensor glass slides with thin film PDMS for 20 
seconds at 50 % power. Immediately after oxygen plasma exposure, each of the four PDMS devices were 
aligned to the heaters and temperature sensors of the glass slides and pressed with modest pressure to 
put the surfaces in contact. These devices were placed on a hotplate at 100 ºC overnight. Finally, molten 
agarose gel (3% agarose heated to 90 ºC and then cooled to 65 ºC) was injected in the gel inlet of the 
device and allowed to cure at room temperature to form the electrokinetic transfer channel and mineral oil 
was injected into pneumatic control channel. A fabricated device is shown in Figure 2.3. 
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Figure 2.3: Photograph of a fabricated microfulidic device filled with dye solutions for visualizations. Scale 
bar: 5 mm. 
2.2.5. Measurement of Electrokinetic Effects on Chamber Properties 
 Chamber pH was observed to evaluate the potential deleterious effects of prolonged electric fields 
on the selection chamber. A fabricated device was filled with TB buffer and an electric field (25 V/cm) was 
applied for varying lengths of time (0 min – 30 min) with cathode located in the selection chamber and 
anode located in the amplification chamber. After the prescribed amount of time elapsed the chamber 
volume was collected and the pH was measured. The process was repeated three times for each time 
course. 
 
2.2.6. Integrated Aptamer Selection Procedure 
 The fabricated device was connected to a syringe pump (New Era Pump Systems, Inc., 
Farmingdale, NY), a multimeter (34420A, Agilent Technologies Inc., CA), a power supply (E3631, Agilent 
Technologies Inc., CA) and a nitrogen tank with pressure regulator (Concoa, Virginia Beach, Virginia). The 
syringe pump was used to introduce buffers, reagents, and beads. The multimeter and power supply 
measured the resistance of the temperature sensor and supplied power to the heater, respectively, and 
were connected to a computer which implements a Labview code for closed-loop temperature control of 
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the device. The pressure regulator was connected to the pneumatic control layer and allowed the oil filled 
channel to be pressurized thereby closing the valve.  
 Integrated SELEX occurred on-chip without the use of any offline processes. Protein functionalized 
microbeads were injected into the selection chamber of the device (20 μL/min) until approximately 40% of 
the selection chamber volume was occupied by beads. Selection of oligonucleotides was then performed 
by infusing randomized library (1 μM in D-PBS buffer) into the device (10 μL/min) for 10 minutes, followed 
by multiple washes with D-PBS buffer (20 μL/min) to remove weakly binding oligonucleotides which were 
collected in a tube and stored. Collected oligonucleotides were amplified off-chip (16 rounds of PCR) and 
imaged with gel electrophoresis to verify successful removal of weakly binding oligonucleotides and 
retention of strongly binding oligonucleotides that bind to targets functionalized on bead surfaces. 
Next, primer functionalized magnetic beads were introduced into the amplification chamber of the 
device and held by an external magnet located beneath the chamber. Tris-boric acid electrolyte buffer (89 
mM Tris, 89 mM boric acid, and 100 mM NaCl) was then injected into the device and platinum wires were 
inserted into the electrode inlets of each chamber to generate an electric field. Meanwhile, strongly bound 
oligonucleotides remaining in the selection chamber were thermally released (50 °C) using the integrated 
heater and temperature sensor. The released oligonucleotides were transferred from the selection chamber 
to the amplification by applying a 25 V/cm electric field for 40 minutes. 
Following transfer of the oligonucleotides to the amplification chamber, the electric field was 
removed. PCR reagents were then introduced into the amplification chamber and bead-based PCR 
progressed utilizing the heater and temperature sensor located beneath the amplification chamber. A PCR 
process of 95 °C for 10 seconds, 59 °C for 30 seconds, and 72 °C for 10 seconds was used. After 20 cycles 
of PCR thermocycling, the protein functionalized microbeads were removed from the selection chamber 
and replaced with new protein functionalized microbeads. Bead based PCR was confirmed by introducing 
a fluorescently modified oligonucleotide library (100 pM) into the amplification chamber containing reverse 
primer functionalized beads and performing 20 cycles of PCR thermal cycling. Bead surfaces were imaged 
using an epifluorescence microscope (IX 71, Olympus, Center Valley, PA) equipped with a CCD (c8484, 
Hamamatsu, Boston, MA) before and after PCR, and after thermally induced ssDNA release. Additional 
information on the detailed procedure is included in the Supplementary Materials.  
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Following amplification, the valve was then opened and oligonucleotides were released from the 
bead surfaces by heating to 95 °C. The released oligonucleotides were transported back to the selection 
chamber through the opened valve via pressure-driven flow (20 uL/min) for further affinity selection with the 
replenished microbeads. This closed-loop process was repeated for a total of four affinity selections and 
three 20-cycle PCR amplifications. 
2.2.7. Aptamer Characterization Procedure 
The enriched aptamer pool collected following completion of SELEX was investigated for its affinity 
and specificity using a fluorescence binding assay [1]. Six different concentrations (100 nM, 50 nM, 25 nM, 
12.5 nM, 6.25 nM and 3.125 nM) of fluorescently tagged oligonucleotides were incubated with IgE-
functionalized beads in triplicate 100 μL volumes. After incubating the oligonucleotides with the beads for 
30 minutes, the beads were washed and the bound oligonucleotides were thermally eluted (95 °C). The 
eluted oligonucleotdies were collected and their relative amounts were determined with a Wallac EnVision 
Multilabel Reader fluorescent spectrometer. The relative amounts were analyzed with a hyperbola 
saturation binding curve fitting (1:1 binding) using GraphPad Prism (GraphPad Software Inc., CA) to 
determine the binding affinity of the oligonucleotide pool towards the target molecule. The specificity of the 
aptamer candidate pool towards IgE was investigated by repeating the binding study with bare beads and 
beads that were functionalized with IgA.    
2.3. Results and Discussion 
We first present results from the characterization of the individual components of the microfluidic 
device, including pH effects, affinity selection, PCR amplification, and loop closure. We then describe 
results from the fully integrated SELEX process as well as the characterization of the resulting aptamer 
candidates. The protein immunoglobulin E (IgE) was used as a representative molecule throughout the 
experiments. 
2.3.1. Electrokinetic Effects on Chamber pH 
 To demonstrate the benefits of the hybrid approach’s ability to avoid the potentially deleterious 
effects of using each method alone we characterized the electrokinetic transfer process. The selection 
chamber pH was evaluated over various time courses (Figure 2.4) with electrodes oriented to allow 
migration from the amplification chamber to the selection chamber. A significant pH drop from 8.3 to 7.25 
was observed in the selection chamber after the application of an electric field for 30 minutes, which can 
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be attributed to the generation hydroxide (OH-) and hydrogen (H+) ions at the cathode and anode, 
respectively[142, 143]. Thus, the electrolysis of buffer during electrokinetic transport of DNA can induce 
changes in the pH levels microchambers, which can potentially compromise the integrity of the target and 
disrupt the electrostatic interactions between the aptamer and oligonucleotides[142, 143]. While 
electrokinetic transport can significantly impact affinity selection, the hybridization interactions between 
complimentary oligonucleotides is more robust and for pH 5–9 the renaturation rate is practically 
independent of pH[144]. Thus, while electrophoresis of oligonucleotides from the amplification chamber to 
the selection chamber may not be desirable, electrokinetic oligonucleotide transport from the selection 
chamber to the amplification chamber is appropriate. These observations are consistent with the rationale 
for our hybrid oligonucleotide transport approach. 
 
Figure 2.4: Electrokinetic effects on chamber pH. Electric field was applied for different time lengths (0 to 
30 min.) and the chamber pH was measured. Error bars represent standard deviations from triplicate 
measurements. 
 
2.3.2. Characterization of Affinity Selection  
Eluates from affinity selection were collected and evaluated using gel electrophoresis (Figure 2.5). A 
band in the electropherogram indicates the presence of oligonucleotides; thus, the strong band in the first 
wash (W1) demonstrates that not all oligonucleotides bound to the target molecule and some were flushed 
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out of the device during the washing stage. The decrease in band intensity from wash 1 to wash 20 shows 
that as washing progressed fewer oligonucleotides were eluted from the target, while the strong band 
intensity in the elution lane (E) demonstrates that oligonucleotides strongly bound to the bead surfaces 
were eluted when heating the chamber to 50° C. Therefore, the selection process partitioned non-binding 
oligonucleotides from binding oligonucleotides which could then be eluted by increasing the temperature. 
The thermally eluted oligonucleotides can be electrokinetically transferred and used for further rounds of 
selection to generate an aptamer pool with high affinity towards its target molecule. 
      
Figure 2.5: (a) Gel electropherogram of amplified eluents obtained during selection process; (b) bar 
graph depicting intensities of lanes W1-E: washes 1, 3, 5, 7, 9, 20, and elution. Error bars represent 
standard deviations from triplicate measurements. 
 
2.3.3. Characterization of Bead-Based PCR Amplification and Loop Closure 
To characterize the bead-based PCR protocol, randomized library strands were amplified on-chip 
using a fluorescently tagged forward primer and monitored with fluorescent microscopy (Figure 2.6). During 
the amplification process, dsDNA is generated consisting of fluorescently labeled amplified library strands 
hybridized to their bead-bound complements. Thus, the increase in fluorescent intensity of beads following 
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20 cycles of PCR indicates that template oligonucleotides were successfully amplified on the bead surfaces 
within the device. The subsequent decrease in fluorescent intensity of the bead surfaces upon heating to 
95 °C demonstrates that the fluorescently modified strands dehybridized from the complementary 
biotynalated strand bound to the bead surface. Affinity selected oligonucleotides can be transferred via 
electrokinetics  to bead-based PCR to allow closed-loop aptamer enrichment. Eluates collected during the 
closed loop process showed successful coupling of affinity selection to bead-based amplification. 
 
Figure 2.6: Fluorescent images of beads (a) before, (b) after 20 cycles of PCR, and (c) after 95 C thermally 
induced oligonucleotide elution. (d) Bar graph depicting the fluorescent intensities. Error bars represent 
standard deviations from triplicate measurements. Scale bar: 200 µm. 
 
2.3.4. Integrated Multi-Round SELEX for Isolation of Aptamers 
Having confirmed the approach’s potential for closed-loop affinity selection and amplification, a 
microchip was used to demonstrate multiround hybrid SELEX where four rounds of affinity selection and 
three rounds of PCR amplification were performed on-chip (Figure 2.7). Eluates were collected during each 
round of affinity selection, amplified by PCR and analyzed using conventional gel electrophoresis. Since 
the brightness of bands in a gel image represents the amount of oligonucleotides in the eluent loaded in 
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the lane, comparison of the band intensities allowed investigation of the SELEX process. In the first round, 
some oligonucleotides were in the washing waste after the completion of the washing process as indicated 
by the presence of a band in lane S1W9. However, the increase in band intensity from S1W9 (selection 1, 
wash 9) to S2W1 (selection 2, wash 1) suggests that oligonucleotides were released from the bead surfaces, 
electrokinetically transferred and amplified by PCR. The lack of a band in S2W9 (selection 2, wash 9) shows 
that weakly bound oligonucleotides were removed from the washing process. The increase in band intensity 
in from S2W9 to S3W1 (selection 3, wash 1) and S3W9 (section 3, wash 9) to S4W1 (selection 4, wash 1) 
suggests that, again, oligonucleotides were thermally released, electrokinetically transferred to the 
amplification chamber, amplified by PCR, and transferred back to the selection chamber via pressure driven 
flow. The presence of oligonucleotides in the elution lane (E) and the lack of detectable oligonucleotides in 
S4W9 (selection 4, wash 9) suggests oligonucleotides were strongly bound to the target after four rounds of 
selection and amplification and were successfully released from the bead surfaces.  
 
Figure 2.7: (A) Gel electropherogram of amplified eluents obtained during closed loop selection and 
amplification. (B) Bar graph depicting intensities, representing the amount ssDNA in the eluent, of lanes 
S1W1- S4W9: Lane S1W1:  selection 1, wash 1; Lane S1W9: selection 1, wash 9; Lane S2W1: selection 2, 
wash 1; Lane S2W9: selection 2, wash 9; Lane S3W1: selection 3, wash 1; Lane S3W9: selection  3, wash 9; 
Lane S4W1: selection 4, wash 1; Lane S4W9: selection  4, wash 9; Lane E: thermally eluted  ssDNA. 
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 The resulting aptamer candidate pool was analyzed for its affinity and specificity towards its 
intended target molecule. When the enriched pool was incubated with IgE-immobilized beads, washed, and 
bound oligonucleotides were thermally eluted and measured, the fluorescent intensity rapidly increased 
until reaching an asymptote (Figure 2.8).  This indicated that the affinity of the enriched oligonucleotide 
pool considerably improved after the microfluidic SELEX process. Because this measurement relied on 
many manual transfers the error increases with higher concentrations of binding aptamer candidates. The 
data were well represented by a Langmuir monovalent binding model, with an equilibrium dissociation 
constant (KD) of approximately 12 nM (obtained via nonlinear regression) as is consistent with that of 
existing IgE aptamers[75, 140]. In contrast, when the enriched pool was incubated with IgA functionalized 
beads or bare beads, washed, and bound oligonucleotides were eluted and measured, the fluorescently 
increased very slowly with the oligonucleotide concentration. This demonstrates the aptamer candidate 
pool binds much more strongly to the IgE functionalized beads than the bare beads, indicating the aptamer 
is indeed specifically binding to the protein target.  
 
Figure 2.8: Fluorescence based binding affinity measurements of enriched pool towards IgE functionalized, 
IgA functionalized and bare microbeads. Error bars represent standard deviations from triplicate 
measurements. 
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A microfluidic approach to integrated isolation of aptamers against biological targets has been 
described. The approach employs a bead-based protocol for affinity selection and amplification of 
oligonucleotides, which are transported within the protocol via combined electrokinetic transport and 
pressure-driven flow. Specifically, oligonucleotides are affinity selected against target-functionalized beads 
and binding strands are transferred under an electric field for bead-based PCR amplification. The amplified 
product is then transferred back for further affinity selection through pressure-driven flow without relying on 
off-chip processes. This hybrid approach simplifies the microfluidic device design and operation by reduced 
pressure-driven flow control requirements, and avoids potentially deleterious effects of the exposure of 
targets to electric fields prior to and during affinity selection. The approach thus allows the entire iterative 
SELEX process to be integrated on a single chip without the requirement for any offline procedures, thereby 
enabling rapid isolation of aptamers.  
The integrated hybrid microfluidic SELEX approach was demonstrated by isolating aptamers with high 
affinity towards the protein immungolubulin E (IgE). Binding oligonucleotides are affinity selected against 
IgE-functionalized beads, electrokinetically transferred to an amplification chamber, hybridized to 
microbeads, amplified by PCR, and transferred back to the selection chamber by pressure-driven flow for 
a new round of affinity selection. The SELEX process was completed in four rounds within a total runtime 
of approximately 10 hours. The resulting aptamer candidates displayed strong target-binding affinity, with 
an equilibrium dissociation constant of 12 nM. These results demonstrate the utility of the approach to 
rapidly isolate aptamers with high affinity to biological targets.  
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Chapter 3: Integrated Microfluidic SELEX using Free Solution Electrokinetics 
3.1. Introduction 
Aptamers are single-stranded oligonucleotides, including single-stranded deoxyribonucleic acid 
(DNA), ribonucleic acid (RNA) and peptide molecules, which can be used for specific molecular recognition 
towards a broad spectrum of targets including small molecules [70], peptides [71], amino acids [72, 73], 
proteins [74, 75], cells [76, 77], viruses [78, 79], and bacteria [82]. In many applications aptamers can be 
used as substitutes to antibodies but with the additional unique advantages of reversible binding, long shelf 
life, low batch-to-batch variability [124], low immunogenicity [123], long-term stability, ease of coupling to 
other functional molecular groups [121, 122], and ability to be discovered through an in vitro process [86, 
125]. Thus, aptamers are being employed as biosensors, drug delivery devices, and bio-imaging probes in 
many applications within basic biological sciences [126], drug discovery [127], and clinical diagnostics and 
therapeutics [125, 128]. 
 The in vitro process used to discover aptamers with high affinity for a particular target is known as 
systematic evolution of ligands by exponential enrichment (SELEX). During the SELEX process an aptamer 
is found from an initial library of randomized combinatorial oligonucleotides with approximately 1012 – 1015 
unique members through iterative rounds of affinity selection and amplification [86, 87, 91]. Affinity selection 
involves incubating the library with a target of interest and then separating library members that bind to the 
target from those that do not bind to the target. The target-binding oligonucleotides are then amplified 
through the polymerase chain reaction (PCR) during the amplification stage and converted back to single-
stranded oligonucleotides. These amplified single-stranded oligonucleotides are then incubated with the 
target as the affinity selection of a new round SELEX begins. Therefore, in every subsequent round of 
selection the oligonucleotides must compete for binding from the oligonucleotides that bound in the previous 
round. These rounds of affinity selection and amplification are repeated until a pool of oligonucleotides is 
isolated with high affinity and specificity towards the target. While effective, this process conventionally 
involves extensive manual handling of reagents, and is time consuming, typically requiring a month or more 
to complete a single SELEX run [129]. 
 Microfluidic technology has been recently applied to the SELEX field to rapidly isolate aptamers at 
low cost in a highly integrated and automated fashion, and additionally with reduced reagent consumption 
 42 
 
and in fewer rounds of iteration. Microfluidic affinity selection has been performed, in conjunction with off-
chip amplification, against targets retained using silica capillary walls [117], microbeads [106-108, 119, 131, 
132, 140, 145] or sol-gels [113-115], or against cells in solution [133, 134], to increase selection stringency 
[106-108, 131-134], create more favorable biomolecular environments [113-115], or allow simultaneous 
positive and negative selections [110]. Moreover, microchips have been developed in an attempt to 
integrate the overall SELEX process using pneumatically based flow control for isolation of aptamers 
against viruses [135], cells [131, 136, 137] and proteins [119, 138-140, 145]. While capable of isolating 
aptamers these microfluidic devices have relied on highly complex fabrication techniques not available to 
most researchers, extensive flow control components (integrated pumps, valves and mixers which all 
require additional off-chip equipment), sophisticated operating equipment, complicated designs, and 
integration of unstable gels. 
 This chapter presents a simplified microfluidic approach using free solution electrokinetic flow 
control to fully integrate the SELEX process on a single microchip.  In this approach, electrophoretic 
transport of oligonucleotides occurs in free solution between selection and amplification chambers through 
a microchannel that is highly resistant to bulk flow and diffusion due to a relatively large length and small 
cross-sectional area. This high resistance prevents cross contamination between the chambers without 
significantly impeding electrophoretic oligonucleotide transport. The design hence obviates the use of 
complex flow handling or gel preparation, thereby allowing simple and efficient transfer of target-binding 
oligonucleotides as well as a high level of device integration. Also, the device is fabricated without the need 
for the multi-layer soft lithography techniques previously reported devices have required.  These 
advantages are combined with a bead-based protocol to achieve on-chip coupling of affinity selection and 
amplification of target-binding oligonucleotides without requiring offline processes. The device is further 
simplified, while the reliability is improved, through optimized design of the microfluidic geometry and use 
of a magnetic microbead retention scheme that make the device considerably less prone to potentially 
catastrophic trapped bubbles [146]. The practical utility of the device is demonstrated with experimental 
results on isolation of DNA aptamers against human immunoglobulin A (IgA) as a representative target. 
3.2. Experimental 
3.2.1. Aptamer Selection Principle 
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 The approach involves iterative rounds of microbead-based affinity selection and PCR amplification 
coupled by electrokinetic fluidic handling (Figure 3.1) carried out on a microchip. Aptamers are enriched 
from an initial single-stranded DNA (ssDNA) library comprised of oligonucleotides with a randomized region 
flanked by a forward primer region on the 5’ end, and a region defined to be complementary to the reverse 
primer on the 3’ end. This initial library is incubated with microbeads functionalized with biomolecular target 
(selection beads) during affinity selection. Through multiple buffer washes non-binding and weakly binding 
oligonucleotides are removed and discarded while strongly bound oligonucleotides remain attached to the 
target-functionalized microbeads. These strong binding oligonucleotides are thermally eluted from the 
target-functionalized microbeads and electrokinetically transferred to a second set of microbeads 
(amplification beads) which have been modified with reverse primers thus causing the library to hybridize 
to the reverse primers tethered to the amplification bead surfaces. PCR reagents are then introduced and 
PCR thermal cycling commences resulting in amplified copies of the target-binding oligonucleotides 
hybridized to the bead surfaces. The amplified product is thermally denatured from the bead bound 
complement and transferred back to replenished selection beads for further rounds of SELEX.  
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Figure 3.1: Principle of microfluidic aptamer development: (a) ssDNA with random sequence is introduced 
to the target. (b) ssDNA is allowed to bind to the target. (c) Weak binding and non-binding oligonucleotides 
are removed by multiple buffer washes. (d) Strong binders are thermally eluted and (e) transferred to the 
amplification chamber with electrokinetics. (f) Transferred oligonucleotides hybridize to surface-immobilized 
reverse primers and (g) amplified through PCR. (h) The amplified single strands are thermally released and 
(i) electrokinetically transported back to the selection chamber for further affinity selection. 
3.2.2. Microfluidic Device Design and Operation 
 The electrokinetic microfluidic approach for aptamer enrichment is realized in an integrated 
microchip (Figure 3.2). The device consists of two (selection and amplification) microchambers of identical 
geometry (~2.8-μL) connected by a microchannel. The microchambers are hexagonal in shape with 
dimensions of 2 mm wide, 7 mm long and 250 um high. The hexagonal chamber shape has been 
demonstrated to be considerably less prone to trapping bubbles which can cause sample purging at 
increased temperatures, act as thermal insulators, create uneven temperature distributions, and reduce the 
effective volume of the chamber [146]. Each microchamber features a resistive heater and temperature 
sensor located beneath the chamber, an inlet, an outlet, and an electrode port. Connecting the two 
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chambers is a single serpentine shaped microchannel (14.75 mm long, 50 μm wide, 20 μm tall) which 
prevents diffusion between the microchambers but allows oligonucleotide migration under an electric field. 
Similarly the electrode port (2 mm diameter) is connected to its microchamber through a long, narrow 
microchannel (4.5 mm long, 50 μm wide, 20 μm tall). The electrode ports allow the insertion of platinum 
wire electrodes.  
 
Figure 3.2: (a) Three-dimensional rendering of the microfluidic device. (b) Top view schematic of the 
microfluidic device. (c) Cross-sectional view of microfluidic device design along line A-A.  
 
 Repetitive, closed-loop cycles of affinity selection and PCR amplification can be achieved in the 
microdevice without the need for offline instruments. First target-functionalized beads are introduced into 
the selection chamber and retained via an external magnet. Affinity selection then occurs by flowing the 
initial randomized library across the beads from the inlet to the outlet, allowing oligonucleotides with affinity 
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towards the target to bind to the target-functionalized beads. The target-functionalized beads are washed 
with flowing buffer to remove weakly binding oligonucleotides. The remaining strongly bound 
oligonucleotides are then eluted by increasing the chamber temperature with the integrated heater located 
beneath the chamber. Meanwhile, an electric field is applied from the selection chamber electrode port to 
the amplification chamber port, inducing migration of the eluted oligonucleotides to the amplification 
chamber wherein amplification beads are located to capture and immobilize the oligonucleotides in the 
amplification chamber. PCR reagents are then introduced to the amplification chamber using the 
amplification chamber inlet and subsequently PCR thermal cycling commences using the integrated heater 
and temperature sensor located beneath the amplification chamber. The amplified product is thermally 
released using the integrated heater, an electric field of reversed polarity is applied, and the 
oligonucleotides are electrokinetically transferred back to the selection chamber where they interact with 
replenished target-functionalized beads as a new round of affinity selection begins. Note, the resulting 
amplified product of the PCR is double stranded oligonucleotides consisting of the amplified enriched library 
and the amplified complement of the enriched library. Partitioning of the desired amplified enriched strands 
from their complementary strands is achieved directly with the amplification beads. The complementary 
strand is an extended reverse primer which is coupled to the beads through temperature invariant 
streptavidin-biotin chemistry while the desired strand is attached to the beads through complementary base 
pairing to the complementary strand. Thus the desired strand can be released from the bead surfaces (while 
its complement remains attached to the beads), and subsequently transferred to the selection chamber, 
with elevated temperatures (~95 °C).  
3.2.3. Materials 
Human Imunnoglobulin A (IgA1) was purchased from Cell Sciences (Newburyport, MA), and Pierce 
NHS-activated microbeads were purchased from Thermo Fisher Scientific (Waltham, MA). Ethanolamine, 
MgCl2, tris, boric acid, and molecular biology grade water were purchased from Sigma-Aldrich (St. Louis, 
MO). Deoxyribonucleotide triphosphates (dNTPs) and GoTaq Flexi DNA polymerase were obtained from 
Promega Corp. (Madison, WI). Randomized oligonucleotide library (5’ – GAA CTT CGC ATC TCA CGG 
TGG – 36N – GGA TCC GAT TCC ATC CTG CTC CTC– 3’) and primers (Forward Primer: 5' – FAM – GAA 
CTT CGC ATC TCA CGG TGG -3', and Reverse Primer: 5' – dual biotin – GAG GAG CAG GAT GGA ATC 
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GG – 3') were synthesized and purified by Integrated DNA Technologies (Coralville, IA). Dulbecco’s 
phosphate-buffered saline (D-PBS), and streptavidin coupled magnetic beads (Dynabeads® M-270 
Streptavidin) were purchased from Invitrogen (Carlsbad, CA). SU-8 (2000, 2025, and 2075 series) negative 
photoresist was purchased from Microchem Corp. (Westborough, MA). Polydimethylsiloxane (PDMS) was 
obtained from Robert McKeown Company (Somerville, NJ) and silicon wafers were purchased from Silicon 
Quest International, Inc. (San Jose, CA).   
Magnetic microbeads (Pirece NHS-activated beads) functionalized with a protein were used for 
selection and magnetic microbeads (Dynabeads® M-270 steptavidin) functionalized with reverse primers 
were used for amplification. The beads for selection were functionalized with a protein (IgA1) through 
covalent coupling between the NHS groups of the microbeads and the amine groups of the protein. Prior 
to an experiment, the protein was incubated with IgA1 under gentle rotation for 1 hour at room temperature, 
and washed with D-PBS buffer. Unreacted NHS groups were passivated by incubating the functionalized 
beads in ethanolamine. The functionalized beads were then suspended in D-PBS buffer. Similarly, 
streptavidin magnetic beads were functionalized by incubation with dual biotin conjugated reverse primers 
through covalent coupling for 30 minutes, washed with D-PBS buffer and suspended in D-PBS buffer. 
3.2.4. Fabrication 
 The microfluidic device was realized in polydimethylsiloxane using soft-lithography techniques 
(Figure 3.3). First, a layer of SU-8 was spun, and developed on a silicon wafer to define the narrow 
channels for oligonucleotide transfer. Then a second, thicker layer of SU-8 was spun, and developed to 
create the selection and amplification chambers to complete the fabrication of the flow-layer. On a separate 
glass-slide substrate chrome (10 nm) and gold (100 nm) were thermally evaporated and then patterned 
and etched to create a glass substrate bearing gold resistive heaters and temperature sensors. A thin layer 
of PDMS was spun on this glass slide and cured to passivate and allow reuse of the heater and temperature 
sensors. PDMS was poured on the wafer containing the flow layer features, degassed in a vacuum chamber, 
and cured at 72 °C for 30 minutes. The hardened PDMS was peeled off, cut, and had inlet and outlet holes 
punched with an autopsy punch.  This flow layer was exposed to oxygen plasma along with the glass slide 
bearing the heater and temperature sensor and the two pieces were bonded and baked at 80 °C overnight. 
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Figure 3.3: (a) Deposition, patterning and passivation of gold temperature sensors and heaters. (b) 
Fabrication of the SU-8 mold defining microfluidic chambers and channels. (c) Casting of the PDMS sheet 
of fluidic chambers and channels. (d) Punching of inlets and outlets and bonding of the PDMS sheet to 
temperature control substrate. (e) A fabricated microchip. 
 
3.2.5. Detailed Aptamer Selection Procedure 
 A schematic of the device setup can be seen in Figure 3.4. The device was interfaced with a 
syringe pump (New Era Pump Systems, Inc., Farmingdale, NY), a power supply (E3631, Agilent 
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Technologies Inc., CA), and a multimeter (34420A, Agilent Technologies Inc., CA). During electrokinetic 
fluid handling platinum wires were inserted into the electrode ports and connected to the power supply. The 
multimeter was used to measure the resistance of the temperature sensor and ultimately interfaced with a 
computer which converted the resistance to a temperature using a calibration curve. The power supply was 
also interfaced to the computer which implemented a PID Labview (National Instruments, Austin, TX) 
algorithm for closed-loop temperature control in the chambers. The syringe pump was used for the buffer 
washes during affinity selection. 
 
Figure 3.4: Experimental setup. 
 The device was first filled with tris-boric acid electrolyte buffer (TB buffer, 89 mM Tris, 89 mM boric 
acid, and 100 mM NaCl) and then target-functionalized magnetic beads (2 μL, 10 mg/mL) were introduced 
into the device using a pipette and an external magnet. A droplet merging technique was used where the 
liquid in the pipette tip was allowed to contact the fluid in the chip. Once this fluidic conduit was established 
an external magnet was used to pull the magnetic beads from the pipette tip into the chip. Library (1 μM, 
100 μL in TB buffer) was then introduced into the selection chamber from the inlet (5 μL/min) and allowed 
to flow across the target-functionalized beads and ultimately to the outlet. An external magnet was held 
beneath the chamber to retain the beads in the selection chamber. The connecting microchannels provided 
sufficient fluidic resistance such that there was no observable flow to the amplification chamber or electrode 
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port. Following a 30-minute incubation with the library, the chamber was washed with eight 5 minute long 
buffer washes at a flow rate of 20 μL/min. The wash buffer exiting the device during this washing process, 
containing weak binding oligonucleotides, was collected, amplified off-chip, and imaged with a gel 
electropherogram to verify the removal of weakly binding oligonucleotides from the device.  
 Amplification beads (2 μL, 10 mg/mL) were then introduced into the amplification chamber using a 
pipette and external magnet. The Labview PID algorithm was implemented to increase the selection 
chamber temperature to 55 °C for 40 minutes thus inducing conformational changes in the oligonucleotides 
which disrupt the binding of the oligonucleotides to the target. Meanwhile a 40 V/cm electric field was 
applied for 40 minutes causing the thermally eluted oligonucleotides to migrate from the selection chamber 
to the amplification chamber wherein they bind to the amplification beads. The external magnet was kept 
beneath the chambers to retain the selection and amplification beads in their respective chambers. 
Following the migration process, PCR reagents were introduced into the amplification chamber using a 
pipette. A Labview algorithm was again implemented to thermally cycle the amplification chamber for 20 
cycles of PCR (cycles of 5s at 95 °C, 15s at 55 °C, and 10s at 72 °C). For characterization purposes, bead 
surfaces were imaged using an epifluorescence microscope (IX 71, Olympus, Center Valley, PA) equipped 
with a CCD (c8484, Hamamatsu, Boston, MA) before and after PCR, and after thermally induced ssDNA 
release. 
 At the conclusion of PCR, the external magnet was removed to allow the selection beads in the 
amplification chamber to be removed and replaced with fresh selection beads with a pipette. With fresh 
selection beads in the selection chamber, the amplification chamber was heated to 95 °C inducing 
dehybridization of the single-stranded oligonucleotide from its complement and the electric field (40 V/cm) 
was again applied in reverse polarity to transfer the amplified oligonucleotides from the amplification 
chamber to the selection chamber. Once the oligonucleotides had travelled to the selection chamber, the 
selection chamber was again washed with eight 5 minute buffer washes at a flow rate of 20 μL/min. 
Following the wash the chamber was heated to 55 °C using the integrated heater and temperature sensor 
and the eluted oligonucleotides were collected and analyzed for their affinity towards the target. 
3.2.6. Aptamer Characterization Procedure 
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The enriched aptamer pool collected following completion of SELEX was investigated for its affinity 
using a fluorescence binding assay [1]. The collected pool was amplified off-chip using a fluorescent forward 
primer and diluted to a final concentration of 100 nM. The 100 nM fluorescently tagged oligonucleotides 
were then incubated in triplicate 100 μL volumes with 20 μL (10 mg/mL) of washed target-functionalized 
beads. After incubation for 30 minutes, the beads were washed three times (100 μL each wash) and the 
bound oligonucleotides were eluted by heating to 95 °C. The relative amount of eluted oligonucleotides was 
measured with a Wallac EnVision Multilabel Reader (PerkinElmer, Waltham, MA) fluorescent spectrometer. 
This was repeated with the library used to initiate the aptamer development process.  
3.3. Results and Discussion 
 The device was first characterized to ensure the device could sufficiently perform the individual 
sub-processes (affinity selection, elution, electrokinetic transport, and PCR amplification). Then closed-loop 
affinity selection and amplification were performed on-chip consisting of two rounds of affinity selection and 
one round of PCR amplification. The device can readily be used for additional cycles of affinity selection 
and amplification when necessitated by the application. 
3.3.1. Heater and Temperature Sensor Characterization 
 The heater and temperature sensor were characterized by placing a fabricated device in an 
environmental chamber (Delta Designs 9023, Cohu, Poway, CA) and ramping the temperature from room 
temperature (~23 °C) to the maximum temperature used for PCR (95 °C) in 10 °C intervals. For every 10 °C 
interval the resistance and temperature was recorded (Figure 3.5). By fitting this highly linear data a 
temperature coefficient of resistance was obtained using the following expression. 
𝑅 − 𝑅0
𝑅0
= 𝛼(𝑇 − 𝑇0) 
In this expression R is the resistance for a given temperature, R0 is the resistance at room temperature, T 
is the temperature, T0 is the room temperature and alpha is the coefficient of resistance. A coefficient of 
resistance of 1.837 Χ 10-3 °C-1 was obtained for the selection chamber temperature sensor and 1.902 Χ 10-
3 °C-1 for the amplification chamber temperature sensor. 
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Figure 3.5: Characterization of the microchip temperature sensors. The linear relationship between 
temperature and resistor resistance for the (a) selection chamber and (b) amplification chamber resistors 
allows determination of a temperature coefficient of resistance 
 
3.3.2. Affinity Selection 
 The affinity selection process must be able to provide an environment that allows potential 
aptamers in the initial starting library to bind to the target functionalized on the magnetic beads. The process 
must also be able to successfully partition binding oligonucleotides from weakly binding oligonucleotides. 
To verify successful affinity selection the initial starting library was introduced into the selection chamber 
which was preloaded with target-functionalized beads. Eight buffer washes were used to remove weakly 
binding oligonucleotides with effluents collected and analyzed. Finally the chamber temperature was 
increased to disrupt the binding between the binding oligonucleotides and the target molecules, and the 
chamber was washed using the same flow rate and volume of buffer that was used for the buffer washing. 
The effluent from this wash was collected and analyzed. All binding effluents were amplified off-chip by 
PCR (16 cycles) and imaged using gel electrophoresis (Figure 3.6). A decrease in band intensity in the gel 
electropherogram indicates fewer oligonucleotide molecules present. Thus, the decreasing band intensity 
from the first wash (W1) to the final wash (W8) indicates that in the initial washes many weakly binding 
oligonucleotides were removed from the selection chamber and as washing progressed few 
oligonucleotides remained that could be removed by washing alone. When the chamber was heated (55 °C), 
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represented by the elution (E) lane, a relatively high amount of oligonucleotides could be removed from the 
selection chamber. This suggests weakly binding oligonucleotides were removed by washing and upon 
heating the remaining strongly bound oligonucleotides could be eluted and collected or, if SELEX was to 
continue, transferred for PCR amplification.  Therefore, the selection process was successful in portioning 
non-binding oligonucleotides, which were washed out of the chamber, from binding oligonucleotides, which 
could be eluted through a modest increase in temperature. 
 
Figure 3.6: (a) Experiment schematic of the selection characterization. (b) Gel electropherogram and (c) 
measured band intensities of amplified eluents obtained during selection process with bar graph depicting 
intensities of lanes W1-E: washes 1, 2, 3, 4, 5, 6, 7, 8, and elution. 
 
3.3.3. Electrokinetic Transfer 
Electrokinetic migration of oligomers was characterized by injecting fluorescently modified 
(fluorescein) oligomers into the selection chamber (100 nM) and applying an electric field (40 V/cm) with 
platinum wires from the selection chamber to the amplification chamber. While applying the electric field, 
an epifluorescent microscope (Eclipse 50i, Nikon, Tokyo, Japan) was focused on the amplification chamber 
and a micrograph of the chamber was acquired in one minute intervals with a charge-coupled device (Orca-
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ER, Hamamatsu Photonics, Hamamatsu, Japan). This process was repeated three times with a 40 V/cm 
electric field and three times without applying an electric field. 
The fluorescent signal of the fluorescein-modified library is shown Figure 3.7. The error bars 
indicate the standard deviation of three repeated measurements, representing experimental errors 
associated with sources such as the imprecision in the volume of nucleotide solution dispensed into the 
inlet well and time variation of the electroknetic properties of the PDMS surfaces [147]. When an electric 
field of 40 V/cm was applied, the intensity of fluorescence, representing the amount of oligonucleotides that 
had been transferred from the selection chamber to the amplification chamber, began increasing after 10 
minutes and then saturated within approximately 37 minutes, In the absence of an electric field, the 
fluorescent intensity of the amplification chamber did not rise above background even for time durations 
longer than one hour (data not shown). Thus, to transfer oligonucleotides between functional chambers an 
electric field of 40 V/cm was applied for 40 minutes, which was considered sufficient for transferring 
oligonucleotides between the chambers.  
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Figure 3.7: Fluorescent ssDNA was introduced to the selection chamber and fluorescent images were 
taken of the transfer microchannel at the amplification chamber after (a) 0 minutes, (b) 20 minutes, and (c) 
40 minutes of applying a 40 V/cm electric field. (d) Time-course fluorescent intensity of selection chamber; 
error bars represent standard error; scale bars: 50 μm. 
 
Considering a transfer channel 14.75 mm long, the oligonucleotide apparent velocity, vapp, was 
approximately 6.145 μm/s. Using this velocity along with the electric field strength, E, an apparent mobility 
electrokinetic, μapp, of the solution can be defined. 
𝜇𝑎𝑝𝑝 =
𝑣𝑎𝑝𝑝
𝐸
 
From this expression an apparent mobility of 1.536 x 10-8 m2/Vs is obtained which agrees with other 
PDMS/PDMS fabricated devices [148]. 
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 On-chip bead-based PCR was verified by injecting fluorescently modified oligonucleotides into the 
amplification chamber containing reverse-primer beads. PCR reagents, including a fluorescently modified 
forward primer, were then introduced and 20 cycles of PCR thermal cycling. Following thermal cycling the 
beads in the chamber were washed to remove non-incorporated fluorescent primers. The fluorescent 
intensity of the beads was measured before thermal cycling, after thermal cycling, and after thermal elution. 
As a control the process was repeated without including taq polymerase (Figure 3.8). The increase in 
brightness of the bead surfaces after the PCR thermal cycling suggests that the PCR process successfully 
amplified the oligomers on the bead surfaces, while the decrease intensity after thermal elution indicates 
that single-stranded oligonucleotides were thermally released from the bead surfaces. The fluorescent 
intensity of the beads used in the no-taq experiment did no increase after thermal cycling. 
 
Figure 3.8: Fluorescent images of beads (A) before, (B) after 20 cycles of PCR, and (C) after 95°C thermally 
induced ssDNA elution. (D) Bar graph depicting fluorescent intensities. Error bars represent standard 
errors. 
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3.3.5. Closed-Loop SELEX 
The microchip performed microfluidic SELEX, which primarily involved integrated affinity selection 
and amplification, for isolation of aptamer candidates that bind to protein IgA1. To investigate the progress 
of the multi-round SELEX experiment, weakly bound ssDNA in each wash in the affinity selection procedure 
of each round, as well as the thermally eluted, strongly protein-binding oligonucleotides in the final round, 
were collected from the selection chamber, amplified and analyzed with gel electrophoresis (Figure 3.9). 
In the first wash of the first round (S1W1) there were a significant amount of oligonucleotides present but 
this decreased as the washing process progressed. In the first wash of the second round (S2W1) there were 
many more oligonucleotides present than the last wash from the first round (S1W8). This indicates 
successful transfer of the oligonucleotides to the amplification, PCR amplification and transfer back to the 
selection chamber for a second round of affinity selection. At the final wash of the second round (S2W8) 
there was not a detectable amount of oligonucleotides present; however, upon thermal elution (S2E) there 
were again detectable amounts of oligonucleotides. Thus, the affinity selection process in these rounds 
effectively removed weakly bound ssDNA as target-binding oligomers became more enriched. Moreover, 
high fluorescence intensity was observed in the thermal eluate (E) from the final round of SELEX, indicating 
that a significant amount of enriched protein-binding oligonucleotides (i.e., aptamer candidates) were 
generated from the SELEX process. 
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Figure 3.9: (a) Gel electropherogram of amplified eluents obtained during closed-loop selection and 
amplification. (b) Bar graph depicting intensities of lanes S1W1-S2E: S1W1:  selection 1, wash 1; S1W10: 
selection 1, wash 10; S2W1: selection 2, wash 1; S2W10: selection 2, wash 10; S2E: oligomers released upon 
thermal elution. (c) Fluorescent intensity of fluorescently labeled enriched pool and library thermally eluted 
from target-functionalized beads after incubation and washing. Error bars represent standard error. 
 
The oligonucleotides isolated from the microfluidic SELEX process were tested for their affinity 
towards IgA1 using a fluorescence binding assay. The background-subtracted average fluorescence 
intensity of the enriched aptamer candidate pool incubated with IgA was significantly higher than the 
fluorescence intensity of the library used to initiate the SELEX process. This indicates the enriched pool 
bound with considerably higher affinity and suggests that the mult-round SELEX process using the 
microchip was successful. Further enrichment of the candidate pool can be achieved with further rounds of 
affinity selection and amplification with the microchip.  
3.4. Conclusion 
 We have presented an integrated, microfluidic approach to isolate aptamer against protein targets 
using a simplified electrokinetic transfer scheme. The approach involves bead-based reactions for 
electrokinetically coupled affinity selection and PCR amplification. The electrokinetic coupling allows highly 
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integrated migration of oligonucleotides with reduced flow control equipment and without the need for 
complicated fabrication methods or gels, while also preventing undesirable diffusion or cross-flow effects. 
Thus, the approach is capable of integrating the iterative cycles of affinity selection and amplification onto 
a single chip without requiring offline processes that are commonly used in existing microfluidic aptamer 
selection devices. The approach was demonstrated by selecting an enriched pool of aptamers with affinity 
towards IgA. Oligonucleotides were affinity selected from a randomized library, electrokinetically transferred, 
PCR amplified, and transferred back for further affinity selection. The approach is readily capable of 
repeating these cycles of selection and amplification to obtain a pool of aptamers with sufficient affinity to 
a target of interest. The resulting enriched pool showed increased affinity towards the target when 
compared with the starting library.  
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Chapter 4: Aptamer Selection with Microfluidic Three-Chamber Approach 
4.1. Introduction 
 In Chapter 3 and Chapter 4, two different microfluidic approaches were presented. One which used 
a system combining electrophoresis transport and pneumatic valves, and the other removing valves 
altogether and employing a long channel with high diffusive resistance to separate two functional 
microchambers while still allowing electrokinetic transport between the two chambers. These approaches 
were successful in isolating aptamers with affinity and specificity towards model immunoglobulin subtypes 
(IgA, IgE). However, for the development of aptamers useful in precision medicine applications aptamers 
with a greater degree of discerning ability are needed, aptamers must be able to specifically recognize an 
epitope that shares many similarities with other biological molecules. Furthermore, both approaches had 
limitations which made accomplishing many rounds of SELEX in a single device challenging. The most 
direct way to increase the affinity and specificity of an aptamer pool is to do more SELEX cycles. As 
discussed in Chapter 2, the hybrid approach was dependent on an agarose gel which had a tendency to 
degrade after a few rounds of SELEX limiting the amount of cycles that could be performed on-chip. On the 
other hand, the electrokinetic approach needed careful control of the dynamic charge conditions in the 
microfluidic chip. Without careful control of the charge conditions, for a given electric field strength and 
direction, the flow between the two chambers could be dominated by either electroosmosis or 
electrophoretics [149]. Depending on which force dominates the flow could go from selection chamber to 
amplification or the other way around. Furthermore, the electrokinetic approach simplified the device 
operation with magnetic beads; however, it was found magnetic beads aggregated at the bottom of 
microchambers creating a flow situation where much of the aptamer library volume passed above the beads 
without interacting with the target molecules. 
 Moreover, both the hybrid and electrokinetic approaches were realized in devices with single 
selection and amplification chambers. While, this simplified the device design, it also limited the ability to 
incorporate rounds of counter selection. The importance of counter selection is lessoned when developing 
aptamers for a specific antibody class (e.g. IgE and IgA), but for precision medicine applications where 
aptamers must be specific for a single population of antibody within an antibody class, the counter selection 
remains an effective stage to increase an aptamer pool specificity. The previously presented approaches 
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could only effectively perform a single round of counter selection which was required to be at the end of the 
SELEX process.  
 Here we present a third microfluidic approach to accomplish the SELEX process on a microchip. 
The approach fully integrates selection, counter selection and amplification on a single microchip and is 
able to accomplish many rounds of SELEX without significant degradation. In this approach pressure-driven 
and pneumatically controlled valves are used to direct affinity-selected oligonucleotides through the SELEX 
process. The pneumatically controlled valves are not only capable of controlling flow direction but also able 
to fully close off functional chambers to reduce cross-contamination. Counter selection is achieved by the 
addition of a third microchamber which sits between selection and amplification chambers, such that 
counter selection occurs automatically as oligonucleotides are transferred for PCR amplification without 
increasing the overall time needed to complete a round of SELEX when compared to the hybrid and 
electrokinetic approaches. Moreover, the pneumatic microvalves employed in the approach can be used 
many times without risk of wear allowing many rounds of the SELEX process to be accomplished. These 
advantages are combined with high capacity agarose bead-based protocols to achieve on-chip coupling of 
affinity selection, counter selection and amplification of affinity selected oligonucleotides without relying on 
offline processes. In this chapter the functional ability of the device to accomplish affinity selection, and 
amplification and coupled multiround SELEX are demonstrated. 
4.2. Experimental 
4.2.1. Principle 
The approach relies on isolating high affinity members from a highly diverse (10^18 member) 
oligonucleotide library through iterative rounds of affinity selection, affinity counter selection, and PCR 
amplification on a microfluidic device. The 87 nucleotide oligonucleotide library is composed of a 40 
nucleotide randomized region surrounded by a fixed nucleotide region at the 5’ end and 3’ ends. Thus, the 
oligonucleotide library has a theoretical limit of 440 members (1024) that can be readily amplified through 
PCR with a reverse and forward primer. This library is passed through target-coupled beads and washed 
with buffer to remove library members that weakly bind to the target. Oligonucleotides that bind to the target 
glycan are eluted from the target beads by modest thermal denaturation and transferred through counter 
target beads before ultimately being captured by reverse-primer functionalized beads (amplification beads) 
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through complementary base pairing. In this way, library members with affinity towards the counter target 
are removed before hybridizing to the reverse-primer beads. The hybridized library is amplified by PCR and 
sense strands to produce double-stranded DNA products on the amplification beads. The amplified product 
is removed from its bead-bound complement through thermal denaturation and transferred back to target 
glycan beads as a new round of selection begins. This process is repeated until the library is sufficiently 
enriched to the point that oligonucleotides with high affinity and specificity can be identified (Figure 4.1). 
 
Figure 4.1: Aptamer selection procedure. (a) Library is introduced and allowed to bind to beads. (b) Non-
binding and weakly binding ssDNA is removed with buffer washes and then (c) counter selected against a 
counter target. (d) ssDNA which binds to the target but does not bind to the counter target is transported to 
the amplification chamber where it hybridizes to reverse primers located on the surface of amplification 
beads. (e) Hybridized ssDNA is amplified by PCR which is then (f) thermally denatured to release the single 
stranded product. This product is transferred back to (a) for further rounds of SELEX. 
4.2.2. Microfluidic Device Design 
The approach is realized in a device consisting of 3 microchambers of similar geometry (~4.5 µL) 
connected by microchannels to form a SELEX capable loop (Figure 4.2). Each microchamber features a 
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fluidic weir which allows buffer to pass but is sufficiently small to prevent beads from passing between 
chambers (20 µm), a bead inlet, secondary inlet, and an outlet. The selection and amplification chamber 
are equipped with a temperature sensor and heater located beneath the chamber to allow temperature 
mediated release of oligonucleotides and PCR. Each chamber is connected to the other two through 
microchannels (~20 um height). Flow is directed between the three cambers by the integrated pneumatic 
microvalves [141]. Fluid moves in a clockwise direction from selection to counter selection to amplification 
and then back to selection.  
 
Figure 4.2: Device design. The approach is realized in a microfluidic device with dedicated chambers for 
selection, counter selection, and amplification. Valves are used to direct flow between these three chambers 
and allow controlled transport of ssDNA to complete rounds of SELEX. 
Beads (selection, counter selection and amplification) are first introduced from the bead inlets and 
trapped by the weir structures in the three chambers. These inlets are then blocked and starting library is 
injected from the secondary inlet and allowed to incubate with the target. Valves are configured at this stage 
to allow buffer to flow from the inlet, across the selection chamber and then exit through the outlet. Following 
incubation, buffer is used to wash weakly binding aptamer candidates by exchanging the library with buffer 
at the inlet. Upon completion of washing only strongly binding oligonucleotides will remain in the device. 
The integrated heaters beneath the selection chamber are then activated to increase the selection chamber 
temperature and induce thermal based elution of binding oligonucleotides. Concurrently with this 
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temperature increase, the valve configuration is reoriented to create buffer flow from the selection chamber, 
through the counter selection chamber and amplification chamber, and out the amplification outlet. Thus 
oligonucleotides which strongly bound to the target molecule are released and are challenged by the 
counter target beads, with those members with affinity towards the counter target being trapped by the 
counter beads and the others ultimately hybridizing to the amplification beads. Once in the amplification 
chamber, PCR reagents are introduced and PCR based thermal cycling commences utilizing the 
temperature sensor and heater located beneath the amplification chamber. The amplified product is washed 
with buffer to remove free-solution oligonucleotides while oligonucleotides generated on bead surfaces 
remain. Selection and counter selection beads are replenished in their respective chambers. The heater 
and temperature sensor are employed again to heat the chamber to 95 ºC to induce thermal based 
dehybridization of the amplified product from its complementary strand used for PCR amplification. 
Meanwhile the valves are again reconfigured to allow flow carrying amplified oligonucleotides from the 
amplification chamber, across the selection chamber, and out the selection chamber outlet. Therefore, 
another cycle of SELEX begins. This process is repeated on a single chip until a pool of high-affinity aptamer 
candidates are generated.  
4.2.3. Microfluidic Device Design 
 The integrated approach is achieved in a microfluidic device capable of performing iterative cycles 
of selection, counter selection and amplification. The device features three microfluidic chambers of 
hexagonal geometry, each 7.5 mm long, 2.5 mm wide and 240 um tall (~4.5 µL). Similar to the electrokinetic 
device in Chapter 3, the hexagonal shape is adopted because it is not as prone to trapping catastrophic 
bubbles [146]. Each selection chamber has a dedicated inlet for the introduction and removal of microbeads 
(700 µm wide, 4500 µm long and 240 um tall). Connecting each of the three chambers to the other two 
chambers is a microfluidic channel of 700 µm linewidth and 20 µm tall and variable length depending on 
the chambers the channel connects (either 16 mm or 28 mm). The reduced height of the connecting 
channels is smaller than the diameter of the microbeads used in the device; therefore, beads are retained 
in three taller chambers. The channel between the amplification chamber and counter selection chamber, 
and the channel between the amplification and selection chamber feature a region (3 mm long) of 
semicircular cross-section which overlaps with the valve channels in the control layer. This region of the 
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channel can be completely closed when the corresponding valve is actuated allowing controlled sealing of 
chambers and control of flow direction. The channel connecting the amplification chamber to the selection 
chamber and the amplification chamber to the counter selection chamber also feature an inlet and outlet to 
allow oligonucleotides and reagents to be introduced. A pair of heater and temperature sensors lie beneath 
the selection chamber and amplification chamber and are composed of 20 nm chrome and 100 nm thick 
gold. The temperature sensor is of rectangular shape with a linewidth of 30 µm and the heater is of 
serpentine shape, filling the area of the chambers and of line width 300 µm. 
 Multiple rounds are able to be achieved on the microdevice. First target beads, counter target beads, 
and amplification beads are respectively introduced in the selection, counter selection, and amplification 
chambers through the bead inlets. The reduction in chamber height from the inlet to the connecting 
chambers allows beads to be retained in the chamber. These inlets are blocked with plugs following bead 
introduction. Affinity selection is then performed by first flowing oligonucleotides, and then washing buffer 
from the selection inlet while the valves are configured to allow flow out the selection outlet. Following 
selection the valves are reconfigured to allow flow from the selection inlet, through the counter selection 
chamber, through the amplification chamber, and out the amplification outlet. Once reconfigured, the 
selection chamber heater and temperature sensor are engaged to increase the temperature and thermally 
elute binding oligonucleotides from their targets while buffer is flowing from the selection inlet to the 
amplification outlet. The oligonucleotides that do not bind to the counter target beads in the counter 
selection chamber hybridize to the amplification beads in the amplification chamber. Following this process, 
the valves are reconfigured again to allow flow from the amplification inlet and out the amplification outlet, 
and a pipette is used to inject PCR reagents from the amplification inlet. The amplification inlet is then 
plugged and the amplification chamber heater and temperature sensors are used to perform 12 cycles of 
PCR (55 ºC for 15 seconds, 72 ºC for 5 seconds, and 92 º C for 2 seconds). During PCR the amplification 
chamber is isolated from the other chambers with valves allowing the selection and counter selection 
chambers to be washed and their beads to be replenished. Following PCR the amplification chamber is 
rinsed with buffer to remove solution phase double stranded oligonucleotides. Then the heater and 
temperature sensor in the amplification chamber are again used to heat the chamber to 95 ºC to de-
hybridize the amplified affinity selected oligonucleotides from their surface bound complements generated 
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during the PCR process. Meanwhile, the valves are once again reconfigured to allow flow from the 
amplification inlet through the selection chamber and out the selection outlet. Buffer flow carries the 
amplified oligonucleotides to the replenished selection chamber as a new cycle of SELEX commences. 
After the amplified product has be transferred, the amplification beads are replenished in the amplification 
chamber. This process continues until a pool of high affinity aptamers can be isolated. 
4.2.4. Materials 
Human Imunnoglobulin A (IgA1) was purchased from Cell Sciences (Newburyport, MA). 
CaptureSelectTM IgA affinity matrix, streptavidin coupled agarose beads (Pierce Streptavidin Agarose), and 
Dulbecco’s phosphate-buffered saline (D-PBS) were purchased from Thermo Fisher Scientific (Waltham, 
MA). Ethanolamine, MgCl2, tris, boric acid, and molecular biology grade water were purchased from Sigma-
Aldrich (St. Louis, MO). Deoxyribonucleotide triphosphates (dNTPs) and GoTaq Flexi DNA polymerase 
were obtained from Promega Corp. (Madison, WI). Randomized oligonucleotide library (5’ – TTG GAT TGA 
GAA ACA TCG CCG C – 40N – TTC CTC CTG ACC ACA TCC GAC– 3’) and primers (Forward Primer: 5' 
– TTG GAT TGA GAA ACA TCG CCG C -3', and Reverse Primer: 5' - biotin – GTC GGA TGT GGT CAG 
GAG GAA – 3') were synthesized and purified by Integrated DNA Technologies (Coralville, IA). SU-8 (2000, 
2025, and 2075 series) negative photoresist was purchased from Microchem Corp. (Westborough, MA). 
AZ 50XT was purchased from Integrated Micro Materials (Argyle, TX). Polydimethylsiloxane (PDMS) was 
obtained from Robert McKeown Company (Somerville, NJ) and silicon wafers were purchased from Silicon 
Quest International, Inc. (San Jose, CA). All other chemicals used for clean-room based fabrication were 
acquired from the City University of New York (CUNY) Advanced Science and Research NanoFabrication 
Facility. 
Agarose microbeads (CaptureSelectTM IgA affinity matrix) functionalized with a protein were used 
for selection and agarose microbeads (Pierce Streptavidin Agarose) functionalized with reverse primers 
were used for amplification. The beads for selection were functionalized with a protein (IgA1) through affinity 
binding of the camelid CaptureSelect antibody which only binds IgA immunoglobulins. Prior to an 
experiment, a stock of selection beads were prepared by incubating the beads with IgA1 under gentle 
rotation for 1 hour at room temperature, and washing with D-PBS buffer. The functionalized beads were 
then suspended in D-PBS buffer. Similarly, streptavidin beads were functionalized by incubation with biotin 
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conjugated reverse primers for 30 minutes, and washing with D-PBS buffer. This coupling relies on the 
biotin-streptavidin affinity interaction. The functionalized beads were suspended in D-PBS buffer. 
4.2.5. Fabrication 
 The devices used to realize the three chamber approach are fabricated in PDMS using standard 
photolithography techniques. First, a silicon wafer is cleaned with piranha (3 parts sulfuric acid and 1 part 
30% hydrogen peroxide), rinsed with water, dried with nitrogen and placed on a hotplate set to 130 ºC for 
1 hour. Following this cleaning process the wafer has chrome (20 nm) and gold (100 nm) deposited on its 
surface using a thermal evaporator (Edwards 306 Thermal Evaporator). Photoresist (AZ 1512, 
MicroChemicals GmbH) is then spun on the wafer (500 rpm for 10 seconds, 3000 rpm for 30 seconds, 500 
rpm/s ramp) and baked on a hotplate at 120 ºC for 2 minutes. After the baking process, the wafer is exposed 
to 95 mJ/cm2 of energy through a custom made mask defining alignment marks using a mask aligner. The 
exposed photoresist is then developed in AZ 300 MIF photoresist for 20 seconds and rinsed with water. 
The wafer is then submerged in first gold etchant (15 seconds), then chromium etchant (15 seconds), DI 
water, acetone, and finally IPA resulting in a silicon wafer with gold alignment marks which can be used for 
the multistep photolithography processes which are to follow. 
 The wafer with alignment marks could then be used for several additive fabrication steps. First AZ 
50XT photoresist was spun onto the wafer (500 rpm for 20 seconds, 1500 rpm for 1 minute, 500 rpm/s 
ramp rate) and it was baked for 2 minutes on a hotplate at 85 ºC and then 5 minutes at 115 ºC. AZ 50XT 
was then deposited onto the wafer again and the wafer was spun using a spin coater (500 rpm for 20 
seconds, 1500 rpm for 1 minute, 500 rpm/s ramp rate), and baked for 2 minutes at 85 ºC and then 5 minutes 
at 115 ºC. The wafer was allowed to rehydrate overnight. The wafer was then exposed to 2500 mJ/cm2 of 
energy through a photomask bearing the valve controlled regions of flow layer with a mask aligner (EVG620 
Mask Aligner). The exposed wafer was submerged in AZ 400K (1:4) developer for 15 minutes and rinsed 
with water. Excess photoresist on the edges of the wafer was removed using an acetone soaked cleanroom 
wipe (Texwipes). This wafer was then placed on a programmable hotplate (Torrey Pines Scientific) which 
ramped the hotplate temperature from room temperature to 200 ºC over 12 hours and then held the 
temperature at 200 ºC for 4 hours. Gradually heating allowed the photoresist to reflow into the semicircular 
shape necessary for valve control without causing bubbles to form in the photoresist. Furthermore, the 
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heating hard-bakes the photoresist so that the solvents in subsequent photolithography steps do not cause 
the dissolution of this layer. 
 A thin layer of SU-8 which includes the entire flow layer, sans the valve controlled regions, was 
then built on the wafer. SU-8 3005 was spun using a spin coater (2000 rpm, 1 minute, 500 rpm/s ramp rate) 
and baked at 95 ºC for 3 minutes. This layer was exposed to 250 mJ/cm2 of energy using a mask aligner 
and a custom designed mask, post baked (65 ºC for 1 minute and 95 C ºfor 2 minutes), and developed with 
SU-8 developer. The developed wafer was rinsed with isopropanol. This layer, while too thin to define 
channels in the final device, takes advantage of the increased adhesion of the 3000 series SU-8 to silicon 
substrates, thus creating an adhesion layer for the additional layers of SU-8 photolithography necessary to 
complete the fabrication of the device. 
 The flow layer bearing the connecting channels and chambers was then fabricated. SU-8 2025 was 
spun on the wafer using a spin coater (300 rpm for 15 seconds, 3000 rpm for 45 seconds, 300 rpm/second 
ramp rate), and baked (65 ºC for 3 minutes and 95 ºC for 6 minutes). The baked wafer was exposed to 400 
mJ/cm2 of energy through a custom made mask using a mask aligner, and returned to a hotplate at 65 ºC 
for 1 minute and 95 ºC for 6 minutes. The baked wafer was placed into SU-8 developer for 1 minute, rinsed 
with isopropanol and dried with a nitrogen gun. The chambers were then created in the wafer. SU-8 2075 
was deposited on the wafer, allowed to settle on the wafer for 10 minutes, and then spun with a spinner 
(300 rpm for 15 seconds, 1000 rpm for 45 seconds, 300 rpm/second ramp rate). This was pre-baked on a 
hotplate at 65 ºC for 7 minutes which was ramped 10 ºC/minute to 95 ºC where it remained for 45 minutes. 
The pre-baked wafer was then exposed to 400 mJ/cm2 energy with a custom mask defining the chambers 
using a mask aligner. Subsequently, the wafer was post-baked on a hotplate at 65 ºC for 5 minutes. The 
temperature was then slowly increased from 65 ºC to 95 ºC over 30 minutes and held at 95 ºC for 15 
minutes. The hotplate was then turned off and allowed to return to room temperature with the wafer still 
remaining on its surface. The slow cooling to room temperature was to reduce the thermal stress on the 
thick SU-8 features which can cause adhesion problems during the development process. The wafer was 
then submerged in SU-8 developer for 10 minutes, rinsed with isopropanol and dried with compressed 
nitrogen thus completing the fabrication of the flow layer silicon mold. 
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 The control layer was then similarly fabricated on a second wafer. SU-8 2025 was deposited onto 
a piranha cleaned wafer and spun using a spin coater (300 rpm for 15 seconds, 3000 rpm for 45 seconds, 
300 rpm/second ramp rate). The spun photoresist was then baked on a hotplate at 65 ºC for 3 minutes and 
then at 95 ºC for 6 minutes. This pre-baked wafer was placed in a mask aligner along with a custom 
designed mask bearing the control layer features and exposed to 400 mJ/cm2 of energy. A post-bake 
commenced consisting of 65 ºC for 1 minute and 95 ºC for 6 minutes on a hotplate. The post-baked wafer 
was then immersed in SU-8 developer for 1 minute, rinsed with isopropanol, and dried with compressed 
nitrogen.  
 Glass slides bearing heaters and temperature sensors were then fabricated. Chrome (20 nm) and 
gold (100 nm) were thermally evaporated onto piranha cleaned microscope slides. AZ 1512 was deposited 
onto them which were next spun (500 rpm for 10 seconds, 3000 rpm for 30 seconds, 500 rpm/s ramp) using 
a spinner. Following the spin, the slides were placed on a hotplate at 120 ºC for 2 minutes. The slides were 
then placed in a mask aligner along with a custom designed film mask bearing the heater and temperature 
sensor designs and exposed to 95 mJ/cm2 of energy. These slides were developed in AZ 300 MIF, rinsed 
with water, and then immersed in first gold etchant (15 seconds) and then chrome etchant (15 seconds). 
Finally the slides were rinsed with acetone to remove remaining photoresist, rinsed in isopropanol, dried 
with compressed nitrogen and placed on a hotplate at 110 ºC for 1 hour to remove unevaporated solvent.  
 With flow and control layer wafers prepared, as well as substrates bearing heaters and temperature 
sensors, PDMS based fabrication began. 30 mL of PDMS (10:1 base: curing agent by weight) was poured 
onto the flow layer wafer, and placed in a vacuum desiccator for 30 minutes to remove bubbles. Following 
bubble removal, the flow layer wafer was placed on a hotplate set to 72 ºC for 30 minutes. The PDMS was 
then peeled off, cut into three identical flow layers, and had inlets and outlets punched using an autopsy 
punch. Meanwhile, 3 mL of PDMS was poured onto the control layer which was then spun using a spinner 
(300 rpm for 15 seconds, 1000 rpm for 45 seconds, 300 rpm/second ramp rate). The control layer was then 
placed on 72 ºC hotplate for 20 minutes. The three flow layer devices and the control layer were then placed 
in an oxygen plasma etcher (Diener Plasma Etch) and exposed to oxygen plasma for 20 seconds at 50% 
power. Immediately after exposure the flow layer devices were aligned to the three control layer features 
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on the flow layer wafer and gently pressed to put their surfaces in contact. The control layer wafer with flow 
layer devices on top of it were then placed on a hotplate at 75 ºC for 1 hour. Following this bake, the flow 
layer devices and the PDMS thin film coating the control layer were permanently bonded and could be 
peeled off together. The peeled off PDMS blocks which bore flow and control layers then had valve inlets 
punched into them. Meanwhile, 3 mL of PDMS were poured onto the glass slides bearing the heaters and 
temperature sensors, spun (300 rpm for 15 seconds, 1000 rpm for 45 seconds, 300 rpm/second ramp rate), 
and baked on a hotplate (72 ºC for 20 minutes). The heater and temperature sensors and the flow and 
control layer devices were then again exposed to oxygen plasma (20 seconds, 50 % power). The exposed 
devices were immediately aligned and gently pressed into the heater and temperature sensor glass slides. 
These were baked at 100 ºC overnight. Finally wires connected to the heaters and temperature sensors 
were soldered onto the contact pads. A fabricated device can be seen in Figure 4.3.  
 
Figure 4.3: Photograph of a fabricated device. 
 
4.2.6. On-chip Procedure 
 The microfluidic chip was interfaced with a syringe pump (New Era NE-1002X), a nitrogen tank, a 
multimeter (HP 3478A) and a power supply (Agilent E3631A). The syringe pump was responsible for 
supplying a fluid source, while the nitrogen tank was used to actuate the valves that controlled the direction 
of this fluid source. The multimeter and power supply were in turn connected a computer which 
implemented a LabView code to control the temperature of functional chambers in the device. This code 
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could implement simple temperature control for the elution of binding oligonucleotides or could perform the 
thermal cycling necessary for PCR amplification.  
Multiround integrated SELEX occurred on-chip without the use of offline processes or equipment. 
First, the appropriate beads (selection, counter selection, and amplification) were pipetted into the three 
chambers (selection, counter selection, and amplification) until the beads filled approximately half of the 
chamber. Next, 100 µL of 100 nM (10 pmoles) of library, which has previously be heated to 95 ºC for 5 
minutes and cooled back to room temperature, was pumped into the device (10 µL/min) using a syringe 
pump. Once the total library volume has passed through the selection chamber, the washing stage 
commenced where buffer (PBS with 2 mM MgCl2) was infused (20 µL/min) through the selection chamber 
to remove weakly binding oligonucleotides for 35 minutes. Buffer flow-through was collected in 5 minute 
intervals, amplified by PCR, and imaged with a gel electropherogram to verify successful removal of non-
binding oligonucleotides through the washes and the retention of strong-binding oligonucleotides.  
Following this wash the valves were reconfigured to allow flow from the selection chamber through 
the counter selection chamber and into the amplification chamber. Once in this configuration, the heater 
and temperature sensor located beneath the selection chamber were used to increase the selection 
chamber temperature to 55 ºC. 20 µL/min flow over a 10 minute period was used to transfer heat released 
oligonucleotides from the selection chamber through the counter selection chamber and finally to the 
amplification chamber where oligonucleotides that do not bind to the counter target hybridize to the reverse 
primer functionalized beads in the amplification chamber. PCR reagents were then pipetted into the 
amplification chamber and all the valves were closed to seal the amplification chamber for PCR. The heater 
and temperature sensor located beneath the amplification chamber were used for 12 rounds of PCR 
thermal cycling (55 ºC for 15 seconds, 72 ºC for 5 seconds, and 92 º C for 3 seconds). PCR amplification 
was confirmed through the amplification of a 100 fM library. An agarose gel was used to determine the 
presence of amplified DNA before amplification, and after amplification and thermally induced single-
stranded DNA release. 
During the PCR process the selection and counter selection chambers were prepared for the 
second round of SELEX. The beads in the selection chamber and counter selection chamber were removed 
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and the chambers were refilled with fresh selection and counter selection beads. The amplification chamber 
was then washed with buffer (PBS with 2 mM MgCl2) for 10 mins using a volumetric flow rate of 20 µL/min. 
After the completion of the washing, the heater and temperature sensor were again used to increase the 
amplification chamber temperature to 95 ºC which caused single stranded DNA to be released from their 
bead bound complements while the valves were again reconfigured to allow flow from the amplification 
chamber to the selection chamber. A flow rate of 20 µL/min was used for this process. After 5 minutes, the 
amplification chamber heater was turned off and the chamber returned to room temperature. The washing 
of the selection chamber then began (20 µL/min) and lasted for 35 minutes as the second round of the 
SELEX process continued. This sequence of events repeated until high affinity aptamer sequences could 
be identified. 
4.3. Results and Discussion 
 Results are presented characterizing the performance of the individual components of the 3-
chamber device. A complete two round process (selection, counter selection, amplification, selection, and 
finally counter selection) is then performed to demonstrate the ability of the device to realize a multi-round 
SELEX process. 
4.3.1. Heater and Temperature Sensor 
 Tight control over the heater and temperature sensor are necessary to ensure consisitent thermal 
based elution of strongly binding oligonucleotides and to ensure PCR amplification can successfully occur. 
The device uses thin film gold resistive temperature sensors and heaters. The heater and temperature 
sensor were first characterized using an environmental chamber (Delta Designs 9023, Cohu, Poway, CA) 
with a temperature probe. The device was placed inside the chamber with its temperature sensor connected 
to a multimeter and the temperature was ramped from room temperature to 95 ºC. The corresponding 
resistance of the device temperature sensors were recorded every 10 ºC (Figure 4.4). 
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Figure 4.4: Resistance of the (a) selection and (b) amplification chamber temperature sensors at various 
temperatures. 
The temperature and resistance information for the device was then plotted and fitted with the following 
expression. 
𝑅 − 𝑅0
𝑅0
= 𝛼(𝑇 − 𝑇0) 
In this expression R is the resistance for a given temperature, R0 is the resistance at room temperature, T 
is the temperature, T0 is the room temperature and alpha is the coefficient of resistance. A coefficient of 
resistance of 2.527 Χ 10-3 °C-1 was obtained for the selection chamber temperature sensor and 2.556 Χ 10-
3 °C-1 for the amplification chamber temperature sensor. 
4.3.2. Affinity Selection 
 The affinity selection was evaluated by performing a single selection and assessing collected 
oligonucleotides. Selection beads were injected into the selection chamber until it was approximately half 
full of beads. The valves were configured to allow flow through the selection chamber inlet and out the 
selection chamber outlet. 100 µL and 100 nM of library (preheated off-chip) was injected into the chip at 10 
µL/min for 10 minutes. Wash buffer (PBS with 2 mM MgCl2) was then injected (20 µL/min) for 35 minutes. 
During the wash the flow through was collected in tubes, exchanging the outflow to a new tube every 5 
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minutes (~100 µL per tube). Finally, the temperature of the chamber was increased to 55 ºC and the outflow 
volume was collected in 5 minute intervals for 10 minutes. These collected volumes were amplified by PCR 
(20 cycles) and imaged with an agarose gel (Figure 4.5). 
 
Figure 4.5: Elution profile for the selection process. Collected eluents were amplified by PCR and imaged 
by gel electrophoresis. (a) Gel electropherogram of the amplified eluates and (b) fluorescent intensity 
readings from the gel electropherogram in (A). W1: wash 1, W2: wash 2, W3: wash 3, W4: wash 4, W5: wash 
5, W6: wash 6: W7: wash 7, W8: wash 8, E: eluted product. 
 It can be seen that during the washing process the brightness of the bands, which is a measure of 
the amount of DNA in each tube, decreased from W1 to W8 (Figure 4.5). This demonstrates that the washing 
process initially removed many weakly binding oligonucleotides but as the washing progressed fewer 
oligonucleotides were able to be removed from the chamber. The elution band (E) is comparatively bright 
compared to the final wash (W8) indicating that after the increase in temperature oligonucleotides which 
were unable to be removed by washing alone could be eluted. These oligonucleotides strongly bound to 
the target and the binding was only disrupted by the modest increase in temperature. 
0
5
10
15
20
25
30
35
40
1 2 3 4 5 6 7 8 9
F
lu
o
re
s
c
e
n
t 
In
te
n
s
it
y
 (
a
.u
.)
W1 W2 W3 W4 W5 W6 W7       W8 E
W1 W2 W3 W4 W5 W6 W7       W8 E
(a)
(b)
 75 
 
4.3.3. Amplification 
 The PCR amplification was confirmed by amplifying a low concentration library and imaging with 
an agarose gel. First buffer was injected into an amplification chamber containing amplification beads and 
the chamber was heated to 95 ºC while exiting solution was collected. This was to provide a no template 
control for the PCR process. Then, 100 µL of 100 fM library was injected (20 µL/min) into the amplification 
containing amplification beads. PCR reagents were pipetted into the chamber, and 12-cycles of PCR 
amplification commenced. The chamber was washed to remove unincorporated primers and double 
stranded DNA in solution. The chamber was then heated to 95 ºC under 20 µL/min flow conditions for 5 
minutes and the exiting solution was collected. This was repeated with a new device where library was 
injected and then heated to remove ssDNA without performing PCR thermal cycling. Collected eluates were 
amplified by PCR off-chip (10 cycles) and imaged by gel electrophoresis. It can be seen that there is only 
a band in the gel for the case where PCR amplification occurred with a template in the device (Figure 4.6).  
 76 
 
 
Figure 4.6: (a) Gel electropherogram of collected eluates from the amplification chamber in conditions 
where no template was included and no thermal cycling was used, where template was injected but thermal 
cycling was not used, where template was injected and thermal cycling was used, and a no template control. 
(b) Measured band brightness from the gel electropherogram. 
4.3.4. Integrated Multi-round SELEX 
 A complete 4-round SELEX was performed to confirm the devices ability to transition from selection 
steps to the amplification stage and back. Four rounds of selection, and counter selection were performed 
with a three rounds of PCR amplification and strand separation (Figure 4.7). Eluates during the process 
were collected, amplified off-chip by 20 cycles of PCR and imaged with a gel to analyze the closed-loop 
process.  
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Figure 4.7: Gel electropherograms from the four round selection process. (A) Amplified eluents measured 
with a gel electropherogram. (B) Measured band intensity from (A). Labeling is as follows, S1W1: Selection 
round 1, wash 1; S1W6: selection round 1, wash 6; S2W1: selection round 2, wash 1; S2W6: selection round 
2, wash 6; S3W1: selection round 3, wash 1; S3W6: selection round 3, wash 6; S4W1: selection round 4, 
wash 1; S4W6: selection round 4, wash 6; E: elution. 
The brightness of the bands in a gel electrophorogram correlates to the initial amount of 
oligonucleotides in the collected eluate which can be compared to investigate the SELEX process. During 
the first round, the brightness of the bands monotonously decreases from the first wash (S1W1) to the last 
wash (S1W6) indicating that the washing process removed weakly binding oligonucleotides. The band 
intensity then increased from the last wash of the first round (S1W6) to the first wash of the second round 
(S2W1). This suggests the ssDNA were successfully transferred to the amplification, amplified by PCR and 
transferred back to the selection chamber. The decrease in band intensity from the first wash of the second 
round (S2W1) to the final wash of the second round (S2W6) again indicates the washing process removed 
weakly binding oligonucleotides. The presence of a band in the elution lane (E) combined with the absence 
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of a band in the final wash of the fourth round shows that oligonucleotides that could not be removed by 
washing were eluted by a change in thermal conditions and were able to be counter selected and collected. 
It is further important to note that during this closed-loop process there was no observed wear on the device 
suggesting the device could be used for many rounds of the SELEX process without deterioration.  
4.4. Conclusion 
 The three chamber microfluidic approach with pressure driven reactions has been described. The 
approach leveraged bead-based reactions within three functional chambers (selection, counter selection, 
and amplification) connected in a loop by microchannels. As such, oligonucleotides are affinity selected 
against target functionalized beads, affinity counter selected against counter target functionalized beads, 
and amplified by reverse primer functionalized beads. The single-stranded amplified product is transferred 
back to the selection chamber for further rounds of SELEX. Therefore, the approach integrates the entire 
SELEX process on a single microchip without the need for offline procedures and drastically reduces the 
time required to obtain aptamer candidates. These components were characterized using IgA as a model 
target. Furthermore, the device showed no appreciable degradation indicating it could be used for SELEX 
beyond four rounds if needed. 
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Chapter 5: Selection of Aptamers to Glycans and Glycosylated Peptides 
5.1. Introduction 
Glycans, one of the four major classes of molecules making up cells (the others being nucleic acids, 
proteins and lipids) [150], are involved in all human developmental activities including structural roles, 
modulatory, intercellular signaling and adhesion [151, 152]. Furthermore, more than 50% of proteins are 
modified by glycosylation [30] which occurs in the Golgi apparatus (for O-linked glycosylation) or 
endoplasmic reticulum (for N-linked glycosylation). Expectantly, aberrant expression of glycans, including 
under- and overexpression, has been found to be associated with many diseases, attracting considerable 
interest in using glycans as disease markers [153-155]. Glycans represent a potential source of biomarkers 
that could stratify patients and allow tailored disease treatment strategies [7]. 
Despite their importance in many biological functions, methods to rapidly and sensitively analyze 
glycan samples remains an unmet challenge [156]. The entire human glycome (estimated to range from 
hundreds to thousands of structures) can be built by branched and linear combinations of only 9 glycome 
building blocks and are recognized by only 70 different glycan binding proteins [151]. The structure of 
glycans cannot be predicted by genomic information [155, 157]. Multi-dimensional liquid chromatogoraphy 
(LC) which separates glycans based on differences in chemical structures (size, hydrophobicity, etc.) has 
been used to discriminate over 500 glycans but has low throughput [158]. Mass spectrometry (MS) is able 
to achieve superior accuracy but glycan samples need extensive preparation steps before use and 
structural isomers (enantiomers, diastereomers, anomers) are challenging to discriminate [159]. Affinity 
receptor methods also remain underdeveloped. Lectins, glycan binding proteins from natural sources, have 
been used in many examples [159-163] but they suffer from low affinity, broad specificities, and, in some 
cases, high toxicity limiting their applications. Anti-carbohydrate antibodies have reduced affinities 
compared to protein or peptide antigens and lack the potential to bind to the full spectrum of the glycome 
[164]. Further, the amount of glycan material needed to generate a specific antibody is often prohibitively 
consumptive. 
Oligonucleotide-based receptors or aptamers can be straightforwardly applied and are 
adapted/engineered to have new properties even in non-specialist laboratories [165, 166]. Thus, aptamers 
have the potential to be customizable synthetic reagents that can be reproducibly used across a wide range 
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of laboratories.  There is a substantial number of individual demonstrations of the isolation of aptamers 
[167] binding to sugars [168-179], spanning from complex saccharides [173, 174] to disaccharides (with 
specificity for particular anomeric configurations) [179], and even monosaccharides [180]. However, lacking 
is a systematic approach to generate individual aptamers, while consuming modest amounts of glycans, 
against thousands of possible oligosaccharide structural motifs in order to implement aptamers as widely 
available off-the-shelf structural and discovery tools available to general users. 
Here we apply the microfluidic approach developed in Chapter 4 to rapidly isolate aptamers with 
high affinity and specificity towards glycan targets with low sample consumption. As discussed in Chapter 
4, the approach relies on the use of an integrated microfluidic chip that is capable of performing the iterative, 
and repeated steps of the aptamer generation process – termed systematic evolution of ligands by 
exponential enrichment (SELEX), while leveraging the high surface to volume ratios and small sample 
consumption afforded by microfluidics. In particular, the device includes dedicated chambers that allow the 
selection and counter selection stages of the SELEX process, as well as a dedicated chamber which can 
perform polymerase chain reaction (PCR) based amplification of enriched aptamer candidates and strand 
separation. Thus, multiple rounds of affinity selection and amplification are coupled in one fluidic device. As 
a result, the device is able to isolate aptamer candidates in a rapid manner (4 rounds of SELEX in 9 hours) 
while consuming <500 µg of purified glycan. The device is applied to the isolation of aptamers with affinity 
towards gangliosides GM1, GM3, and GD3 with limited cross-reactivity. Furthermore, the approach is 
applied to the selection of aptamers with affinity towards a glycosylation pattern in a peptide. This is 
demonstrated through the isolation of aptamers for an IgA hinge region peptide with N-acetylgalactosaminyl 
(GalNAc) glycosylation. 
5.2. Materials and Methods 
5.2.1. Materials 
MgCl2, imMedia Growth Media, TOPO TA Cloning Kit for Sequencing with One Shot, lyso-GM1 
ganglioside and molecular biology grade water were purchased from Sigma-Aldrich (St. Louis, MO). 
Deoxyribonucleotide triphosphates (dNTPs) and GoTaq Flexi DNA polymerase were obtained from 
Promega Corp. (Madison, WI). Protein G ELISA plates, Dulbecco’s phosphate buffered saline (D-PBS), 
Pierce NHS-Activated Agarose Slurry, and streptavidin coupled agarose beads (Pierce Streptavidin 
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Agarose) were purchased from ThermoFisher (Waltham, MA). Streptavidin surface plasmon resonance 
chips and 2D carboxydimethyldextran (2D CMD) chips were purchased from BioNavis (Tampere, Finland). 
E.Z.N.A. DNA Extraction kit was purchased from Omega Bio-tek (Norcross, GA). Randomized 
oligonucleotide library (5’ – TTG GAT TGA GAA ACA TCG CCG C – 40N – TTC CTC CTG ACC ACA TCC 
GAC– 3’) and primers (Forward Primer: 5' – TTG GAT TGA GAA ACA TCG CCG C -3', and Reverse Primer: 
5' – biotin – GTC GGA TGT GGT CAG GAG GAA – 3') were synthesized and purified by Integrated DNA 
Technologies (Coralville, IA).Gangliosides GM1, GM3 and GD3 were purchased from Avanti (Alabaster, 
AL). Gangliosides GD3, and GM3 with stearic acid cleaved were acquired from Milan Stojanovic. IgA hinge 
region peptide VPSTPPTPSPSTPPTPSPSCCHPR and its GalNAcosylated version were acquired from 
Jan Novak. Tube-O-DIALYZER was purchased from VWR (Radnor, PA). 
5.2.2. Aptamer Selection 
 Aptamers were selected using the methodology developed in Chapter 5 with some modifications. 
Selection beads were prepared by washing NHS agarose beads three times in PBS buffer. Then lyso-
ganglioside was incubated for one hour. The beads were then washed five times in selection buffer (PBS 
with 2 mM MgCl2) and then blocked with ethanolamine (1 M) for 30 minutes. The beads were washed 10 
times and stored at 4 ºC. Similarly, counter selection beads were prepared by first washing NHS agarose 
beads with PBS three times and then incubating with ethanolamine (1 M) for 30 minutes. The beads were 
then washed 10 times with 200 µL of selection buffer and stored at 4 ºC.  
To reduce non-specific binding of the library to agarose beads, a pre-selected library was created. 
Prior to selection, a library (300 nM and 1 mL) was passed through an ethanolamine blocked agarose 
column three times. The column effluent was then passed through a second ethanolamine blocked column 
three times. The oligonucleotides that did not bind to the column were collected, measured for concentration 
and diluted as necessary for microfluidic SELEX.  
The preselected library (300 nM and 1 mL) was then injected into a microfluidic device that has 
previously been prepared with selection and counter selection beads at a flow rate of 10 µL/min for 10 
minutes. Following this library introduction, the beads were washed with buffer (PBS with 2 mM MgCl2) for 
35 minutes at 20 µL/min. An additional wash with sialic acid, chosen because sialic acid is a shared 
component amongst all gangliosides, was then performed for 10 minutes at 20 µL/min. Strongly bound 
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oligonucleotides that were not removed by washing with buffer or with counter target were eluted by heating 
the selection chamber to 55 °C using the heater and temperature sensor located beneath the selection 
chamber. Eluted oligonucleotides were carried by 20 µL/min buffer flow through the counter selection bead 
filled counter selection chamber until finally they reach the amplification chamber. Thus, oligonucleotides 
were counter selected before reaching the amplification chamber where they hybridized to the reverse 
primers conjugated to the amplification beads and remain in the amplification chamber. PCR reagents were 
then injected using a pipette into the amplification chamber and the heater and temperature sensor beneath 
the amplification chamber are used to thermal cycle the amplification chamber for PCR. Following 12 cycles 
of PCR, the chamber was washed to remove in-solution double stranded DNA. Then the amplification 
chamber heater and temperature sensor were again used to the increase the chamber temperature to 95 °C 
inducing de-hybridization of the single-stranded DNA from its bead-bound complement. Meanwhile, buffer 
flow (20 µL/min) transported this single stranded DNA from the amplification chamber back to the selection 
chamber as another round of SELEX begins. As the SELEX process continues longer sialic acid washes 
were used in an effort to increase the specificity of the aptamer pool. In the first round, 10 minutes of sialic 
acid washing was used. This was increased to 15 minutes in the second round, 20 minutes in the third, and 
25 minutes in the fourth round. After four rounds of selection and counter selection, aptamer candidates 
were removed the device, sequenced and characterized for their binding properties. The same process 
was employed for the GM1, GM3 and GD3 gangliosides.  
Aliquots collected during this process were PCR amplified with 20 cycles of PCR in an off-chip 
thermal cycler and analyzed through gel electrophoresis. The relative fluorescent brightness of a band in 
gel electrophoresis can be correlated to the amount of DNA present in the lane and this indicated the 
amount of DNA in the various stages of the selection process. Relative amounts of DNA during the selection 
informed the success of the selection process. 
5.2.3. Subcloning and Sequencing 
 Aptamer candidates were identified by first subcloning the pool and then sequencing selected 
colonies from the subcloning. Aliquots from the aptamer selection process were PCR amplified for 20 cycles 
and then precipitated in ethanol with 10% sodium acetate overnight at -20 ºC. The precipitate was 
centrifuged, washed with 70% ethanol, resuspended in water and measured with a spectrophotometer 
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(Implen). This DNA was then used with a TOPO vector kit following the manufacturer’s instructions. Briefly, 
the DNA was combined with the TOPO vector and one shot E. coli at 4 ºC, heat shocked at 42 ºC, and then 
combined with SOC solution. This was then spread onto Amp Blue culture dishes and incubated overnight 
at 37 ºC. Colonies were selected from the dish by contacting a pipette tip to a colony. This tip was then 
dropped into a 1.5 mL tube containing sugar culture media and cultured at 37 ºC on a shaking incubator for 
16 hours. DNA from these cultures were extracted with an EZNA cleanup kit following the manufacturer’s 
instructions and measured with a spectrophotometer. The resulting DNA was sequenced by Genewiz 
through a Sanger Sequencing protocol. 
5.2.4. Surface Plasmon Resonance (SPR) 
 Aptamer candidates are characterized for their specificity and affinity using multi-parametric SPR 
(MP-SPR). In MP-SPR, a ligand (the aptamer in our case), is functionalized onto a gold surface. Then an 
analyte in solution (glycan or aptamer) is injected through microfluidic channels located on top of the 
functionalized gold surface. A surface plasmon is generated by directing a beam of light at a specific 
wavelength through a prism at the resonance angle. This resonant angle will depend on the wavelength of 
light, material properties of gold, and the prism. As the mass changes on the gold surface, as would happen 
during an analyte-ligand binding interaction, the properties of the sensing surface deviates resulting in a 
change in the angle needed to generate a surface plasmon. This change in angle is detectable by the 
intensity of light reflecting from the laser, off the gold and into a detector. Thus, it is possible to measure 
binding interactions without the use of a label and to provide kinetic information on binding including 
equilibrium constant, association constant, and dissociation constant. Unlike conventional SPR that uses a 
fixed angle for the incoming light, MP-SPR sweeps the angle of the incoming light to obtain the full SPR 
curve. The angle at which the surface plasmon effect is produced, which is the angle that produces the 
minimum reflection to the detector, is used as the measurement metric informing the binding interactions 
of the analyte and the ligand.  
 MP-SPR was used in both configurations where the aptamer was bound to the surface as the ligand 
and the glycan served as the analyte, and also with the glycan conjugated to the surface as ligand and the 
aptamer being used as analyte. When the aptamer was used as a ligand, it was bound to a regenerable 
avidin chip (BioNavis, Tampere, Finland) which has a mutated avidin surface that can be completely 
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removed upon citric acid washing. The avidin chip was rinsed in double distilled water, dried with 
compressed air, and placed into the SPR instrument (Naavi 220A, BioNavis, Tampere, Finland). Once the 
chip was inserted into the instrument, a series of injections were setup to prepare the sensor surface and 
to functionalize the surface with the aptamer. First, the surface was washed with the manufacturer provided 
Regeneration Solution 2 (2.5% citric acid with 0.5% SDS) for two minutes at 20 µL/min. A wait time of two 
minutes was used after the first regeneration solution and then Regeneration Solution 1 (0.5% SDS) was 
injected for two minutes at 20 µL/min. An avidin solution (50 µg/mL) was injected for two minutes after this 
this injection over both fluidic channels at flow rate of 20 µL/min for ten minutes with a five minute post wait 
time. Biotinylated aptamer (25 µg/mL) was then injected for 7 minutes at 20 µL/min in one fluidic channel 
while a scrambled sequence (identical 5’ primer and 3’ end to the aptamer sequence but a random 40 
nucleotide middle region). The baseline was allowed to stabilize before injecting analyte and recording the 
interaction (Figure 5.1). All analytes were injected at 20 µL/min for five minutes with a dissociation wait 
time of at least ten minutes. After every analyte injection the process of injecting regeneration solutions and 
aptamer were repeated to strip the surface of the aptamer and replace it with fresh aptamer. Binding curves 
for different concentrations of analyte were analyzed to determine the kinetic binding parameters. 
 
Figure 5.1: Avidin SPR chip setup. The surface is washed, then avidin is injected and finally aptamer is 
injected on one channel while a scrambled sequence is injected on the other 
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 Aptamer candidates were also analyzed by SPR with glycan acting as ligand and the aptamer 
serving as the in-solution analyte. This SPR format was only possible for lyso-gangliosides that have an 
amine group exposed by the cleavage of the stearic acid. A 2-D carboxymethyldextran (CMD 2D) chip was 
rinsed with double-distilled water, dried with compressed air and placed into the SPR instrument. A series 
of injections were then performed to covalently attach the glycan to the sensor surface. First, a solution of 
2 M NaCL and 0.01 M NaOH were injected to clean the sensing surface for seven minutes at 20 µL/min. 
The dextran surface was then activated by injecting freshly made 0.05 M NHS and 0.2 M EDC were mixed 
1:1 and injected for seven minutes at 20 µL/min. Glycan (0.2 mg/mL) in PBS buffer (pH 8.5) was injected 
over one of the activated channels at 10 µL/min for 15 minutes to covalently attach the glycan through the 
amine group. Following this, ethanolamine (1 M) was injected (20 µL/min for 5 minutes) over both channels 
to block unreacted NHS groups. Once the chip surface was prepared, a series of analyte injections were 
performed. All analytes were injected with a flow rate of 20 µL/min for five minutes with 10 minutes allowed 
for dissociation. The surface was regenerated with injections of ammonium sulfate (1 M) at 20 µL/min for 
five minutes. After the injection of regeneration solutions the baseline was allowed to stabilize for at least 
45 minutes before injecting a new solution of analyte. The functionalization of the sensor surface can be 
seen in Figure 5.2. 
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Figure 5.2: Functionalization of the sensor surface. First ECD/NHS was injected over a cleaned surface. 
Lyso-GM1 was then injected over one of the flow channels. Finally, both of the channels were blocked with 
ethanolamine. 
 All the data collected from the SPR instrument was formatted and exported with BioNavis Data 
Viewer. Centroid data was used as the measurement of binding to the surface as it was found to have the 
lowest measurement noise and the highest sensitivity. The reference channel was subtracted from the 
experimental channel in all data collection such that the binding data only captured the specific binding of 
the aptamer to the glycan. Saturation binding curves were developed from the binding interaction curves 
and analyzed by GraphPad Prism (GraphPad Software Inc., La Jolla, CA) with a specific 1:1 binding model. 
Aberrant curve spikes were removed from the data to facilitate the rate constant curve fitting process. 
5.2.5. Isothermal Titration Calorimetry (ITC) 
 Aptamers were also characterized for their binding parameters through isothermal titration 
calorimetry (ITC). In ITC binding constants and the thermodynamics of bindings are obtained by diluting 
and injecting the ligand into a sample cell. During this interaction, the instrument maintains constant 
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temperature and records the amount of power needed to maintain a constant temperature. Thus, the data 
consists of a series of power spikes of varying heights depending on the dilution of the injection. These 
spikes can be integrated over time to get the heat of the interaction between the macromolecule in the 
sample cell and the ligand, which can also be correlated to the molarity of the injection and fitted to a 
sigmoidal curve to obtain the dissociation constant. With the dissociation constant and enthalpy of 
interaction, the Gibb’s free energy and entropy can be found through the following equation: 
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 = ∆𝐻 − 𝑇∆𝑆 
Where G is the Gibb’s free energy, R is the gas constant, T is temperature, Ka is the association constant, 
H is the enthalpy and S is the entropy. 
Aptamers were dialyzed in 2 L of selection buffer (PBS with 2 mM MgCl2) with a Tube-O-Dialyzer for 
24 hours. Aptamer (300 µM) was used as the ligand and glycan (30 µM) was used as the macromolecule 
in a MicroCAL ITC 200 instrument. First aptamer was loaded into the syringe and injected in a series of 
dilutions into selection buffer to provide the heat of dilution. These injections were used as a reference for 
the aptamer-glycan interaction. Then aptamer was injected in a series of dilutions into the glycan 
macromolecule. The buffer reference was subtracted from the glycan-aptamer interaction curves. The 
resulting curves were analyzed in Origin (OriginLabs, Northampton, MA) for thermodynamic and binding 
constant information. 
5.3. Results and Discussion 
 This section introduces the results of the SELEX process for the three ganglioside targets and the 
glycosylated peptide. First, it is confirmed that SELEX was completed on chip as designed by analyzing 
binding effluents from the selection process. Then, the sequences from the selection process are identified 
and presented. Finally, the binding ability of isolated sequences are assessed using SPR and ITC.  
5.3.1. Aptamer Selection 
 Four rounds of closed-loop aptamer selection were performed on the chip. Aptamers were selected 
for GM1, GM3, GD3 and glycosylated peptide. For each of the ganglioside cases, solution phase sialic acid 
was used as a counter as well as ethanolamine blocked beads. For the glycosylated peptide, the counter 
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target consisted of agarose beads with the same peptide as the target but without glycosylation. A gel 
electropherogram was used to assess the success of the selection process prior to characterization of the 
aptamer pool (Figure 5.3). Aliquots from the selection washing effluents were amplified by 20 cycles of 
PCR and imaged on an agarose gel. From the gel electropherogram, the bright band in the first wash of 
every selection round indicates that weakly binding DNA is washed off of bead surfaces during the early 
wash. While, the decrease in band intensity in the final wash of every SELEX round indicates that less DNA 
is being washed from the surfaces. The increase in band intensity from the final wash of one SELEX round 
to the first wash in the next round of SELEX demonstrates that the PCR amplification, which occurred 
between these rounds, was successful and increased the amount of DNA such that the SELEX process 
could continue on-chip. Also, the increase intensity from the last wash of the final round to the elution 
suggests that strongly bound DNA strands that could not be removed from washing were eluted by the 
increase in temperature and could be collected for further analysis.  
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Figure 5.3: Gel electropherograms from the selection process for glycan targets. (a) GM1 SELEX 
eluents. (b) GM3 SELEX eluents. (c) GD3 SELEX eluents. (d) GalNAc SELEX eluents. (e) Measured 
band intensity from (a)-(d). (a)-(e) labeling is as follows, S1W1: Selection round 1, wash 1; S1W6: selection 
round1, wash 6; S2W1: selection round 2, wash 1; S2W6: selection round 2, wash 6; S3W1: selection round 
3, wash 1; S3W6: selection round 3, wash 6; S4W1: selection round 4, wash 1; S4W6: selection round 4, 
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wash 6; E: elution. Note the GalNAc SELEX consisted of three rounds of selection so round 4 bar graphs 
in (E) omit GalNAc information. 
5.3.2. Sequencing 
 The resulting pool from the SELEX process was collected and sequenced. Approximately 28 clones 
were chosen at random for sequencing (Table 5.1). From the sequencing results, it can be seen that while 
the library did not fully converge onto a few sequences, repeated sequences were present for each target 
indicating the pools were converging. Furthermore, the SELEXs for different targets did not yield 
overlapping sequences. Thus, the resulting sequences were unique to each target and appreciable library 
contamination was not observed. Four aptamers candidates from each pool were selected based on shared 
motifs and synthesized to be further characterized for their binding affinities and specificities. 
Table 5.1: Sequences for Ganglioside SELEX 
GM1 Sequences  
GM1S1 TGGAGTTTAAGGTCTCATTCTTGGATTACGGGACTTAAG 
GM1S2 TTCCGGTTTGTTATTCGGGTATCGACATAAATAAGTGTAA 
GM1S3 GGGGGTGCTATGTACGGTTGGTTGACTGTAGGGCTAAGGC 
GM1S4 CAATAGCAATAGGAATCTAATTGTCAAGTGTGCTTCTCTG 
GM1S5 AGTTTGGATCCACGTTCCCTAGAGCTGAAGATGGCATCGG 
GM1S6 TTGAGTCGCGTCATTATATTCATTGTCAAGGCTTTAAACA 
GM1S7 TTGGATTATTTGAAGTATATTTATTTTAGGCTAATAATTA 
GM1S8 TCATCGATCTTGTTTTGTGGGTTATGTTGTAATATTCGTC 
GM1S10 AAAGACCGGGTGCCTGGGTAGATGTTGCGGGGATAATTAG 
GM1S11 AAGAACCGTACGCTTTAAAAATCATTAAGTGAGTTTCTAA 
GM1S12 TCGTCCTTAGTTCGAAAGCACTTGGTTTATCGGCAACTGT 
GM1S13 AGCCCGCGAGGTTGCACAAGACAGAGAGTCACAACGGCTC 
GM1S14 TTTGGCGCGCACCTGTAGCTCTACATCTTGAAGCGGTGAG 
GM1S15 CGAAGGTGCTTTTATACGAGCCTATCTTCGTATTCGTTTG 
GM1S16 TATTTGGCTAAGAGATGACTGTCCGCCTGCCGAATAAGGT 
GM1S17 TGATTAGGCAAATGGCCACTTCTAGTGCGCGGATCGTTGG 
GM1S18 TGATTGGGCTTAGATTAATGATTCAGGACTACTGTCTTGG 
GM1S19 TAGTTAACGTTTTTACCTCAAAAATGTGTATGAGTGCGGC 
GM1S20 GCCATGTGTTGGTCTTCTAAATGGTTGAGGTATTGCCGCG 
GM1S21 ACCTAATCTTAAGCTTTGGGACTATGCTCCATACCTGTAT 
GM1S22 AGTTTGGATCCACGTTCCCTAGAGCTGAAGATGGCATCGG 
GM1S23 TAGAGGTCAATACAACTTTTAACGAGTATGCCGAATCGTT 
GM1S24 ATCCTTCTTAGTCACAGGATCAACCGAAGAGGCCGTTCAT 
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GM3 Sequences  
GM3S1 CTGCAGAACTATGG 
GM3S2 TCCAATTTTAACAGATCTTCTTTCTCTGTATCTTTTCTAT 
GM3S3 TTATTTACGTAGGGCTAATCGTAGTTTTGCTGACGTAGTT 
GM3S4 TAGCAATAGAAATTTATAGTTAACAACCTTTGATTACGTA 
GM3S5 CAATCCCCTGTGACACTACCAGTCACGGTACGAGTTACGT 
GM3S6 TCCTTTGAAAAGCTAATCTACGGGCGGATCCATATTATGG 
GM3S7 GCTGGTTACCTTTGTTTGTTGTACATAGTTTTTCACACGT 
GM3S8 TCTATGCCTTGTTGTTTTAGGTATATAGATTTAGGCCCTG 
GM3S9 GCACAGACTAGCATGACGTGAAAGGTAGGTAGGTGGGTTA 
GM3S10 CCGTAGTTAATGTCATTATTGGGTAGCCAGACGTTAAGCA 
GM3S11 CGCCTTTTTTGTTAAGTTGACTTGAGTTTCCTTATTATCT 
GM3S12 ATAGGTTTTCAGGATTGTCCTGCTATTCATTTGTCCATTG 
GM3S13 ACTGCCTTCTTGAGTTCTTGGGTTTTACCACTTCACAGGG 
GM3S14 GATTTGATTAGTTTGCCATGATTTTACCGTAAGCTTAACC 
GM3S15 GGCCAAGTACGGCAAGCAATATCGCTAATCGTACTCTCGA 
GM3S16 TTTTATACTCTGGTAATTTACTCTATAGGATTCATGCAAT 
GM3S17 CAGATACTTGACTAGCTGTTTATGGATCGTATTAGCGCTT 
GM3S18 AGGGATCACAGGATAACTGAGTTATCATGGAATCNATAAG 
GM3S19 AACGTTACGTCTCGTTATATGAATTAAGGACTCCGACAGA 
GM3S20 CTATATGGAGGGGGAAACAAAACTTATCGTCATTGAAAGC 
GM3S21 ATAAGATACTTTCTTTCTTTAGTACAAACTAATGATTTAA 
GM3S22 CGTATCCTTTTGAATAGTTGTAATATACTTTTTCTGCAGG 
GM3S23 ATAACATGAATATCTAAGATATATTTTTAATGAAGTATCT 
GM3S24 TTTCGTGGGGCGATAGTACGACGATAATCGCGGAACGGCG 
GM3S25 GGTGTAAAAGATAAGTGAAGCCTTGTTGTATTAGTTGGTG 
GM3S26 GGGGATATGAGCTTCTCTTAAAAATTAATGCACCATTCTA 
GM3S27 CCAATATAATTATTTGTCTCTTACCCTCACGGTAGAGTCT 
GM3S28 AACCTCCAATTACTAAGATCCTACAATAATTGTCTCACTA 
GD3 Sequences   
GD3S1 TAATATCGCTAGTGCAAACGGATCTTAGGTAGGGCAGCAA 
GD3S2 CTCTGCGCATGCAGATTTTTTACAGGTCCTTGTAAGCCTT 
GD3S4 GCAGGGTAAGTCCGACGGTATCGTTTGAGCGAGCTCGATA 
GD3S5 TATATGTTTGTTTAGATAGAATTCACCTGACTCAGGGGGA 
GD3S6 GTTTTTCGCTGTCAAATCTCGCAATTATACGCTAACCCGG 
GD3S7 TGAGTAAGCCAGCAGGGGAGATGTGAGTGGGGAAGTCGGT 
GD3S8 GTTCGTCGGGTAACTTAACGACGTACCAGTTCGGCTGGGA 
GD3S9 GGTAGCTCTTATAATTACATTAATCTTGTTTTATAGGTTA 
GD3S10 CTGGTGGATATCAGCTCGGTAGGCTGTGTGATCCTGACGT 
GD3S11 AGTATCAACACTCTTTAGTAGCGCACGAAGATTACGTTTA 
GD3S12 GCTATGTTACAACAAAGGCAAGTTCCCTAACGGGATCGCC 
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GD3S13 TTGCTCCCGCAAAGTAATTAAAGCATGTGTGTACTAGCAA 
GD3S14 AGAATAAATTGCTTGTTCTTCATAGCCGGTACGGTGAACG 
GD3S15 TGAGGTTTTCTGAGTATCATGCCGAACGGTGACCTGCATC 
GD3S16 GCTTGGTATTGATCTAATTCCCGCCTGCCAGGAGTGTAAT 
GD3S17 GTTATTGGGCATTCGATATTAGAGCATAAAGCCCACTCGG 
GD3S18 GTGATCACTTCTTTGGAGCAGCCAGTAGACATTTCATACG 
GD3S19 TTGTAGGCTGGTCACAACAGACGGCCAGGTTAGCACAT 
GD3S20 CGCATGGCCCGCCGTCAGGGGCTTTAGGTGGCAGGTGGGG 
GD3S22 TAGAAACCTACCTCGAGTTCGCGCTTCTCACGTGGACTTC 
GD3S23 GTGACATGTGTGTTTTTATTCGGCAGATACGCGTTAAGTA 
GD3S24 AATGAGGGTAGCGGTTTGAGCAGACGTTTCTAAGCCCATG 
GD3S25 ATCAATGTCATGGCGTGTTAAGAACAGTGCCATTAACTTT 
GD3S26 TCGCCTGGTGGCTAACTTAAATCCAACGTCTAACTGTTGC 
GD3S27 TCATGGGCGTATTCCGCGCGCACGCGGGATATAAGGGAAC 
GD3S28 TGTGAGGTTTTACAACTAGAACACATCTTCTGTCGGGACG 
GalNAc Sequences  
GalNAcS1 TCATGGATTACACCGTATGAATCAGCATCGCAGTTTTACA 
GalNAcS2 CGGACAAATGAAGTTGATTGGTTTGAAGTCTAGGTGAGAT 
GalNAcS4 CACTTTATCAGTTCGATACCGTGATGGCTAGTGTAAGGGT 
GalNAcS5 GGAGGCTTAGTGGGGCGTAGCGCATTTCCAGCAACAAGCA 
GalNAcS6 GCTTTGATGTCTGTGTAGATCTATACTAATGGCCCCGTAG 
GalNAcS7 ACTAGTCCAGGTGAACGCCGTTGGGGGTTGCCCGGGCTAA 
GalNAcS8 CCATGGAAACTTGGTGGGTTCTGGGATACCCCATTCTATT 
GalNAcS9 CTAGCGTAAATATGGGGAGGTCTGCGTCTGTCTTTGCTAC 
GalNAcS10 TGGAGGAACACTTAAGCACGGCGACAAGATGCTGCGGTGT 
GalNAcS11 ATTATGAACTCTCAACATGGCTCGAAATACCCGGTTTTTT 
GalNAcS12 AACATATTCGAGGCCCTAAGCTCACTTCACTACCAAGCAT 
GalNAcS13 CAAGTGTAGCAGACAGTCGGAAGAGGGACTGCGTCGCAGG 
GalNAcS14 GGCTAGTGGGTAACATCAATTCGCCCTAGCGGTTGCCCCA 
GalNAcS16 TTGAACTTTTAGCCGCCGATAGTAGCTTGTTATTGAAGTA 
GalNAcS17 TCCTTAAAATCGGGGAAACATCGCGTCAACAAATAACTCCCG 
GalNAcS18 CACATGGGACAAGTTTACTCGCACCGAGTACTGGGACACC 
GalNAcS20 TCGCGTAGCAATCGGTGCGAACAGGGCGTGCAATAATGGG 
GalNAcS21 GTGCTGTCCCGAGCACACACTTCTGAGTTATTTAATCACT 
GalNAcS22 TTGTTATATTCGAATTTAGCCTTAATGATCGCGTTTGTGT 
GalNAcS23 CTGGATATAATTGCCAGAAATGTCTATCTTCTTGTATTTC 
GalNAcS24 TTACTTCTGACGGAACTGGGTCGACGGACTCGACCGGGA 
GalNAcS25 TAGTCACTCACAACAAATTTTCTATTCCGTCTTAACGCAG 
GalNAcS26 CAGCTGGTTTTTATTTTCCATAGTAATATAGGCAGATTCG 
GalNAcS27 TTTGCTCCATGCCGCTTTATTATGATAGGTATGGGGAACG 
GalNAcS28 GTCTAGAAGACTTTGGATTGCCCTGAGTATGGGCATGCAT 
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5.3.3. Lyso-Ganglioside SPR 
 Aptamer candidates were screened by SPR to determine equilibrium binding constants. Lyso-GM1 
and lyso-GM3 were conjugated to the SPR sensor surface and aptamers were driven through the flow 
channel while binding interaction information was collected. Injections were increased from a low 
concentration to successively higher concentrations (31.25 nM, 62.5 nM, 125 nM, 250 nM and 500 nM of 
aptamer). This was repeated three times on the same sensor surface (Figure 5.4). Resulting interaction 
curves were analyzed to discern binding parameters. Sequence GM1S6 was found to have the greatest 
affinity towards GM1 with a binding dissociation constant (Kd) of 35.23 ± 9.575 nM while GM3S256 was 
found to have the greatest affinity towards GM3 with a binding dissociation constant of 33.49 ± 3.445 nM. 
These binding affinities are orders of magnitude lower than known probes for GM1 and GM3 suggesting 
these aptamers could be used for ganglioside analytical assays. Binding data for the sequences tested can 
be seen in Table 5.2.  
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Figure 5.4: Representative surface plasmon resonance responses of various concentrations of aptamer. 
All curves are the resultant curves after subtracting an ethanolamine control channel response. (a) GM1S4 
over a lyso-GM1 surface. This was repeated three times and yielded an average Kd value of 49.6 ± 9.978 
nM through curve fitting with a 1:1 binding model. (b) GM3S15 over a lyso-GM3 surface. This was repeated 
three times and yielded an average Kd value of 43.59 ± 8.58 nM. 
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Table 5.2: Binding affinities of lyso-GM1 and lyso-GM3 aptamers towards their target molecule. 
 
Average KD 
(nM) 
Standard 
Deviation (nM) 
GM1S4 49.6 9.978 
GM1S5 88.79 23.05 
GM1S6 35.23 9.575 
GM1S16 52.58 7.937 
GM3S3 47.45 13 
GM3S15 43.59 8.58 
GM3S21 64.84 23.44 
GM3S25 33.49 3.445 
 
The binding of these aptamer candidates were compared to a scrambled sequence. Triplicate 
injections of 500 nM aptamer or scrambled sequence were performed and the average response from the 
100th second to the 300th second was recorded and compared.  All of the aptamers all displayed much 
greater binding to the target than the scrambled sequence (Figure 5.5). 
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Figure 5.5: Sequence binding during a 500 nM injection compared to a scrambled control. All sequences 
were injected three times with error bars representing the standard deviations from these injections. (a) 
GM1 aptamer sequence injections over a lyso-GM1 surface. (b) GM3 aptamer sequence injections over a 
lyso-GM3 surface. 
5.3.4. Full Ganglioside SPR 
Full gangliosides were also investigated for the GM1, and GD3 aptamer candidates. For these 
cases, aptamer was functionalized to the SPR sensor surface by biotin/streptavidin interactions and the 
ganglioside was introduced in solution while binding interaction data was collected. From these studies it 
was found that GM1S4 had an affinity of 741 nM towards the intact ganglioside GM1 with minimal cross 
reactivity to the other gangliosides (Figure 5.6). Similarly, GD3S16 had an affinity of 2.48 µM with limited 
cross reactivity. 
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Figure 5.6: (a) SPR curves for GM1 aptamer sequence 4 with various concentrations of full GM1 
ganglioside injected. (b) SPR curves for GM1 sequence 4 responding to 5 µM injections of GM1, GM3 and 
GD3. (c) Response curves for GD3S16 towards various concentrations of full GD3 ganglioside injections. 
(d) SPR curves with GD3 sequence 16 on the surface and 5 µM of GM1, GM3 and GD3 injected. 
Full ganglioside binding was challenged by the inherent tendency of gangliosides to form micelles. 
Micelles are an aggregate of gangliosides in a sphere or bilayer sheet. Once in this form the molecule is no 
longer in a similar orientation to that used for the aptamer selection process which interferes with the 
aptamer’s ability to recognize the target. Micelles form at micromolar concentrations that coincides with the 
measurement range needed for dissociation constant determination in the SPR instrument [181]. On the 
other hand, lyso-GM1 has a stearic acid removed so micelles are not possible and is bound to a solid 
support preventing micelle formation in any case. The discrepancy between lyso-GM1 binding affinity (2.5 
nM) and full GM1 binding affinity (741 nM) may be explained by the formation of micelles interfering with 
the aptamer binding to the target. The test format could also contribute to the difference in binding as the 
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lyso-GM1 was immobilized while the aptamer was in solution. It is possible the immobilized GM1 is more 
recognizable by the aptamer, and indeed that would match selection conditions more closely. Furthermore, 
it is possible the aptamer loses some recognition ability when constrained to the surface of the sensor 
through the biotin-streptavidin link. 
5.3.5. Isothermal Titration Calorimetry 
 Aptamer candidates that demonstrated binding affinity towards the target in SPR were examined 
by ITC. A high concentration of aptamer (300 uM) was used in the syringe and diluted into a lower 
concentration of the sugar group of each ganglioside remaining in the cell (30 uM). Each binding pair used 
a series of 25 dilutions. Results were compared to injections into a reference cell (Figure 5.7). 
 
Figure 5.7: ITC curves for gangliosides. (A) ITC curves for GM1 ganglioside with GM1S4 in the syringe. 
(B) ITC curves for GM3 gangliosides with GM3S16 in the syringe. 
 For GM1 a binding affinity of 18.76 µM was found with a ∆H of 14.92 kcal/mol. The ∆H indicates 
this was an exothermic reaction. Exothermic reactions are not uncommon for aptamers and they typically 
(a) (b)
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suggest an entropy driven binding process. Electrostatic based binding is possible for entropy driven 
processes and that can also drive aptamer-target recognition. The binding affinity characterized by ITC was 
similar to the full ganglioside binding affinity found through SPR but indicated much weaker binding than 
the lyso-GM1 binding in SPR. This could be because the aptamer does not bind as well to the sugar group 
as it does to the entire molecule. 
For GM3 the binding affinity was found to be 17.51 µM with a ∆H of 8 kcal/mol. Again the reaction 
was exothermic which could indicate that the aptamer binds to the GM3 target through electrostatic forces. 
The GD3 aptamer did not bind in the isothermal titration calorimeter. This could be overcome with full 
ganglioside injections in the ITC; however, micelle formation may prevent the binding of the aptamer to the 
target at these concentrations. ITC fluid cells with lower concentrations of ganglioside may overcome the 
issues presented by micelle formation; however, lowering the concentration may move the measurement 
outside the useful range to determine the binding affinity of the aptamer candidates. The binding affinities 
of the sequences with the highest affinity towards the ganglioside target for the various formats tested are 
summarized in Table 5.3. 
Table 5.3: Aptamer affinity towards gangliosides in various formats 
  
Lyso-
Ganglioside 
Dissociation 
Constant (nM) 
Full 
Ganglioside 
Dissociation 
Constant SPR 
(µM) 
Sugar Group 
Dissociation 
Constant ITC 
(µM) 
GM1 49.6 0.741 18.76 
GM3 43.59 NA 17.51 
GD3 NA 2.48 NA 
 
5.3.6. Glycosylated Peptide 
 A glycosylated peptide was characterized using SPR. The binding assessment was considerably 
more straightforward than the gangliosides considering the size of the glycosylated peptide. Biotinylated 
aptamer was conjugated to the streptavidin sensor surface through the biotin-streptavidin affinity interaction. 
Various concentrations (62.5 nM, 125 nM, 250 nM, and 500 nM) of glycosylated peptide were then injected. 
This was repeated using the non-glycosylated version of the peptide such that binding dissociation 
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constants were found for the target molecule and for the counter target molecule (Figure 5.8). Binding data 
was found for three sequences that were selected from the cloning (Table 5.4). 
 
Figure 5.8: Representative SPR curve for peptide SELEX. (A) Injections of GalNAc peptide on a GalNAcS9 
surface. (B) Injections of the same peptide without glycosylation over a GalNAcS9 aptamer sequence 
surface. 
 In all cases, the aptamer candidate bound with higher affinity than the control molecule. The 
aptamer with the highest affinity was GalNAcS4 with an affinity of 15 nM compared to an affinity of 3.2 µM 
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for the non-glycosylated peptide. Thus the aptamer had ~200 fold higher affinity to the control molecule 
over the counter target. Therefore, the device is capable of isolating aptamers with preference for a 
glycosylation pattern in peptide samples.  
Table 5.4: Binding affinities of aptamers towards glycosylated and non-glycosylated peptides. 
  
GalNAcS4 GalNAcS9 GalNAcS22 
Average KD (nM) towards GalNAc Peptide 15 59 172 
Average KD (µM) towards non-GalNAc Peptide 3.2 18.5 250 
 
5.4. Conclusion 
 Aptamers were isolated for four different targets, each taking approximately one day to isolate with 
a microfluidic approach. Aptamer candidates are affinity selected, counter selected, amplified, and 
conditioned back to single-stranded for further rounds of SELEX. The microfluidic device performed four 
rounds of SELEX for the ganglioside targets and three rounds of SELEX for the glycosylated peptide. All 
selection procedures used less than 500 µg of target and counter target. After isolation the aptamer 
candidates were characterized for their affinity and specificity. Aptamers with nanomolar affinity towards 
GM1, GM3 and the glycosylated peptide were isolated, while aptamers with micromolar affinity towards 
GD3 were isolated. It was further discovered that the format of the binding test can influence the binding 
affinity of the aptamer towards its target. Thus it is likely the binding affinities of the GD3 aptamers towards 
lyso-GD3 are much lower. 
 In the future, additional binding characterization will be performed on the GD3 aptamers. In 
particular, lyso-gangliosides will be prepared and tested on a CMD SPR sensor surface. The lyso-
gangliosides can also be investigated by ITC without the concern for micelle formation. Furthermore, the 
ability of the aptamers to recognize targets in clinically relevant assays will be pursued. Of particular interest 
is the binding of GalNAc peptides in aptameric ELISA formats. 
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Chapter 6: Personalized Selection of Aptamers against Multiple Myeloma 
Proteins 
6.1. Introduction 
Multiple myeloma (MM) is a cancer of plasma cells primarily found in the bone marrow (BM). A 
common blood cancer, MM affects nearly 96,000 in the U.S.. Roughly 0.7% of men and women will be 
diagnosed with MM at some point during their lifetime [182]. The goal of treating MM is to achieve complete 
response (CR), defined as the absence of the hallmark monoclonal immunoglobulin (M-Ig) protein by 
immunofixation and less than 5% plasma cells in bone marrow (BM). Of patients who achieve CR, those 
who are negative for minimal residual disease (MRD), i.e., the presence of small numbers of myeloma cells 
in a patient’s body [183], have better survival than those who are MRD positive [184]. Detection and 
monitoring of MRD is hence emerging as a cornerstone in selecting and guiding therapeutic strategies.   
Sensitive detection of M-Ig in peripheral blood remains an unmet medical need. Currently available 
methods have a low sensitivity as they are not tumor-specific and are limited by background polyclonals 
and physiological variations (e.g., infections, renal impairment or recovery, and light chain ratio variability 
secondary to neoplasms). Serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) 
are current ‘gold standards’ for serum-based MM diagnosis and follow-up, but do not allow MRD detection. 
SPEP, which visualizes migration of monoclonal proteins in the γ, β, or α2 region [185], has a limit of 
detection (LOD) of 500-2000 mg/L [186]. IFE (LOD: 100-150 mg/L [187]) allows identification of specific 
types of heavy (IgG, IgA, IgM, IgD, IgE) and light (λ or κ) chains, but is incapable of M-Ig quantification. 
Other related methods are also inadequate. For example, quantification of free light chain (FLC) ratios [188, 
189] (LOD: ~1 mg/L [186]) is limited by background monoclonals, can be falsely positive due to deteriorating 
renal function or infection, and apply primarily to diagnosis and follow-up of light chain-producing MM 
(LCMM, 20% of MM [190]). Allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) in 
peripheral blood, currently under research, has been found to be comparable to SPEP/IFE in sensitivity 
[191].  
Affinity receptors targeting variable regions (i.e., ‘idiotypes’) of M-Ig would allow sensitive M-Ig 
detection in serum. Idiotypes are tumor-specific and unique to the patient [192]; an affinity receptor that 
specifically recognizes an idiotype would hence allow low concentrations of M-Ig to be detected by 
effectively rejecting the effects of unspecific background proteins. The clinical application requires that 
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idiotype-targeting aptamers be generated for each individual patient in a timely fashion. Unfortunately, this 
is impractical with conventional receptors such as antibodies, which are costly and time-consuming to 
produce and have poor batch-to-batch reproducibility. This is also impractical for aptamers which are 
identified with labor-intensive and time-consuming conventional SELEX platforms. Ultimately, conventional 
SELEX techniques involve extensive manual handling of reagents, requiring usually a month to complete 
just 10 cycles. Robotic automation can alleviate this issue but is cost prohibitive [129]. Alternative methods 
using affinity selection in solution followed by capillary electrophoresis (CE-SELEX) [100, 101] can reduce 
the overall processing time, but still requires tedious manual handling. Instead, rapid and efficient aptamer 
isolation exploiting microfluidic technology to create miniature and integrated SELEX devices at low cost, 
with minimized reagent consumption and in much shortened time is exploited. Such devices produce 
aptamers with high affinity due to intimate molecular interactions in microscale geometries 
 Here we apply the approach developed in Chapter 4 to rapidly isolate aptamers with high affinity 
and selectivity towards a myeloma patient’s M-Ig. First, Rituximab, a monoclonal IgG antibody used in the 
treatment of cancer, is used as a model IgG monoclonal. Rituximab is chosen because of its availability to 
be acquired in purified form and because its immunoglobulin type (IgG) matches the most prevalent type 
of multiple myeloma (IgG myeloma) [193]. After isolating and characterizing aptamers with affinity towards 
Rituximab, we apply the protocol to isolate aptamers with affinity towards a myeloma patient’s serum M-Ig 
(Figure 6.1). A multiple myeloma patient’s serum sample is collected and conditioned to remove non-IgG 
type proteins, and bound to beads which are then directly injected into the device. Six rounds of SELEX 
were performed on the chip to generate high affinity aptamers without offline processes. Collected samples 
from each round of SELEX were comprehensively characterized through high throughput sequencing 
techniques. These aptamers were synthesized and screened for their binding abilities. Ultimately, an 
aptamer that can be used in an aptamer formatted Enzyme Linked Immunoassay (ELISA) to detect the 
presence of the cancer patient’s M-Ig is rapidly isolated (within a day) while consuming only modest 
amounts of a patient’s serum sample (<100 µg). 
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Figure 6.1: Aptamer selection process for a multiple myeloma patient. First the patient serum sample is 
conditioned to remove non-IgG proteins. The remaining IgG proteins are then bound to beads and used as 
the target in the microfluidic SELEX process. The sequences are evaluated through high throughput 
sequencing techniques and high potential candidates are synthesized for analysis. 
6.2. Materials and Methods 
6.2.1. Materials 
MgCl2, human polyclonal IgG and molecular biology grade water were purchased from Sigma-Aldrich 
(St. Louis, MO). Deoxyribonucleotide triphosphates (dNTPs) and GoTaq Flexi DNA polymerase were 
obtained from Promega Corp. (Madison, WI). Protein G ELISA plates, Dulbecco’s phosphate buffered 
saline (D-PBS), Melon Gel IgG Spin Purification kits, GeneJET Purification Kits, Zeba Desaling Columns 
and streptavidin coupled agarose beads (Pierce Streptavidin Agarose) were purchased from ThermoFisher 
(Waltham, MA). Streptavidin surface plasmon resonance chips were purchased from Nicoya Lifesciences 
(Kitchener, ON, Canada). MiSeq 300 v2 kits and PhiX Control were purchased from Illumina (San Diego, 
CA). Next generation sequencing Kappa Hyper Prep Kits were purchased from Roche (Basel, Switzerland). 
AMPure XP magnetic purification beads were purchased from Beckman Coulter (Pasadena, CA). 
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Randomized oligonucleotide library (5’ – TGC CAG CAT CGT AAT AGC CTC – 40N – ACC AAG TGA ATG 
AGC GGT ACG– 3’) and primers (Forward Primer: 5' – TGC CAG CAT CGT AAT AGC CTC -3', and 
Reverse Primer: 5' – CGT ACC GCT CAT TCA CTT GGT – 3') were synthesized and purified by Integrated 
DNA Technologies (Coralville, IA). Rituximab was acquired from Milan Stojanovic and multiple myeloma 
patient serum was acquired from Tilla Worgall. Protein G beads were purchased from Santa Curz 
Biotechnology (Dallas, TX). Barcodes with Illumina adapters were purchased from Bioo Scientific (Austin, 
TX). 
6.2.2. Selection of Aptamers towards Model Monoclonal  
 The general protocol was first implemented with Rituximab, a humanized IgG monoclonal antibody 
used as a pharmaceutical. Selection and counter selection beads were first prepared. Rituximab incubated 
for 30 minutes in Protein G beads which had previously been rinsed three times with selection buffer. The 
beads were then washed 5 times with selection buffer. Polyclonal IgG beads was used as the counter target 
and were prepared by incubating pre-rinsed polyclonal IgG with Protein G beads for 30 minutes and 
washing. Reverse primer beads were prepared as discussed in Chapter 4. 
 The general procedure followed the framework in Chapter 4 with some modifications (Table 6.1). 
The Rituximab modified beads were used for a target in affinity selection, and the polyclonal IgG beads 
were used as a counter target. The first rounds of SELEX consisted of selection with the Rituximab beads 
and then direct transfer to the amplification chamber for PCR amplification. Counter selection was not used 
in this first round to reduce the potential for losing sequences which present at low copy numbers early in 
the SELEX process. The second round of SELEX consisted of positive selection with the Rituximab beads, 
counter selection with bare Protein G beads, and PCR amplification. A Protein G counter was used in the 
second round to remove aptamer candidates which have an affinity for the matrix used to immobilize the 
protein. The third and fourth rounds of SELEX included positive selection with Rituximab beads, counter 
selection with polyclonal IgG and PCR amplification.  
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Table 6.1: Selection parameters for Rituximab SELEX. 
Round Wash Flow Rate Wash Time Counter Selection 
1 20 µL/min 35 min None 
2 20 µL/min 35 min Protein G Beads 
3 20 µL/min 35 min Polyclonal Beads 
4 20 µL/min 35 min Polyclonal Beads 
 
6.2.3. Selection of Aptamers towards Patient M-Protein 
 A myeloma patient’s serum sample was first prepared for the SELEX first. Patient serum was 
purified with Melon Gel following the manufacturer’s protocol. The melon gel binds to all serum proteins 
except IgG allowing extraction of a patient’s IgG. Because of the nature of IgG myeloma, the extracted IgG 
from the patient’s serum will be dominated by the monoclonal IgG. The extracted IgG was suspended in 
selection buffer (PBS with 2 mM MgCl2) and measured by UV-Vis (Implen P300, Implen GmbH, Munich, 
Germany). Protein G beads were rinsed three times with selection buffer and incubated with the patient 
IgG for 30 minutes. The beads were then washed five times with selection buffer. Extracts of this process 
were collected and used to verify successful conjugation by polyacrylamide gel electrophoresis (PAGE). 
Similarly, counter selection beads were prepared by incubating polyclonal IgG with washed protein G beads 
for 30 minutes and then washing the beads five times with selection buffer.  
 With selection beads prepared, six rounds of the SELEX process were performed as described in 
Chapter 4 with some modifications. First, 20 pmoles of library were used to initiate the SELEX process. A 
greater amount of starting library amount was used to increase the potential to isolate aptamers with very 
high specificity. Second, in the first round of SELEX counter selection beads were not used. This was to 
reduce the potential for losing high affinity sequences that are present at low abundance, as would be 
expected from library members. The second round used unreacted protein G beads as counter targets. 
Rounds three to six used polyclonal IgG beads as a counter target. Further, in the final two rounds (five and 
six) the washing time was increased from 35 minutes (700 µL) to 45 minutes (900 µL) to increase the 
selection pressure on these later rounds of the process (Table 6.2). Finally, a fraction of the eluted product 
of each round was collected for analysis by next generation sequencing (NGS).      
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Table 6.2: Selection parameters for patient monoclonal protein SELEX. 
Round Wash Flow Rate Wash Time Counter Selection 
1 20 µL/min 35 min None 
2 20 µL/min 35 min Protein G Beads 
3 20 µL/min 35 min Polyclonal Beads 
4 20 µL/min 35 min Polyclonal Beads 
5 20 µL/min 45 min Polyclonal Beads 
6 20 µL/min 45 min Polyclonal Beads 
 
6.2.4. Sanger Sequencing 
Aptamer candidates for the Rituximab target were identified by first subcloning the pool and then 
sequencing selected colonies from the subcloning using a protocol similar to the presented in Chapter 5. 
Briefly, aliquots from the aptamer selection process were PCR amplified and purified. The purified product 
was then used with a TOPO vector kit and cultured onto dishes. Colonies were then chosen from the dishes 
and cultured. The cultures were then purified with an E.Z.N.A. purification kit, diluted and sequenced by 
Genewiz (South Plainfield, NJ) through a Sanger Sequencing service. 
6.2.5. Surface Plasmon Resonance (SPR) 
 SPR was used to discern the binding properties of the Rituximab IgG towards aptamer candidates. 
Biotinylated aptamers (500 nM) were injected over a streptavidin chip (Nicoya, Kitchener, ON, Canada) at 
a flow rate of 20 uL/min for 5 minutes. After allowing the baseline to settle, a range of concentrations of 
Rituximab (50 nM, 100 nM, 200 nM, 400 nM, and 800 nM) were injected. Surfaces were regenerated with 
1 M sodium acetate between injections. Specificity was confirmed by injecting the polyclonal IgG over the 
sensor surface. Data from all injections was analyzed by 1:1 model fitting with BIAevaluate (Biacore, 
Slovakia). 
6.2.6. High Throughput Sequencing 
 For the SELEX used to isolate aptamers towards the patient sample, aptamer candidates from 
each round were sequenced using a MiSeq platform (Illumina, San Diego, CA). First the collected products 
of each round were amplified off-chip by PCR and checked with a gel electropherogram. The amplified 
product was purified and suspended in molecular biology grade water with a GeneJet DNA clean up kit to 
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remove primers and the amount of DNA was quantified in the resulting solution using an Implen 
Spectrophotometer (Implen GmbH, Munich, Germany). 250 ng of the amplified product was used with a 
Kapa Hyper Prep kit and Bioo Scientific barcodes to ligate Illumina adapters. A unique barcode (6 total) 
was ligated to the product of each round of the SELEX allowing sequences from each round to be 
discernible in the NGS read file. The ligated product was verified to be of the correct length and to be of 
high purity by gel electrophoresis and the amount of DNA was quantified with an Implen spectrophotometer.  
 The barcoded samples were sequenced in two sequencing reactions. The first sequencing process 
sequenced rounds one to four, and a second sequencing process was used to sequence rounds five and 
six. Both reactions were prepared with the following procedure. A MiSeq 300 v2 cartridge was thawed to 
room temperature. Meanwhile, the barcoded samples were combined and diluted to create a 4 nM and 5 
µL combined sample pool equally represented by each SELEX round (rounds 1-4 or rounds 5 and 6). 5 µL 
of 0.2 N NaOH was added to the 4 nM combined pool, mixed and left to incubate for 5 minutes at room 
temperature. A 1 mL and 20 pM solution was then prepared by adding 990 µL of the HT1 buffer provided 
by Illumina. A 600 uL and 4 pM solution was then prepared by withdrawing 120 uL from this solution and 
adding 480 µL of HT1 buffer. PhiX control was similarly diluted in HT1 buffer to produce a 4 pM solution of 
PhiX. The 4 pM PhiX (120 µL) and combined pool were mixed together to form a 600 µL solution. This 
solution was injected into the Illumina MiSeq cartridge and sequenced with an Illumina MiSeq instrument. 
 Raw data grouped by barcode was downloaded from Illumina’s Basespace. Aptasuite version 0.8.9 
was used to evaluate the reads. From this software the cluster, and sequence analysis modules were used 
to determine which sequences should be ordered for in vitro testing. 
6.2.7. Enzyme-Linked Immunoassay (ELISA) 
 Aptamers were screened for their ability to bind to the monoclonal using an aptameric ELISA. The 
ELISA format consisted of monoclonal protein bound to the wells through protein G which then had a 
solution phase biotinylated aptamer applied. An increase in the absorbency intensity was indicative of 
aptamers binding to the target monoclonal protein. The wells were first washed three times with wash buffer 
(PBS with 2 mM MgCl2 added). Then 2.5 pmoles of target IgG or polyclonal IgG diluted in SuperBlock 
blocking buffer with 0.05% tween added were applied to the wells. The protein was incubated in the wells 
for 30 minutes at room temperature on a rotator. These wells were then washed eight times (~200 µL per 
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well per wash) with wash buffer. A 25 pmol solution of biotinylated aptamers in 100 µL of wash buffer were 
incubated in the washed wells for 60 minutes on a rotator. The wells were washed ten times (~200 µL per 
well per wash) with wash buffer following the aptamer incubation. Following the wash, streptavidin 
horseradish peroxidase was diluted according to the manufacturer’s instructions in wash buffer and bovine 
serum albumin (BSA) and then applied to each well and allowed to incubate for 30 minutes at room 
temperature with an opaque cover. The wells were then washed 12 times with wash buffer. Finally freshly 
mixed tetramethylbenzidine and substrate (1:1) were added to each well and the absorbance was recorded 
by an absorbance plate reader (VersaMax, Molecular Devices, San Jose, CA). Measurements were made 
at 450 nm in ten minute intervals. 
6.3. Results and Discussion 
 Aptamers were first isolated for a model IgG protein (Rituximab) which could be acquired in purified 
form. Aptamers were selected and characterized for this protein with results presented in this section. Then 
aptamers were isolated for a multiple myeloma patient’s monoclonal IgG. 
6.3.1. Rituximab Selection 
 The SELEX consisted of four rounds of selection to generate a pool of aptamer candidates. During 
this process, aliquots from the washing stages were collected and used to assess the success of the SELEX. 
During the 35 minute washing procedure, the washing fluid exiting the microfluidic device was collected 
into a tube. A new tube was used for every five minute interval of the washing process such that six tubes 
with 100 µL of wash fluid were generated. From these volumes, 2 µL were removed from the first wash of 
a SELEX round, the last wash of a SELEX round and the final eluted product. This aliquot was amplified by 
20 cycles of PCR and imaged by gel electrophoresis techniques (Figure 6.2). From the gel 
electropherogram it can be seen that the first wash of a SELEX cycle always contained more 
oligonucleotides than the last wash of a selection cycle. Thus confirming the washing process removes 
weakly binding ssDNA. It can also be seen that the last wash of a given SELEX cycles always contains 
less DNA than the first wash of the next SELEX cycle. This confirms that the ssDNA is PCR amplified with 
the integrated PCR system in the amplification chamber. Finally the last wash of the final round of SELEX 
contains less DNA than the elution band confirming that ssDNA remained strongly bound to the target 
molecule and could be removed with a modest temperature increase. 
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Figure 6.2: Collected eluates from the Rituximab aptamer selection process. (a) Gel electropherogram of 
amplified eluates and (b) bar graph depicting band intensity.S1W1: selection 1, wash 1; S1W6: selection 1, 
wash 6; S2W1: selection 2, wash 1; S2W6: selection 2, wash 6; S3W1: selection 3, wash 1; S3W6: selection 
3, wash 6; S4W1: selection 4, wash 1; S4W6: selection 4, wash 6; E: elution. 
6.3.2. Rituximab Sequencing 
 A sample from the eluted product was amplified by PCR and sequenced. A total of 24 colonies 
were selected for sequencing (Table 6.3). The sequences were analyzed for shared motifs and 
sequences with the most common regions with other sequences were synthesized and further tested. 
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Table 6.3: Sequences from Rituximab SELEX. 
 
6.3.3. Rituximab SPR 
 Aptamer candidates were evaluated for their affinity towards Rituximab by SPR. The aptamer 
sequence RituxS13 was found to have the highest affinity towards the target (Figure 6.3). A binding 
dissociation constant of 35.8 nM was obtained with limited binding to the polyclonal IgG. The binding of the 
aptamer towards Rituximab was compared to the binding towards polyclonal IgG. Rituximab and polyclonal 
IgG were injected at 400 nM concentration and the average response from the 200th minute to the 250th 
were compared. The aptamer showed much greater response towards Rituximab than towards the 
polyclonal IgG indicating the aptamer specifically binds to the model monoclonal protein. 
Sequence ID Sequence
RituxS1 TTGGATTGAGAAACATCGCCGCGTTTTAGGTTCAGCGACTCACTGACACTACTCCTTGTACCTTCCTCCTGACCACATCCGAC
RituxS2 TTGGATTGAGAAACATCGCCGCTTAGACCTCGAGTGATGACCTGTGAATGCGCTACGTTGATTTCCTCCTGACCACATCCGAC
RituxS3 TTGGATTGAGAAACATCGCCGCACTAACTCTGCCTTCCGGCTTTTTATTATTTTGTGTTATTTTCCTCCTGACCACATCCGAC
RituxS4 TTGGATTGAGAAACATCGCCGCTTTGCGTAAGAACGGCTGCACCTCGGGACTATTGGTACTCTTCCTCCTGACCACATCCGAC
RituxS5 TTGGATTGAGAAACATCGCCGCTAGTTCCCTTTTATGATTTGCGATCACCCGCGGGAGTGTTTTCCTCCTGACCACATCCGAC
RituxS6 TTGGATTGAGAAACATCGCCGCATTTAATTACCTACAATCGTTCTATGTTTTTCTACACTGCTTCCTCCTGACCACATCCGAC
RituxS7 TTGGATTGAGAAACATCGCCGCGTTGGCCCAGGAGGTGCCGTGCGGTATGGGGGCCCGGGCGTTCCTCCTGACCACATCCGAC
RituxS8 TTGGATTGAGAAACATCGCCGCGCTGACGACTATTTAGTATTTTACACAGGTTCGCATTGGGTTCCTCCTGACCACATCCGAC
RituxS9 TTGGATTGAGAAACATCGCCGCGTCGGGGGGCGCGGCCGGTACGCTAGGGTTGAGTGCCTTGTTCCTCCTGACCACATCCGAC
RituxS10 TTGGATTGAGAAACATCGCCGCGGGCCCTTTTAAACGGAAGTTTCCACCGCTAGAGTGGGGTTTCCTCCTGACCACATCCGAC
RituxS11 TTGGATTGAGAAACATCGCCGCCCGTTGCTCTTTTATTTCGTGTACCACCGCTTCGGTATGATTCCTCCTGACCACATCCGAC
RituxS12 TTGGATTGAGAAACATCGCCGCGTGTTACGATGTCCAGTTAGGTCGTTGTAAAGATCTCCATTCCTCCTGACCACATCCGAC
RituxS13 TTGGATTGAGAAACATCGCCGCGGGGGCAAACTTTCCGCTGTGGGTTATACTGAACACGGACTTCCTCCTGACCACATCCGAC
RituxS14 TTGGATTGAGAAACATCGCCGCTGACTACTAAATCGGAAACGTTCCGAGAGCGGATGGTACGTTCCTCCTGACCACATCCGAC
RituxS15 TTGGATTGAGAAACATCGCCGCGCAGCGGTGCTGTCCAGCCCAGGTGGAACGCTTAGCGTTCTTCCTCCTGACCACATCCGAC
RituxS16 TTGGATTGAGAAACATCGCCGCTAACCAGGAGGGGTTGAGGCGGCAGCGGGTGAGGGGTGTGTTCCTCCTGACCACATCCGAC
RituxS17 TTGGATTGAGAAACATCGCCGCGATTTTAAGACATGATATGTCTTTCTGAGGCAGTTCGTACTTCCTCCTGACCACATCCGAC
RituxS18 TTGGATTGAGAAACATCGCCGCGAGAAAACGGAGAGGTCTGAAGCGACAAGCAGGGACGTCCTTCCTCCTGACCACATCCGAC
RituxS19 TTGGATTGAGAAACATCGCCGCTCCAGGGACGTTTCAAACTCAAAGCTATTGAGAGCATGATTTCCTCCTGACCACATCCGAC
RituxS20 TTGGATTGAGAAACATCGCCGCGTGGGCTAAACGTGGTGGTTAATGGTGAGGGGGGGTCGTCTTCCTCCTGACCACATCCGAC
RituxS21 TTGGATTGAGAAACATCGCCGCCTTTTAGTCTGGGATAGATTTCAGTGGTGCGGCGGTACAATTCCTCCTGACCACATCCGAC
RituxS22 TTGGATTGAGAAACATCGCCGCTTAAACTTTCCATATGATGCCCTAATCGATTTGGCCACTATTCCTCCTGACCACATCCGAC
RituxS23 TTGGATTGAGAAACATCGCCGCTGTTGAGAGGTGTTACGATCATTAGCGGCAGCTTAACATATTCCTCCTGACCACATCCGAC
RituxS24 TTGGATTGAGAAACATCGCCGCTGGACGCATTACGGTTATATTATTGGGAGTCGGGCGGAAGTTCCTCCTGACCACATCCGAC
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Figure 6.3: Rituximab aptamer binding characterization by SPR. (a) Aptamer RituxS13 surface with 
increasing concentrations of Rituximab injected. (b) Comparison of aptamer response when 400 nM of 
either Rituximab or polyclonal IgG are injected. 
6.3.4. Rituximab ELISA 
 The sequence with the highest affinity from SPR (RituxS13) was further tested for its affinity in an 
aptamer style ELISA. Rituximab and polyclonal IgG were functionalized onto protein G wells and a 
biotinylated RituxS13 was incubated, washed, and exposed to biotinylated horseradish peroxidase (Figure 
6.4). The aptamer RituxS13 was found to preferentially bind to Rituximab thus confirming the specificity of 
the resultant aptamer towards the target. Therefore, the microfluidic selection approach was able to isolate 
an aptamer towards a monoclonal protein within a day and this aptamer could be used in a clinically relevant 
assay.  
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Figure 6.4: Aptamer formatted ELISA. Rituximab aptamer sequence RituxS13 was tested for its ability to 
bind Rituximab and the polyclonal IgG. Error bars represent standard deviations. 
6.3.5. MM Patient Selection 
 The microfluidic approach was next used to isolate a patient specific aptamer. The success of the 
overall chip performance was first assessed using eluates collected during the selection process. These 
eluates were amplified off-chip by PCR and imaged by gel electrophoresis. As can be seen in Figure 6.5 
for every SELEX round the amount of DNA collected becomes less as the washing progresses. However, 
after the thermal conditions of the selection chamber are changed, a large amount of DNA that was strongly 
bound and eluted under the different environmental conditions could be collected. Each round of SELEX 
showed the monotonous decrease in the amount of DNA during washing. The first wash of the first round 
of selection appears to have a lower intensity but is actually artifact of having an excess of DNA in the PCR 
reaction. All samples were subjected to the same amount of PCR cycles (19 cycles) which proved to be 
excessive for that first wash. Later rounds of SELEX had more oligonucleotides in the elution compared to 
even the first wash indicating more of the pool was binding to the target beads than being washed away 
during the later rounds of SELEX. 
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Figure 6.5: Collected eluates from the six round selection process, amplified by PCR and imaged with gel 
electrophoresis. (a) Gel electropherogram of amplified eluates and (b) bar graph representing 
electropherogram band intensity. Bar color indicates selection round. W1 is the first wash of a selection 
round. W6 is the final wash for section rounds 1-4. The final wash for rounds 5 and 6 is W8. E is the eluted 
product. 
 
6.3.6. High Throughput Sequencing 
 High throughput sequencing data was analyzed with the AptaSuite toolkit [194]. The toolkit 
fractioned the raw sequencing files into the six rounds of SELEX and accepted 3,818,436 reads as having 
correct forward primers and reverse primers. Of these reads, approximately all (>95%) had a randomized 
region size matching the starting library (40 nucleotides). The identified barcodes for each round of SELEX 
were approximately evenly distributed (first round: 19.1%, second round: 18.38%, third round: 17.31%, 
fourth round: 13.31%, fifth round: 16.12%, and sixth round: 15.57%). The amount of singletons, defined as 
sequences that appear with a count of one, decreased on every round of SELEX (Figure 6.6). Further, the 
amount of enriched species, defined as sequences that also appear in other rounds of SELEX increased 
as expected during every round of SELEX. Conversely, the unique fraction (sequences that only appear in 
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that SELEX round) decreases as the SELEX process progressed. It appears the singletons and enriched 
sequences slightly increased on the sixth round. This could indicate the process began to saturate after six 
rounds. 
 
Figure 6.6: Singletons, enriched species and unique fraction of every SELEX round. Singletons are 
sequences that appear with a frequency of 1. Enriched species are sequences that are found in other 
rounds. The unique fraction are the sequences that do not appear in any other round. 
 A cluster program was run to group aptamer sequences by their similarities and the clusters of 
similar sequences. Clusters consisted of sequences that had randomized regions with only a single 
nucleotide allowed to mismatch. Clusters that appear at very high frequencies in the sixth round of SELEX 
were further evaluated for their progression through the other rounds of SELEX. A sequence of low 
abundancy but that is rapidly increasing in frequency in the later rounds of SELEX could suggest a potential 
high affinity sequence becoming enriched. The clusters were checked against the most frequent non-
clustered sequences to ensure highly frequent sequences were not missed by the clustering algorithm. 
Sequences that contained a single nucleotide between primers were considered artifacts from the PCR 
processes and purification processes and discarded. The progression of the ten most abundant sequences 
from the sixth round are shown Figure 6.7.  
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Figure 6.7: Abundance of the top 10 most frequent sequences from the sixth round of SELEX. Significant 
enrichment occurs from the fourth round to the fifth round.  
 All of the most frequent sequences increased from the fifth round to the sixth round. The most 
significant enrichment of the sequences occurred after the fourth round indicating that SELEX cycles 
beyond four could enhance the probability of identifying a high affinity aptamer. The most frequent 
sequences of the fourth and sixth SELEX rounds were synthesized for further in vitro testing. These 
sequences are tableted below (Table 6.4). 
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Table 6.4: Next generation sequencing results for each round of SELEX for the 10 most frequent 
sequences found in the 6th round of SELEX. 
Sequence 
ID Sequence 
Round 
1 
Counts 
per 
Million 
Round 
2 
Counts 
per 
Million 
Round 
3 
Counts 
per 
Million 
Round 
4 
Counts 
per 
Million 
Round 
5 
Counts 
per 
Million 
Round 
6 
Counts 
per 
Million 
P3S1 AGAGATGGTCGGTATATATCCAATCGTGAATGCCAAGTGAA 0 1.425 1.513 15.746 190.074 339.804 
P3S2 TTATTTCCTACGATCACCAAGTGAAATCCAAGTGTATGAGA 0 0 0 35.429 190.074 324.665 
P3S3 GTTAATGCTAATGCCTCGTGTTTTCCAAGTGTTGAGTCGGA 0 0 9.077 29.524 173.828 254.011 
P3S4 CAAGTGACATAGCAAGGGGATGAGGAAAAGAGAGTGGGCGA 0 7.123 4.539 25.588 121.842 211.957 
P3S5 GGGTGTAGAATTCTCAATAACAAGTGGATGAGTTAAGCGGA 1.356 0 3.026 23.619 102.348 148.032 
P3S6 CGATAGCGAGATGTAGTCGCATTAGGAAAAGTGTGAGCGGA 0 0 3.026 37.397 63.358 139.622 
P3S7 AAAGCAATACAAAGAGACAGCAACCAAGTACGAATGGGCGA 1.356 1.425 1.513 21.651 125.091 141.304 
P3S8 AACCATGCCAAGTGATTAAGGTATAAATACCAAGTGAAGTA 0 2.849 9.077 23.619 77.979 137.941 
P3S9 TTACGTTGATTGTGGTCCATGTGCATGAGGGAAGGAGCGGA 0 0 0 25.588 77.979 136.258 
P3S10 AGTAAACCAAGTAAAGAGTGTACCAGTTCTAAGTGAATG 0 1.425 3.026 43.302 261.554 348.218 
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6.3.7. Aptameric ELISA 
 The ability of the aptamers to bind to the target myeloma patient M-Ig could be demonstrated by 
aptameric ELISA (Figure 6.8). Conceivable, ELISA could be a test used to track patient M-Ig during disease 
progression. Thus, ELISA was not only used to demonstrate aptamer binding but to illustrate the potential 
of the aptamers in a clinical test. Ten sequences identified from the high throughput sequencing were 
screened with the aptameric ELISA. From these clones, the observed binding was higher towards the M-
Ig than towards polyclonal IgG for sequences P3S1, P3S3, P3S5, P3S6, P3S9 and P3S10. Of these, it was 
determined P3S10 and P3S5 had the greatest difference in binding towards the M-Ig than the polyclonal. 
 
Figure 6.8: Aptameric ELISA results of a patient monoclonal IgG bound to the well surface through protein 
G and solution phase aptamer. Absorbance was measured at 370 nm in 10 minute intervals. Measurement 
shown is after 75 minutes. Error bars represented standard deviations from triplicate measurements. 
These results can be compared to their enrichment found through NGS where sequence 10 was 
the most prevalent sequence for the fourth, fifth, and sixth SELEX round. While it was the most prevalent 
for the sequences tested, there were other sequences at the fourth round which were more frequent than 
P3S10 but these sequences became less frequent in the fifth and sixth round.  
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6.3.8. SPR Analysis 
The aptamer with greatest binding from the ELISA (P3S10) was further analyzed by SPR. A biotinylated 
version of the aptamer was bound to one of the sensing surfaces while a scrambled control was bound to 
the other. SPR measurements were taken from the difference of these two channels such that only the 
specific binding of the aptamer to the injected molecule was considered. Patient serum purified for IgG by 
Melon Gel was injected into the SPR instrument in various concentrations. The aptamer and scrambled 
sequence were then regenerated and human polyclonal IgG was then injected at the same concentrations 
and compared to the patient injections (Figure 6.9). These experiments were performed in triplicate for 
both the M-Ig and polyclonal IgG. 
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Figure 6.9: Representative SPR response curves for aptamer P3S10 from triplicate experiments. (a) 
Aptamer response towards patient 3 IgG and (b) aptamer response to a polyclonal IgG used as a control. 
From the SPR responses it can be observed that significant binding was found to the patient IgG protein 
while negligible binding was found when the polyclonal human IgG was injected. By applying a 1:1 fitting 
model to the M-Ig binding curves, a binding dissociation constant of (KD) of ~27.7 nM is obtained. Therefore, 
a patient M-Ig specific aptamer has been isolated. The concentrations of protein used in these SPR plots 
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are orders of magnitude lower than the limit of detection for conventional MM diagnostics, though it must 
be noted the SPR proteins were diluted in buffer.  
6.4. Conclusion 
The microfluidic approach was used to perform SELEX on a model monoclonal protein, Rituximab. An 
aptamer was identified with a binding dissociation constant of 35 nM and the aptamer could be further used 
in an aptamer formatted ELISA. With this insight, the approach was applied to the isolation of a patient 
derived monoclonal protein. This protein was first isolated from serum and then put onto selection beads 
which were injected into the microfluidic device. High throughput sequencing was used to analyze the 
resulting aptamer pools and to select sequences to be further analyzed. These sequences were analyzed 
by an aptameric ELISA and sequences P3S10 was found to have higher binding to the patient M-Ig than 
to the polyclonal control. P3S10 was further analyzed by SPR and found to have a specific response to the 
patient IgG and negligible response to a polyclonal IgG pool. The rapid isolation time of these aptamers 
(<12 hours) could allow the development of personalized probes for MRD diagnostics for a cohort of 
patients. 
 The application of this aptamer for minimal residual disease needs further exploration. ELISA 
studies in physiological media, such as serum, would help determine its clinical applicability. Also, finding 
the limit of detection in buffer and in serum through a titration from a higher concentration would provide 
this information. As this is the first isolation of an aptamer towards a myeloma patient M-Ig, it would be 
beneficial to investigate it further before isolating additional aptamers for other patients. Binding studies to 
determine the generalized binding dissociation constant would be illustrative for future selections though 
for an aptamer to work in ELISA it generally needs dissociation constants in the nanomolar range. Additional 
purification of the patient IgG sample would allow curve fitting from the SPR results. The study would also 
benefit from fragment screening or crystallography studies to determine where exactly the aptamer binds 
to the patient protein and if it is indeed targeting the protein idiotype. Finally, additional selections of 
aptamers towards other IgG myeloma patients and myeloma patients of other immunoglobulin subtypes 
would demonstrate the robustness of the approach.   
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Chapter 7: Concluding Remarks 
7.1. Thesis Summary 
 Precision medicine is in need of tools that can detect expressed biomarkers. Mass spectrometry 
techniques lack the required sensitivity needed for many applications, and monoclonal antibodies, while 
they can act as sensitive probes, have a prohibitively expensive development process making them poor 
candidates as probes for the thousands of relevant biomarkers. Aptamers are capable diagnostic probes 
but the development of aptamers towards new biomarkers also suffers from time, and resource 
consumptive processes.  
 In this thesis, the aptamer development process is integrated into a microfluidic device which 
results in a reduction in the amount of time and reagents needed to isolate aptamers of high affinity. This 
reduction in time is the result of the larger surface area to volume ratios afforded in microscale geometries 
and the high degree of integration which enables seamless transition from one step of SELEX to the next. 
As such, the aptamer development time can be completed within a day thereby allowing the selection of 
aptamers towards precision medicine probes at a realistic scale. The first part of this thesis involves the 
development of microfluidic SELEX techniques for rapid aptamer isolation while the second part applies 
this technology to a few examples within precision medicine. A series of aptamers are generated to several 
targets including a small molecule glycan, a glycosylated peptide, and an IgG protein.  
Specific results of this thesis include: 
7.1.1. Hybrid SELEX Approach 
 A microfluidic approach for aptamer isolation is explored which uses electrophoretic locomotion to 
transport ssDNA from the selection chamber to the amplification chamber and then pressure driven flow to 
transport PCR amplified ssDNA back to the selection chamber for further rounds of SELEX. Thus the chip 
leveraged the simplified work flow of previously reported electrokinetic SELEX devices, while also 
preventing the exposure of the target molecule to potentially deleterious electric field effects. The device 
was fully capable of performing 4 rounds of SELEX on a single chip without the need for off-line processes. 
Using IgE as a model target, an aptamer pool with an equilibrium dissociation constant (KD) of 
approximately 12 nM and limited cross-reactivity towards IgA. 
 123 
 
7.1.2. Electrokinetic SELEX Approach 
 A second microfluidic SELEX approach which used purely electrokinetics to transport ssDNA 
between various SELEX stages was developed. The approach simplifies the device fabrication and design 
while integrating the affinity selection and amplification stages of SELEX with free solution electrokinetic 
oligonucleotide transfer. As such, the SELEX process can be completed without the need for flow control 
components or gel components. The approach was realized in a microfluidic chip consisting of two 
microchambers separated by a long, torturous, serpentine channel of high flow resistance. While this 
channel would prevent diffusion and flow under normal operating conditions, with the application of an 
electric field between the two microchambers, oligonucleotides could be transferred between the two 
microchambers, allowing oligonucleotides to be transferred from the affinity selection microchamber to the 
PCR amplification microchamber. Thus the approach is capable of multi-round enrichment of 
oligonucleotides using simple transfer processes while maintaining a high level of device integration, as 
demonstrated by the isolation of an aptamer pool against a protein target (IgA) with significantly higher 
binding affinity than the starting library in approximately 4 hours of processing time.  
7.1.3. Three Chamber Approach 
 A third microfluidic approach was developed which featured a selection chamber, a counter 
selection chamber, and amplification chamber connected by microchannels to form an integrated SELEX 
capable loop. The approach affinity selected aptamers in one channel, then transferred selected aptamers 
through a counter selection chamber until finally reaching a PCR amplification chamber. Therefore, for 
every round of SELEX aptamer candidates are affinity selected, counter selected and PCR amplified. The 
amplified PCR product would then be thermally eluted and transferred back to the selection chamber for 
further rounds of SELEX. The device used to realize the approach employed integrated microvalves to 
control the fluid motion, and thus oligonucleotides, within the device. Gel electropherograms confirmed the 
device was capable of performing selection and amplification stages of SELEX. Furthermore, the approach 
could be used for many rounds of SELEX without degrading. It was concluded in this chapter that a device 
with sufficient reliability and robustness to pursue precision medicine applications had been developed. 
7.1.4. Glycan Binding Aptamer Isolation 
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 The three chamber approach was employed to select aptamers towards glycan molecules. 
Gangliosides GM1, GM3, and GD3 were chosen as targets for aptamer development. Aptamers were 
isolated with 4 rounds of SELEX for each of these targets and characterized by SPR and ITC techniques. 
These aptamers displayed binding dissociation constants, KD, of 49.6 nM towards GM1, 43.59 nM towards 
GM3, and 2.48 µM towards GD3. It was also observed the binding test format had a large influence on the 
binding behavior of the aptamer candidates. These glycan approaches were extended to the isolation of 
aptamers with affinity towards a glycosylated peptide. A synthesized glycosylated peptide was used as a 
target for SELEX while its non-glycosylated version was used as a counter target. After 3 rounds of SELEX, 
aptamers were isolated with binding affinities (KD) as low as 15 nM towards the glycosylated peptide and 
3.2 µM towards the non-glycosylated version. 
7.1.5. Monoclonal Protein Aptamer Isolation 
 Multiple myeloma is a cancer of the plasma cell for which sensitive methods to track disease 
progression remain scarce. The hallmark of the disease is a monoclonal protein that is unique for every 
patient. Targeting this monoclonal protein would allow sensitive monitoring of disease progression for these 
patients but doing so would require a unique probe for each myeloma patient. The three chamber approach 
is used to first isolate an aptamer towards a model monoclonal protein (Rituximab) of the same class as 
the most frequent cases of multiple myeloma. An aptamer with an affinity (KD) of 32 nM is isolated for 
Rituximab. A myeloma patient serum sample is then used in the device to obtain patient specific aptamers. 
The cancer related protein is purified from the patient serum sample and used within the microfluidic device. 
Resulting aptamer pools were sequenced using next generation techniques and screened in an aptamer 
formatted ELISA resulting in the discovery of an aptamer which non-specifically responds to the patient 
cancer protein. The aptamer was also tested with SPR and was shown to only bind to the patient associated 
monoclonal protein. 
7.2. Future Work 
 The devices demonstrated in this work were proofs-of-concept and have opportunity for further 
improvement. 
7.2.1. On-chip Aptamer Development Tracking 
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 The devices presented are effective at performing the stages of SELEX and generating a pool of 
aptamer candidates which can then be characterized; however, they do not offer information of the selection 
process while it is occurring. The amount of selection cycles to perform is based on experience and must 
be determined before the SELEX begins, as are the amount of PCR cycles performed for the amplification 
stage. If the device included features which could assess the amount of ssDNA binding during the selection 
stage of SELEX then the device operator could determine the point at which the SELEX should be 
concluded. Timely termination could prevent wasted time on characterization of aptamer candidates from 
a pool that is not sufficiently enriched, or conversely the loss of aptamer candidates from too many SELEX 
cycles to PCR preferential sequences which do not have an affinity towards the target molecule. 
 Incorporating qPCR into the amplification stage could allow monitoring of the SELEX process. By 
employing qPCR the amplification process can be monitored and terminated at the same amplification level 
for every round of SELEX. The advantages of this are two-fold. First selection cycles are normalized 
between rounds with equal starting material. Second, the amount of cycles needed to reach the specified 
amount of DNA can be used as an indicator for the amount of ssDNA that bound to the target during the 
selection phase. Thus, the success of the selection stage can be monitored with a single qPCR stage. 
 Preliminary results indicate this is possible by including a SYBR fluorescent dye in the PCR 
reagents (Figure 7.1). SYBR dye is frequently used to assess the amount of dsDNA in qPCR. Three rounds 
of SELEX were performed with this dye in the amplification buffer. Images were taken for every PCR cycle 
with an epifluorescent microscope. As the SELEX process proceeded, increasing amounts of dsDNA were 
generated for each SELEX cycle. While this demonstrated the potential for qPCR to be used in SELEX it 
had some limitations. First, a system to control the amplification in automated fashion needs to be 
developed. The qPCR plots could only be generated retrospectively and a set number of PCR cycles were 
used during the amplification process. Second, passivation techniques which prevent the absorption of the 
fluorescent dye into the PDMS microchip architecture need to be further explored. It was observed that the 
amplification curves for the later SELEX rounds were influenced by the residual dye in the PDMS 
microchamber walls which could not be removed by washing. However, there are a multitude of solutions 
to overcome these limitations [195-198]. 
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Figure 7.1: Amplification curves for 4 rounds of SELEX. SYBR green dye was included with the PCR 
reagents to allow fluorescent imaging of the amplification process. 
 
7.2.2. Selection as a Diagnostic 
 Extensive research has focused on employing microfluidics for sensors, including sensors which 
use aptamers as a readout. It is envisioned that microfluidic sensing technology could be combined with 
SELEX into a microfluidic platform where sensing and aptamer development occur simultaneously, thereby 
eliminating the need for time consuming aptamer characterization assays. The selection stage of SELEX 
process is similar to many affinity assays - a ligand is immobilized and an analyte is introduced and washed 
away. If aptamer tracking can be successfully implemented into a SELEX device then a baseline can be 
created for a specific amount of target and aptamer. Once this is established a target sample of unknown 
concentration could be introduced and the amount of binding aptamer could be measured to determine if 
the target sample contains more or less than the baseline. In this simplified example, the characterization 
of the aptamers occurs during the selection process thus eliminating off-chip characterization. Furthermore, 
it is often observed aptamer candidates prefer target molecules in the selection format and sometimes will 
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not bind in other formats. This issue is obviated if the ultimate aptamer diagnostic assay directly mimics the 
selection condition. 
7.2.3. Automation of Devices 
 The devices presented were developed such that they could be fully automated with proper 
supporting equipment. However, for the proof-of-principle demonstrations the aptamer selection process 
relied on semi-automated syringe pumps and the pipetting of beads and reagents into the functional 
microchambers. These processes could be replaced with the integration of a computer controlled valving 
and pumping manifold as recently presented by the Fordyce Lab [199]. Such a setup would allow aptamer 
isolation without the presence of an operator. This could allow high throughput aptamer selections which 
not only could generate aptamers for many different targets, but would also create opportunities to further 
optimize the SELEX process. It is envisioned an aptamer library could be created with standardized 
selection procedures and information on targets and selection conditions. 
Characterization and Applications of Glycan Binding Aptamers 
 The glycan binding aptamers all showed affinity to their targets but the affinity was dependent on 
the format of the binding test. Lyso-gangliosides were used for the selection of the aptamers but only the 
GM1 and GM3 aptamers were tested for affinity with the lyso-ganglioside, and unsurprisingly, they showed 
high affinity to the target in that format. Binding characterization studies still need to be performed on the 
lyso-GD3 gangliosides and it is expected the aptamers will show higher affinity to the lyso-targets than they 
did for the intact ganglioside. Dissociation constants were found for these aptamers because they can 
provide a generalized measure of binding ability which a glycoscientist would be able build an assay around. 
It would be further illustrative of the aptamers potential to also apply the aptamers to commonly used assays 
within the glycan research field. For example, the aptamers could be used in a glycan microarray or in a 
flow cytometry example case.  
 Furthermore, glycans used in these proof-of-principle studies were chosen to demonstrate the 
ability of the approach to isolate aptamers that could distinguish similar glycan molecules. There are still 
more than 60 known gangliosides for which it would be useful to have affinity probes. It is expected 
additional modifications to the SELEX procedure will be needed to get the desired specificity, but one 
potential approach to overcome specificity shortcomings could rely on building a library of aptamers and 
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then using this library to block shared features between glycan molecules. For example, an aptamer that is 
isolated and found to bind to GD3 could be used in the selection of GD1 aptamers to block the shared 
structures between the two gangliosides.  
 Most proteins are glycosylated and aberrant glycosylation patterns have been implicated in many 
diseases. Aptamers for these aberrant glycosylation patterns could prove to be important diagnostic probes. 
This thesis demonstrated the feasibility of isolating such probes but did not examine a specific disease. 
Future work will focus on the isolation of aptamer candidates towards a well characterized disease. 
7.2.4. Application of Aptamers to Histological Patient Serum 
The aptamers isolated in Chapter 6 had affinity towards the patient specific monoclonal protein and 
could potentially be used to monitor this patient’s disease state. Further studies on the aptamer’s binding 
ability in pure serum need investigation. These studies could be done in the aptamer formatted ELISA or 
other clinically relevant assay. Limits of detection and limits of quantification would illustrate the usefulness 
of these aptamers in tracking a patient’s cancer, especially for cases where the patient has minimal residual 
disease. With a sufficiently sensitive aptamer, studies using histological serum samples could be conducted 
with potential to change the diagnostic procedures used in multiple myeloma treatment. Isolation of 
aptamers to additional patients could also assess the widespread applicability of the approach to multiple 
myeloma patients. Aptamers for a group of patients could provide information on the similarities and 
differences between patients within multiple myeloma. A database of aptamers and myeloma patients could 
be created to allow further separation of myeloma patients into smaller population groups for more tailored 
treatment. 
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